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ABSTRACT 
 
JESSICA HYUI-SU PARK:  Design of β-hairpins and β-sheets for Molecular Recognition 
(Under the direction of Marcey L. Waters) 
 
 
 Protein-nucleic acid interactions are essential in a multitude of biological processes.  
Protein interactions with single-stranded DNA are particularly important in DNA replication, 
repair, and telomere regulation.  Previously, our laboratory had designed a β-hairpin dimer, 
(WKWK)2 which binds ssDNA with a Kd of 3 µM and dsDNA with a Kd of 5 µM.  These 
results later led to the redesign of a β-sheet peptide from a native protein which displayed 10-
fold selectivity for dsDNA but overall lower affinity for ssDNA at a Kd of 20 µM.  In this 
work, with the insight gained from these studies, a third de novo β-sheet was designed, S123.  
This new system was found to bind ssDNA with a dissociation constant of 170 nM.  Several 
derivatives were investigated to determine the origins of the marked improvement in binding 
affinity.  It was found that high β-sheet structure was necessary to achieve the observed 
nanomolar affinity of S123 to ssDNA. 
 In another study, the use of the copper(I)-assisted azide-alkyne cycloaddition as a 
method of β-hairpin stabilization was investigated at several different positions.  It was 
determined that the CuAAC reaction was a suitable method for locking in β-hairpin structure 
in peptides possessing the type I’ turn, VNGO and the type II’ turn, VpGO.  All cyclic 
variants exhibited improved thermal stability and resistance to proteolysis as compared to the 
non-cyclic peptides.  Additionally, the function of the CuAAC cyclized peptides was not 
altered as exhibited by similar binding affinities for ATP as the WKWK peptide.  These 
iv 
 
studies provided a comprehensive method for CuAAC cyclization of β-hairpin peptides, 
which could further be utilized in the inhibition of protein-protein interactions. 
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 CHAPTER I 
INTRODUCTION 
A.  Model systems: design principles of β-hairpins and β-sheets   
 Chemists and biologists alike admire the complexity of even the simplest mechanisms 
in living systems.  Understanding the complex function of biomolecules, in concert or alone, 
remains an elusive challenge.  Often when studying a single interaction or event in vivo a 
host of other downstream effects convoluting the results are created leading to more 
questions to answer.  To simplify these challenges, researchers have devised model systems 
to study complex systems.  Model systems are advantageous because they allow for the study 
of a single interaction under a controlled environment.  Examples of methods for the design 
of model systems include: recreation of the system outside of the living organism using 
native parts, creation of an artificial system, and chemical synthesis of a portion of the 
system based on design principles as well as a variety of other approaches.
1
  
 For many years model systems have been utilized to study protein structure and 
function.
2
  Secondary structure stabilization of α-helices, β-sheets, and β-turns has been a 
sought after goal to understand native protein folding and function.  In addition such insights 
will aide in the design of minimalistic functional peptides and novel enzymes for catalysis of 
new reactions.  Design rules for forming stable monomeric and multimeric α-helices have 
long been established.
3,2a,2e
  However, insights into β-hairpin and β-sheet design have lagged 
behind due to poor stability and solubility in water as well as their tendency to aggregate.
4
   
2 
 
Despite these limitations, over the past two decades, a significant amount of work has 
been accomplished in the investigation of peptides that form β-hairpins.  The first de novo β-
hairpin was reported in 1993 and was based on residues 15-23 of Tendamistat, a protein 
which inhibits α-amylases.5  Shortly after, the same group reported on the isolation of a 
second hairpin from Streptococcal protein G which was found to be 40% folded, native-like 
β-hairpin structure, via NMR studies.6  These early discoveries and characterizations of 
isolable β-hairpins/sheets defined structural factors that contributed to numerous reports of 
stable β-sheets in the late 90’s and early 2000’s.7 
β-Hairpins, the smallest secondary structural motif, are composed of two β-strands 
oriented in an antiparallel fashion connected by a turn sequence.  When designing a stable 
monomeric hairpin there are several aspects to consider: the sequence of the turn residues, 
side-chain–side-chain interactions, and the β-sheet propensities of amino acids.4,8  The 
residues that nucleate the turn are of particular importance as they can impart proper strand 
alignment and stability.  The common β-turn motifs are the Type I and Type II turns as well 
as their mirror images, Type I’ and Type II’ turns, which are very strong turn promoters of 
structure in β-hairpins.9  These turn types also furnish a right-handed twist which occurs in 
native antiparallel β-sheets.4  Thus turn sequence known to adopt either Type I’ or Type II’ 
conformations were used in the β-hairpins and β-sheets in the work presented in this thesis 
(Figure 1.1).   
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Figure 1.1  Representation of a β-hairpin.  (A) Cartoon 3D representation showing the two 
faces, hydrogen bonded (HB, red) and non-hydrogen bonded (NHB, blue) faces, of a β-
hairpin.  This figure depicts the hydrogen bonding (red dashes) and possible interactions 
between cross-strand NHB residues (blue dashes).  (B) Example structure of a typical β-
hairpin showing the turn nucleating sequence (blue box) and again the hydrogen bonds (red 
dashes) present within the peptide backbone.  Shown here is a type II’ turn sequence, dPro-
Gly.  
 
 
Side-chain–sidechain interactions are also a major contributing factor to hairpin 
stability.  The residues in the HB sites are known to be packed together due to the inherent 
twist in a β-hairpin.  Thus, the HB residues are typically quite hydrophobic and less flexible 
to substitution.
10
  The residues in the NHB sites tend to have the greatest interaction with 
each other as cross-strand residues are pointed towards each other in an antiparallel 
configuration.
11
  It is for this reason that β-hairpins have been used to elucidate a variety of 
interactions such as hydrogen bonding
12
, salt bridge formation
13, π-π14,13a and cation-π 
interactions
15
, interactions between post-translational modifications
16
, and proton/electron 
transfer
17
.  Using a small peptide scaffold to understand the driving forces of stability 
provides insight into how these interactions aid in the formation of larger protein complexes.   
4 
 
More recently, β-hairpins and β-sheets have been designed for functional purposes.  
Robinson and co-workers have made great strides in developing cyclic β-hairpin mimics of 
α-helices18 and portions of antibodies19 that work to inhibit protein-protein18a and protein-
nucleic acid interactions.
20
  The Schneider lab has taken a different approach using design 
principles to synthesize β-hairpins that self assemble under environmentally controlled 
conditions allowing for biological applications such as drug delivery.
21
 Our lab has had an 
interest in targeting nucleotides, in particular the selective recognition of single-stranded 
DNA (ssDNA) over duplex DNA.
22
  Successful developments of minimalistic model systems 
for this goal will be discussed in further detail in Chapter II. 
B.  Targeting ssDNA  
i.  Proteins and nucleotides: the importance of protein-ssDNA interactions 
Proteins and nucleotides are essential in all aspects of the central dogma of biology.  
From single nucleotide triphosphates to individual strands of ribonucleic acid (RNA) and 
deoxyribonucleic acid (DNA), nucleotides are involved in far more complex functions than 
previously hypothesized.  Several of these processes require highly specific interactions with 
regulatory protein complexes.  A portion of the work presented here aims to define the nature 
of these protein-nucleotide interactions via the design of β-sheet model systems containing a 
nucleotide recognition motif.  A major theme in the first part of this dissertation will be the 
understanding of the nature of the specific interactions necessary for targeting ssDNA. 
The interactions between proteins and ssDNA are critical in a number of biological 
processes such as recombination, DNA replication repair
23
, the cold shock response
24
, and 
telomere maintenance.
25
  Understanding the specifics of why and how these interactions bind 
selectively to ssDNA yet are promiscuous in sequence recognition requires knowledge of the 
5 
 
physical and chemical properties of ssDNA.  The repeating unit of ssDNA, the nucleotide, is 
composed of a nucleoside base, a sugar, and a negatively charged phosphate tail.  All of these 
features are exploited by single-stranded binding proteins and the need to manipulate DNA in 
single stranded form has given rise to a specialized set of proteins.   
Nearly all proteins that recognize and interact with ssDNA share a common structural 
motif called the OB-fold (oligosaccharide/oligonucleotide binding fold) that enables them to 
bind ssDNA.
26, 23c, 23d
  Structurally, most OB-fold domains consist of a closed β-barrel 
consisting of five β-strands with an α-helix cap lying between the third and fourth β-strands 
(Figure 1.2A).  These domains can range from 70 to 150 amino acids and of the known OB-
fold family members there is no strong sequence homology.
27
  These are, however, easily 
recognized within proteins due to the distinct structure of these domains.  The recognition of  
 
A B 
 
 
Figure 1.2  The OB-fold.  (A) Cartoon representation of the OB-fold, also known as the 
Greek key motif.  (B) Crystal structure of Cold shock protein A (CspA) one of the simplest 
OB-folds.  Solvent exposed aromatic residues (red) participate in ssDNA recognition. PDB: 
2L15. 
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ssDNA by OB-fold domains is mediated by aromatic stacking and edge-to-face interactions 
between prevalent aromatic residues on the solvent exposed face of the protein and the 
aromatic bases of the ssDNA.
28
  The OB-fold motif and aromatic residues are clearly 
identified in the crystal structure of Cold shock protein A (CspA, Figure 1.2B) and the co-
crystal structure of Protection of telomeres 1 (POT1, Figure 1.3).  The negatively charged 
phosphate backbone of ssDNA provides a handle for electrostatic interactions with OB-fold 
proteins which contain a number of positively charged basic residues.
29
  The sugar moiety is 
often less utilized by ssDNA binding proteins as it is not readily accessible.  However, as 
presence of the 2’ hydroxyl group on the sugar in RNA is the only chemical difference in 
RNA and DNA, proteins that bind ssRNA can be make use of this to increase affinity for 
ssRNA versus ssDNA.
30
  These binding sites that are highly selective for ssRNA are 
typically found in DNA or RNA polymerases. 
 
 
Figure 1.3  POT1 bound to ssDNA.  Co-crystal structure of Protection of telomeres 1 (POT1, 
purple and cyan) bound with ssDNA (grey). Aromatic residues (blue) aid in recognition of 
ssDNA via aromatic interactions such as edge-to-face and π-π stacking. PDB: 1XJV. 
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To highlight the importance and complexity of the protein-ssDNA interactions in 
biological systems, we can turn to Replication protein A (RPA) and downstream protein 
players (Figure 1.4).  RPA (Figure 1.5A), a classic example of a ssDNA binding protein in 
eukaryotes, is a heterotrimer consisting of six OB-folds, four of which are used in the binding 
event.
23,26,31
  As the name suggests, RPA is important in replication as it prevents ssDNA 
from forming secondary structures.  RPA is also implicated in telomere maintenance as is 
POT1 and tripeptidylpeptidase 1 (TPP1, Figure 1.5B).
32
  RPA and POT1 work in conjunction 
to activate or suppress the ATR checkpoint kinase of telomeres, respectively.  Activation of 
the ATR checkpoint halts the cell cycle progression and promotes DNA repair.  This process 
is mediated by yet another OB-fold containing protein, hnRNPA1, which is bound to 
telomeric repeat-containing RNA (TERRA) in the early S phase of the cell cycle.  However, 
in late S phase, TERRA levels decline allowing hnRNPA1 to displace RPA.  After S phase, it 
is presumed that TERRA reaccumulates thereby removing hnRNPA1 and allowing 
POT1/TPP1 to bind the telomeric ssDNA, which inhibits ATR kinase activation allowing the 
cell cycle to continue.
33 
 
 
Figure 1.4  Schematic of the hnRPA1 mediated ATR kinase deactivation.  
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Figure 1.5  RPA and TPP1.  Crystal structures of (A) Replication protein A (RPA) which has 
six OB-folds, PDB: 1L1O, and (B) Tripeptidylpeptidase 1 (TPP1), PDB: 2I46. 
 
 
RPA also functions to bind ssDNA during the initial phase of homologous 
recombination, an important process in DNA repair.
 
 Again, RPA prevents ssDNA secondary 
formation thus allowing Rad51, the central protein of recombination
34
, and its cofactors to 
bind.  This process has been found to be encouraged by BRCA2, a tumor suppressor protein 
associated with breast cancer susceptibility.
35
  This recognition allows error-free repair of 
DNA double strand breaks.  Dysregulation of the BRCA2 protein or mutations in the gene 
leads to nonfunctional protein, inhibiting DNA repair and potentially causing uncontrolled 
cellular replication thereby forming a tumor.
36
   
Other examples of β-hairpin or β-sheet containing proteins involved in DNA repair 
include UvrB
37
, Chlorella virus DNA ligase
38
, RecA
39
, and Rad4.
40
  All of the 
aforementioned proteins exemplify the variety of roles that OB-fold domains play in DNA 
recognition.  Dysregulation of any of these proteins can lead to a variety of different disease 
states, most implicated in cancer.  Understanding the interactions between the OB-fold 
containing proteins and ssDNA is essential in the development of novel drug candidates.  
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Thus it is important to study and fully understand the critical contacts necessary for ssDNA 
recognition. 
ii.  Mimicking the OB-fold 
The significance of nucleotides in biology has led our laboratory to explore the use of 
designed β-hairpins and β-sheets to recognize ATP, ssDNA as well as RNA structures.  One 
of the earliest works included the design of a 12-residue β-hairpin peptide, WKWK, to bind 
ATP preferentially over ADP and AMP due to electrostatic interactions.
41
  The details of 
WKWK binding to ATP are covered in Chapter IV.  This minimalistic model laid the ground 
work for understanding how OB-fold containing proteins can interact with ssDNA.  It was 
later found that dimerization of the WKWK peptide via a disulfide linkage between N-
terminal Cys residues, (WKWK)2 (Figure 1.6), could bind ssDNA sequences with slight 
selectivity over dsDNA.
22a
  Structural studies of (WKWK)2 were conducted to determine the 
contributing factors for ssDNA recognition and were insightful towards the possible modes 
of dsDNA recognition.  It was proposed that dsDNA recognition by the WKWK dimer was 
not only mediated by electrostatic interactions between the positively charged basic residues 
and the negatively charged phosphate backbone but could also be achieved through DNA 
groove binding.
22b
  In order to test this theory, the WKWK motif was grafted on to a WW 
domain which is composed of a three stranded β-sheet.22c  By addition of the third strand, the 
peptide achieved much higher selectivity for ssDNA than (WKWK)2 as it was now too large 
for dsDNA groove binding.  The aforementioned peptides will be discussed in detail in 
Chapter II.   
10 
 
 
 
Figure 1.6  Dimer of WKWK.  Structure of WKWK dimerized via N-terminal Cys residues 
(orange).  Trp and Lys residues (blue) are involved in the recognition of ssDNA.  Trp 
residues participate in stacking interaction with the nucleotide bases while the Lys provide 
electrostatic interactions with the phosphates of ssDNA. 
 
 
C.  Stabilizing secondary structures for targeting biomolecules 
 i.  Covalent modifications in peptide chemistry to stabilize secondary structures  
 The development of orthogonality in peptide synthesis for biological applications 
dates back to the mid 1950’s when chemists realized the need for methods to functionalize 
peptides post or during synthesis.  Early and contemporary bioorthogonal methods in peptide 
synthesis involved heavy use of various protecting group strategies.  While these methods are 
still useful they have notoriously low yields and can be quite labor intensive thus reactions 
that do not require additional protecting groups have been developed.  New bioorthogonal 
methods have been used extensively in peptide synthesis for stabilization of secondary 
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structure and bioconjugation of either a reactive handle or probe.  For the purpose of this 
research only examples of secondary structure stabilization will be mentioned. 
 The most notable examples of secondary structural stabilization are those of 
Verdine
42
 and Arora
43, where each worked to stabilize biologically important α-helices 
through inclusion of orthogonal chemical functionalities.  Verdine and coworkers 
successfully employed ring closing metathesis (RCM) with Grubbs-I catalyst on an α-helix 
of the dnMAML1 protein, to give what has been termed a “stapled” peptide (Figure 1.7).42c  
dnMAML1 is known to bind the Notch1:Lag1 complex which has been linked to several 
different cancers, in particular leukemia.
44
  The RCM between two unnatural side chains 
containing terminal alkenes at i and i+4 positions gave a highly structured α-helix and 
studies showed that without the preorganized α-helical structure the peptide was unable to 
efficiently antagonize Notch signaling.   
Arora and coworkers used RCM between reactive alkenes at the backbone carbonyl 
and amide at i and i+4 positions to afford a hydrogen bond surrogate (HBS).
43c
  They aimed 
to stabilize a portion of the HIF-1α protein which mediates the cellular response in low tissue 
oxygen concentrations.  The recognition of p300 by HIF-1α is accomplished via helical 
domains.
45
  Thus by stabilizing an α-helical portion of the HIF-1α via a HBS, Arora and 
coworkers effectively inhibited the interaction.  These two cases exemplify the need for 
robust methods of secondary stabilization.  The copper(I)-assisted azide-alkyne cycloaddition 
holds promise as one such reactions.  These examples show that covalent methods of 
secondary structure stabilization are useful and allow for temporal control.   
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Figure 1.7  A minimalistic mimic for dnMAML1.  (A) Co-crystal structure of Notch1 
(cyan):Lag1 (green):dnMAML1 (magenta) complex bound to DNA, PDB: 2F8X.  (B) 
Scheme of the Grubbs I catalyzed RCM of a fragment of dnMAML1 to yield a structured α-
helix that can act like a dnMAML1 mimic.
42c 
 
 
 ii.  A click reaction: the copper(I)-assisted azide-alkyne cycloaddition (CuAAC) 
in peptidomimetics 
Click chemistry is often misconstrued as the single reaction between an azide and 
alkyne but it should be understood that it defines a class of reactions.  A click reaction is one 
in which several requirements are met
46
: the reaction should 1) be modular, 2) be wide in 
scope, 3) give very high chemical yields, 4) generate only inoffensive byproducts, 5) be 
stereospecific, 6) be physiologically stable, 7) exhibit a large thermodynamic driving force, 
(8) have high atom economy.  Additionally the process should 1) have simple reaction 
conditions, 2) use readily available starting materials, 3) use no solvent or use a solvent that 
is benign or easily removed, such as water, and 4) provide simple product isolation by non-
13 
 
chromatographic methods.  This chapter serves as a report on the discovery and utilization of 
one such click reaction, the copper(I)-assisted azide-alkyne cycloaddition (CuAAC), as it 
pertains to peptidomimetics. 
The inception of the CuAAC began in the early 1900s with Otto Dimroth’s discovery 
of the 1,3-dipolar cycloaddition between an organic azide and an acetylene to give a 1,2,3-
triazole
47
 (Figure 1.8).  Its mechanism and scope of use was expanded upon some sixty years 
later by Rolf Huisgen for whom the reaction was named, the Huisgen cycloaddition.  Initial 
mechanistic studies led to the belief that the reaction proceeded via a diradical intermediate; 
however, this was met with controversy and was largely disproved by Huisgen who showed 
that it was indeed a concerted process.
48  
Huisgen was also the first to capitalize on the 
usefulness of this reaction as a clean method to produce a large number of 5-membered 
heterocycles.  This transformation has the advantage of high chemoselectivity since few 
functional groups react with azides or alkynes in the absence of other reagents.  However, the 
reaction conditions of the Huisgen cycloaddition require high heat and as such degradation 
and safety concerns arose.  In addition, this reaction exhibits poor regioselectivity as both the 
1,4- and 1,5-adducts are observed.  Despite these limitations, the Huisgen cycloaddition has 
found use in bioorganic and organic chemistry. 
 
 
Figure 1.8  Scheme for 1,3-dipolar cycloadditions.  The 1,3 dipolar cycloaddition between a 
terminal alkyne (blue) and an azide (red) which affords the 1,4- and 1,5-adducts. 
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The utility of the azide-alkyne Huisgen cycloaddition led to the development of the 
copper(I)-assisted azide-alkyne cycloaddition (CuAAC), commonly referred to as the “click” 
reaction.  This reaction was concurrently discovered and developed by Sharpless and Meldal 
in 2002.
49
  It was found that the use of a copper(I) catalyst dramatically accelerated the 
reaction and made it completely regioselective for the 1,4-adduct.  The mechanism will be 
briefly discussed in subsequent chapters.  Following its discovery, this conjugation method 
rapidly became a work-horse reaction finding application in drug discovery, polymer and 
materials synthesis, bioconjugation, carbohydrate chemistry, and peptidomimetics.  For the 
purpose of this thesis its applicability in peptidomimetics will be discussed. 
The triazole functionality resulting from the CuAAC reaction is of unique interest to 
bioorganic chemists as the triazole moiety bears strong physicochemical resemblance to 
amide bonds due to their relative planarity and strong dipole moment, ~5 D (Figure 1.9).  In 
addition biologically active molecules typically suffer enzymatic degradation, hydrolysis, 
and oxidation whereas traizoles are robust in these conditions.  Consequently, the CuAAC 
reaction has been utilized as a means to incorporate the 1,4-triazole as an amide bond 
surrogate in small molecules and peptides.  For example, the CuAAC reaction has been used 
to ligate two small molecules generating a mimic, AB2, of the HIV-1 protease inhibitor 
amprenavir
50
 (Figure 1.10).  Simulations and crystallographic analyses showed AB2 was able 
to bind to the HIV-1 protease active site with the triazole moiety localized to the position that 
the amide bond in amprenavir would be.  Additionally, the central nitrogen atom of the 
triazole was situated such that it could participate in a hydrogen bond with a water molecule 
within the active site.   
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Figure 1.9  Amide bond versus 1,4 triazole.  Comparison of (A) a typical amide bond to (B) 
a 1,4-triazole.   
 
 
A  
 
 
 
B 
 
 
 
 
Figure 1.10  Triazole substitution for amprenavir.  (A) Structure of amprenavir, the HIV-1 
protease inhibitor and AB2 which has a triazole substituted for an amide bond (yellow).  (B) 
X-ray crystal overlay of amprenavir (colored) with AB2 (grey) to show 3D structural 
similarities.  
 
 
Other research with small molecule ligations have shown that the 1,4-substituted 
triazole serves as a more appropriate surrogate for the amide functionality over the 1,5-
substitution.  This can be exemplified by the research of Di Marzo and coworkers where the 
amide group was substituted with triazoles in the natural products of capsaicinoids, which 
interact with the vanilloid receptor TRPV1.  Both the 1,4- and 1,5- triazole substitutions were 
16 
 
made by the CuAAC reaction and ruthenium(II) catalyzed Huisgen cycloaddition (RuAAC), 
respectively.
51
  These derivatives were tested for biological activity and the 1,4-triazole 
containing capsaicinoid exhibited comparable efficacy at ~4-fold less activity as compared to 
capsaicin.  However, the 1,5-substituted triazole was found to be 10 to 20-fold less active 
compared to capsaicin.  The results demonstrated that 1) the 1,4-triazole serves as a better 
amide bond surrogate in this system and 2) the CuAAC reaction can be used to generate 
potent biologically active lead compounds.  Thus it was found that the 1,4-triazole is a better 
substitute for trans-peptide bonds, whereas 1,5-triazoles promote cis-peptide bonds.
 
The above examples highlight the use of the CuAAC reaction to first ligate small 
molecules as well as replace single amides susceptible to enzymatic degradation.  Longer 
chain sequences have been generated with the CuAAC reaction where the triazole units 
replace some or all amide bonds in a biomimetic oligomeric backbone.  Several groups have 
reported the synthesis of peptidotriazoles where peptide bonds and triazole units were 
alternated through the backbone in an (AB)n pattern
52
 as well as completely triazole 
backbone substituted polypeptide mimic
53
, termed triazolamers (Figure 1.11A).  Solution 
NMR analysis of these triazolamers, trimers and tetramers, suggests that they adopt an anti 
conformation, much like a beta-strand, preferentially over syn conformations (Figure 1.11B).  
In addition dipole-dipole interactions between neighboring triazole rings are postulated to 
stabilize these conformations.  Because proteases are known to have substrates in a β-strand 
conformation, the protease resistance conferred by triazole moieties could be tested.  
Screening of a small library of such triazolamers led to the discovery of HIV-1 protease 
inhibitors.
53c 
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Figure 1.11  Triazolamer structures.  (A) Structure of a typical triazolamer.  (B) Possible anti 
and syn conformations for a peptide triazolamer.  Anti conformations are approximately 4 
kcal/mol more stable than syn conformers. 
 
 
Single insertions of triazole motifs into structured peptides, including alpha-helices 
and beta-sheets, have been accomplished by several researchers.  Perhaps the most noted 
example of the 1,4-triazole moiety in alpha helices is the modification of GCN4, a well-
characterized α-helical peptide known to form coiled-coil bundles.  In this work Ghadiri and 
coworkers replaced a dipeptide in various positions along the backbone of the helix with a 
unit containing the triazole to determine the influence on helix formation.
54
  Circular 
dichroism studies showed that the peptides retained substantial α-helical character in the 
presence of the substitution when they were placed near the termini rather than in the core of 
the helix.  In some of the cases, interestingly an unusual right-handed interhelical crossover 
structure was observed such that the helix formed by one strand was completed by residues 
in the other strand participating in the coiled-coil tetramer in a “slip-pairing” manner.  
Interchain interactions consisting of backbone hydrogen bonding involving the N
2
 atom of 
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the triazole moiety with an amide NH group as well as the triazole proton with backbone 
carbonyl groups was observed.  Recently, Klaveness and Bong have also used the CuAAC 
reaction to stabilize 3,10-helices
55
 and α-helices.56 
The CuAAC reaction in peptidomimetics has been widely applied to 
macrocyclizations and turn mimetics.  However, it has often been reported that the major 
product observed from these reactions was a macrocyclic dimer with little to no macrocyclic 
monomer.
57
  This was initially met with disappointment however, researchers have used this 
to their advantage and have been able to synthesize cyclic ditriazole peptides to be used for 
organized nanotube structures
58
 and generate large libraries of ditriazole and monotriazole 
containing peptides.
59
  Studies using γ-peptides or peptoids conclude that a critical density of 
hydrogen bond networks between two adjacent peptide chains is responsible for positioning 
the reactive groups in an antiparallel fashion thus facilitating the cyclodimerization.
60
  
Presumably the cyclodimerization can be overcome by incorporating turn promoting 
sequences such that the intrastrand azide and alkyne are proximal to each other than with 
those on another strand.  The CuAAC has additionally been used as a turn mimetic by 
reacting two strands each with either a terminal azide or alkyne, as seen in the research by 
Guan and coworkers.
61
  In this work, intermolecular CuAAC produced a β-turn confirmed by 
NOEs between strands. 
 Most recently, Holland-Nell and Meldal have successfully replaced two native 
disulfide bridges in tachylepsin-I (TP-I), a 17-residue bicyclic peptide possessing 
antimicrobial activity, with triazoles (Figure 1.12).
62
  The first two cysteines, Cys3 and Cys7, 
were replaced with propargylglycine, and Cys12 and Cys16 were replaced with either 5-
azido-norvaline or 2-amino-4-azido-butyric acid.  CuAAC cyclization of these mutants led  
19 
 
 
 
Figure 1.12  Tachylepsin I 1,4-triazole substitution.  Scheme for the substitution of 1,4-
triazole for disulfide linkages in the antimicrobial peptide, tachylepsin-I.  The CuAAC 
reaction yields both misfolded and properly folded analogues.  Propargylglycine was used as 
the alkyne and either the diaminopropionioc and diaminobutyric acid derived as the terminal 
azides. 
 
 
to two different structures: a misfolded and properly folded β-hairpin, as seen in the native 
TP-I, peptide.  The properly folded bicyclic analogues exhibited comparable biological 
activity to the native TP-I peptide while the misfolded and linear peptides did not possess 
antimicrobial activity.  Solution phase NMR structures confirmed the active peptides were a 
close mimic of TP-I.  This work demonstrates that triazoles can be approximate mimics of 
disulfide bridges in peptides.  All the aforementioned examples validate that the 1,4-triazole 
furnished by the CuAAC reaction is a viable method for introducing orthogonality to peptide 
systems.  
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D.  Structural characterization 
 The two main techniques used to characterize the structure of the peptides in this 
work were circular dichroism (CD) and 1D and 2D NMR.  Since CD and NMR are used 
extensively throughout this thesis a brief explanation of these methods is warranted 
(additional details are provided in the experimental sections).  Circular dichroism measures 
difference in the absorption of left-handed versus right-handed polarized light and is used to 
study optically active chiral molecules.  Thus CD can be used to ascertain information about 
protein/peptide secondary structure as the building blocks, the amino acids, are chiral.  In 
CD, the β-sheet structure is commonly characterized by a global minimum between 210 nm 
and 215 nm with a corresponding maximum at 195 nm.  A random coil peptide is expected to 
have a global minimum at 195 nm.  While CD is a good method for the approximation of 
global peptide secondary structure, additional details gained by NMR are required for full 
characterization. 
The 
1
H NMR spectra of β-sheet/β-hairpin peptides are typically well dispersed 
making analysis by conventional 1D and 2D NMR techniques possible.  A number of NMR 
methods are used to confirm β-hairpin structure and quantify β-hairpin stability.  The Hα 
chemical shifts of amino acids relative to random coil values obtained through 2D TOCSY 
NMR is a common method to confirm β-hairpin structure (Figure 1.13A).  Relative 
downfield shifts of greater than 0.1 ppm are consistent with β-hairpin formation (Figure 
1.14A).
63
  Extensive downfield shifting of the amide proton relative to random coil values is 
also observed at the residues where cross-strand hydrogen bonding is occurring in 
antiparallel β-sheets.   
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Figure 1.13  Representation of NMR control peptides.  (A)  Example of unstructured 
peptides used to obtain random coil chemical shifts.  (B) Example of a fully folded control β-
hairpin cyclized via disulfide bond between terminal Cys residues (orange).  The 
diastereotpic glycine protons (blue) are also used to calculate fraction folded. 
   
The chemical shift of the glycine protons in the turn sequence is also indicative of β-
hairpin formation at the residues near the turn.
64
  The Hα’s at this glycine are diastereotopic 
thus their chemical shifts differ significantly in β-hairpin structures (Figure 1.14B).  The 
more well-folded a β-hairpin is the greater the splitting between the two glycine protons.  In 
order to determine fraction folded, the glycine splitting of a β-hairpin is compared to a 
disulfide cyclized control peptide (Figure 1.13B) which is considered to be fully folded.
65
   
Folding has been found to be two state,
66
 thus fraction folded defines the relative population 
of β-hairpin versus the unfolded state.  This is quantifiable since folding is fast on the NMR 
timescale so the Hα’s are an average of the two populations.66  Fraction folded can also be 
calculated on a per residue basis where the Hα chemical shifts are compared to the fully 
folded and random coil peptides.  The Hα of the residues at the HB positions are the most 
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accurate way to calculate overall fraction folded as they have minimal contacts with cross-
strand residues which can influence the chemical shift.
65
   
 
A 
 
 
B  
 
 
Figure 1.14  Representation of NMR data for β-hairpin peptides.  (A) Example of Hα shifts a 
12 residue β-hairpin peptide with a Type II’ dPro-Gly turn.  Hydrogen bonded residues are 
highlighted with red squares.  (C) Example of Gly splitting observed from a Type I’ Asn-Gly 
turn.  
 
 
 Proximity between residues on opposite strands can be determined from the 2D 
through space NMR technique, NOESY.  Additionally, data from NOESY spectra will also 
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confirm the folded state as well as correct strand registry.  One must be careful when 
interpreting NOE spectra as either a lack of NOEs represents a poorly folded β-hairpin or a 
well-folded but highly dynamic hairpin structure.  Most well folded β-hairpins will display at 
the least critical NOEs that are present between HB residues which confirm correct cross-
strand registries, but not always show an overabundance in aqueous solution.  NMR is an 
established method to analyze formation of β-hairpin structure and can provide minute 
details. 
E.  Conclusions 
The purpose of the work presented here is two-fold: to present 1) the de novo design 
of a preorganized three stranded β-sheet as a minimalistic model system of an OB-fold for 
the recognition of ssDNA and 2) a method for β-hairpin cyclization to improve stability yet 
maintain functionality with the use of the CuAAC reaction.  β-sheet and β-hairpin structures 
are being found to be crucial in the recognition of oligonucleotides and at the interface of 
protein-protein interactions.  A more thorough understanding of how these interactions occur 
in minimal models will shed light on the specific function of the domains participating in the 
recognition motif.  This work also aims to improve the understanding of the drive forces 
behind β-sheet and β-hairpin structure stabilization, which will be useful in the development 
of novel systems for disruption of protein-nucleotide and protein-protein interactions. 
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 CHAPTER II 
DE NOVO DESIGN OF A THREE-STRANDED β-SHEET PEPTIDE  
FOR RECOGNITION OF ssDNA 
A.  Background and significance 
 There has been much research into elucidating the mechanism by which proteins 
interact with double-stranded DNA;
1
 however, there has been less focus in understanding 
protein interactions with single-stranded DNA.  To this end, our laboratory has designed 
several β-hairpin and β-sheet systems as minimalistic models of the oligosaccharide/ 
oligonucleotide binding motif (OB-fold) to probe protein interactions with ssDNA.
2
  A 
peptide dimer, (WKWK)2, composed of two identical well-folded β-hairpins has previously 
been found to bind ssDNA with a Kd of 3 µM.
2a
  This recognition event was achieved via 
aromatic interactions with two diagonal Trp residues cross-strand combined with electrostatic 
interactions with two Lys residues on the same face of the β-hairpin.  The Kd of (WKWK)2 is 
comparable to that of the native cold shock protein A (CspA), which contains a single OB-
fold and binds ssDNA with a Kd of 6 µM.
3
  (WKWK)2 is able to mimic the OB-fold through 
a combination of aromatic and electrostatic interactions provided by the Trp and Lys residues 
at the surface of the β-sheet to bind the unpaired bases in ssDNA.   
In addition to binding ssDNA with low micromolar affinity, it was found that 
(WKWK)2 was also able to bind dsDNA with similar affinity as ssDNA, primarily through 
electrostatic interactions.  Structure-function studies of this system demonstrated that there 
were additional differences in the mechanism of binding to ss- and ds-DNA.
4
  In particular, 
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these studies indicated that binding to dsDNA appeared to occur through a groove binding 
mechanism.  Thus, it was hypothesized that addition of a third strand to the WKWK 
monomer would inhibit dsDNA recognition via groove binding while maintaining and 
possibly enhancing affinity for ssDNA.  For this purpose, a three-stranded β-sheet was 
designed, based on the FBP11 (formin binding protein 11) WW1 domain peptide, to bind 
ssDNA.
2b
  WW domains are three-stranded β-sheet mini proteins characterized by their 
conserved tryptophan residues, which are often used in recognition of polyproline helices 
(Figure 2.1A).
6
  The redesign of the WW domain involved grafting on the WKWK motif 
(Figure 2.1B) and incorporation of the type I’ turn sequence, VNGO.  This new peptide, 
Mut1, was found to bind ssDNA with a Kd of 20 µM and dsDNA with a Kd of 190 µM.  The 
dissociation constant of WKWK alone to the same strand of ssDNA was found to be 40 µM.  
Further mutation studies of Mut1 demonstrated that the third strand allowed for additional 
stabilizing contacts with the ssDNA.  Though the affinity of Mut1 for ssDNA was less than 
the (WKWK)2 peptide, it exhibited 20-fold selectivity for ssDNA over dsDNA.   
 
A B 
 
 
Figure 2.1  (A) Crystal structure of FBP11 bound to the native polyproline ligand, PPLP 
(PDB: 2DYF).  (B) Structure of Mut1, redesigned from the FBP11 WW1 domain peptide by 
grafting on the WKWK motif (blue).  
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 From these examples, it was confirmed that addition of a third strand was necessary 
to inhibit the recognition of dsDNA.  The decrease in affinity of ssDNA by Mut1 could be 
attributed to the lack of a second binding site as is available in (WKWK)2.  This led to a de 
novo designed three-stranded β-sheet that introduced a third strand to WKWK to incorporate 
another potential binding pocket.  The new β-sheet peptide, S123, was found to bind ssDNA 
with a Kd of 170 nM, which is a marked improvement over both (WKWK)2 and Mut1.  
These model systems provide a method to reveal the factors which contribute to protein-
nucleic acid recognition. 
B.  System design 
A three-stranded β-sheet peptide, S123, was designed to incorporate the WKWK 
peptide to aid in recognition of ssDNA (Figure 2.2).  A third Trp and Lys residue were added 
via the third strand to provide an additional binding pocket for nucleobases.  Consistent with 
WKWK, the type I’ turn Asn-Gly turn sequence was used in hairpin 2 of S123 as this was 
shown to nucleate a favorable turn for binding ssDNA.  Two pairs of Cys residues were 
incorporated cross-strand from each other at residues 1/14 and 9/22 as points for disulfide 
cyclization, as it is known that disulfide cyclization enhances β-hairpin structure.5  The 
necessity for the disulfide cyclization will be expanded upon in Chapter III.  The Orn17 
residue was incorporated as part of the turn sequence and for additional charge.  Tyr18 was 
incorporated to provide a potential cation-π interaction with the cross-strand Lys13.  The 
Leu20 included used for its high β-sheet propensity and to aid in hydrophobic packing with 
the cross-strand Ile11.   
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oligo1: 5’- C C A T C G C T A C C - 3' 
 
Figure 2.2  Structure of S123 containting the WKWK motif (blue), the addition of a Trp and 
Lys for ssDNA recognition (green) and two pairs of cross-strand Cys for disulfide cyclization 
(red).  Sequence for the ssDNA, oligo1 is shown. 
 
 
For comparison, four peptides were also synthesized: S12, S23, S12C, and S23C 
(Figure 2.3), as controls to investigate the contribution of each turn to structure.  S12 and S23 
are the individual hairpins that compose the β-sheet: strands 1/2 and strands 2/3; while S12C 
and S23C are the disulfide cyclized versions.  Several other mutants were designed to further 
understand and characterize the interaction between peptide and ssDNA, which will be 
discussed in Chapter III. 
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A B 
  
C D 
  
Figure 2.3  Structures of (A) S12, (B) S23, (C) S12C, (D) S23C. 
 
C.  Structural characterization 
 S123 was characterized by circular dichroism and NMR, as previously described in 
Chapter I, to understand the impacts structure has on binding affinity.  The structures of S12, 
S23, S12C, and S23C were used as controls to elucidate the impact of the third strand to the 
WKWK peptide.  The CD spectrum of S12 confirmed that this peptide adopts a β-hairpin 
conformation as evidenced by a minimum at 210 nm with a modest maximum around 190 
nm and a slight peak at 230 nm arising from exciton coupling between aromatic residues 
(Figure 2.4A).  As expected, S12C displayed a similar spectrum to S12 with the exception of  
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B 
 
Figure 2.4  (A) Circular dichroism spectra for S123 (red), S12 (black), S12C (grey), S23 
(blue), and S23oC (light blue) at 40-60 µM in 10 mM sodium phosphate buffer, pH 7.5 at 
298K.  (B) Hα chemical shift differences for S123 (red), S12 (black), S12C (grey), S23 
(blue), and S23C (light blue) from random coil peptides.  Values calculated from data 
obtained at 293 K in 50 mM potassium phosphate-d2, pD 7.0 (uncorrected).  The Gly bars 
reflect the glycine splitting. 
 
a more intense minimum.  S23 exhibited two minima at 215 nm and 195 nm indicative of 
both β-hairpin and random coil formation with the latter being far more pronounced.  
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Disulfide cyclization of S23 moderately stabilized β-hairpin formation as evidenced by the 
increase in intensity at 208 nm.  The CD spectrum of the full β-sheet, S123, displayed the 
most intense minimum at 210 nm with a corresponding maximum at 190 nm, indicative of β-
sheet formation.  These data suggest that all three strands are necessary for the observed 
structure, as the WKWK motif stabilizes the third strand to give an overall β-sheet 
conformation. 
The Hα chemical shift differences of all the peptides agreed with the data obtained by 
circular dichroism (Figure 2.4B).  It was determined that cyclization of both S12 and S23 
yielded more well-folded β-hairpins as evidenced by the increase in the extent of downfield 
shifting.  The Hα chemical shifts were further downfield in strand 3 of S123 as compared to 
S23 and were comparable to the shifts observed for S23C.  A similar trend was observed in 
the NMR of S123 where the Hα chemical shifts of hairpin 1 were comparable to those of 
S12C.  The glycine splitting values are also in agreement with the CD data (Table 2.1).  It 
was observed that the S123 hairpin structure was only slightly perturbed as compared to each 
individual fully cyclized β-hairpins.  However, the overall structure was still maintained with 
each hairpin exhibiting a fraction folded of 0.91 based on the glycine splitting.  These data 
demonstrate that addition of the third strand to WKWK did not disrupt global folding and 
enhanced the overall β-sheet structure.  Moreover, they indicate that the correct disulfides 
spontaneously form which was confirmed by the cross-strand NOEs observed between the 
Hα protons of the disulfide pairs and Trp3/ Lys12 (see experimental section).  This suggests 
that some degree of non-covalent interactions stabilizing the proper conformation is present 
prior to oxidation such that the disulfide pairing occurs. 
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Table 2.1  Fraction folded for β-hairpin controls and S123* 
 
Glycine Splitting Fraction Folded 
Peptide Hairpin 1 Hairpin 2 Hairpin 1 Hairpin 2 
S12C 0.75 -- -- -- 
S23C -- 0.67 -- -- 
S12 0.71 -- 0.95 -- 
S23 -- 0.12 -- 0.18 
S123 0.68 0.61 0.91 0.91 
*Concentration of peptides were at least 1 mM in 50 mM KD2PO4, 0.5 mM DSS, pH 7.0 
(uncorrected) at 298 K.  Error is ± 0.01 stemming from accuracy of peak assignments. 
 
 
D.  Characterization of the recognition of ssDNA by S123 
 i.  Binding of S123 to ssDNA 
Binding of the single-stranded DNA, oligo1, to S123 was ascertained by isothermal 
calorimetry (ITC), experimental details can be found in section F.  The dissociation constant 
was determined to be 170 nM to oligo1 (Figure 2.4), which is about 17-fold better than the 
(WKWK)2 peptide to the same ssDNA sequence.  From the data obtained by ITC, the free 
energy of binding between oligo1 and S123 was calculated to be -9.3 kcal/mol, whereas the 
free energy of binding for the (WKWK)2 to oligo1 was determined to be -7.5 kcal/mol.  
These data suggest that Trp19 is participating in the recognition event by providing an extra 
aromatic pocket with Trp10 for interaction with the nucleobases or that there are other 
contributing factors to the mode of recognition.  Addition of the third strand to WKWK 
dramatically improved binding affinity for oligo1 compared to (WKWK)2, as was 
hypothesized. 
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Figure 2.5  Example of a binding isotherm obtained from ITC experiment with ssDNA (150 
µM) titrated in to S123 (40 µM) at 298K in 10 mM sodium phosphate, 100 mM NaCl, pH 
7.5.  The association constant was found to be 5.09 x 10
6
 M, enthalpy was -1.2 x 10
4
 cal/mol, 
entropy was -8.7 cal/mol·K.  The ssDNA sequence is 5’-CCATCGCTACC-3’. 
 
Several differences between S123 and (WKWK)2 should be noted including the net 
charge and binding stoichiometry.  The net charge of S123 is +6; whereas (WKWK)2 has a 
net charge of +8.  This difference is important to consider as it was determined that 
electrostatic interactions contributed to the binding event between (WKWK)2 and oligo1.  
The decrease in net charge coupled with the 10-fold increase in binding affinity for oligo1 by 
S123 suggests that there are additional contacts favorable for binding and that perhaps 
binding is cooperative.  Further discussion of this hypothesis will be presented in Chapter III.  
A second significant difference between S123 and (WKWK)2, as well as Mut1, was the 
binding stoichiometry which determined by ITC to be between 1:3 and 1:2 oligo1 to peptide. 
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In both (WKWK)2 and Mut1, the binding stoichiometry was found to be 1:1 suggesting that 
perhaps S123 is more structured than either (WKWK)2 or Mut1 allowing the ssDNA to 
accommodate more peptides.  These results demonstrate that addition of an extra binding 
pocket via a third strand to WKWK was successful in enhancing the affinity for ssDNA. 
 As S123 was found to have a binding stoichiometry for 1:3 DNA to peptide with a 
11-mer oligonucletodie, further investigation on the minimal length of recognition of DNA 
by S123 is warranted.  This is of particular biological interest as Replication Protein A 
(RPA), a protein implicated in replication and repair, binds ssDNA sequences of about 30 
nucleotides with subnanomolar affinity.
7a
  RPA is composed of 6 OB-fold domains of which 
only 4 are known to interact with ssDNA which averages to about 8 nucleotides per OB-fold, 
similar to the minimal length of DNA for recognition by S123.  Additionally, similar protein-
ssDNA interactions are known to be implicated in telomere maintenance such as Cdc13.
8
  
The recognition of telomeric ssDNA by telomeric binding proteins is controlled by the length 
of the telomere.  In normal cells, the telomere is shortened at each cell division and 
eventually becomes truncated such that telomere protecting proteins can no longer recognize 
the ssDNA thereby leading to cell senescence and apoptosis.  This has the effect of keeping 
the total cell count in equilibirum.
7
  However, in cancer cells it has been found that telomere 
shortening can also cause chromosomal instability which further progresses the cancer.
9
  
Whereas the checkpoint signaling protects against tumor formation, increased genetic 
instability is likely to speed up the tumorigenic process.  Thus methods of stabilizing the 
short strands of ssDNA could be a viable method to inhibit tumor growth.  
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E.  Conclusions 
 Introduction of a second binding pocket to WKWK via the incorporation of a third 
strand was a successful method in developing a minimalistic model of the OB-fold domain.  
This new peptide, S123, was found to bind ssDNA with low nanomolar affinity.  The free 
energy differences between (WKWK)2 and S123 binding with ssDNA confirmed that the 
addition of the extra Trp and Lys was indeed utilized in the recognition event.  Furthermore, 
the binding stoichiometry could prove useful in understanding the mechanism by which 
native OB-fold containing proteins interact with ssDNA.  This model system provides a 
conceptual mimic of the OB-fold and provides insight into the mechanism of the high affinity 
of these proteins for ssDNA. 
F.  Experimental section 
i.  Peptide synthesis and purification 
Peptides were synthesized by automated solid-phase peptide synthesis on a Thuramed 
Tetras peptide synthesizer using Fmoc-protected amino acids on CLEAR-amide resin 
purchased from Peptides International.  All natural Fmoc-[N]-protected amino acids were 
purchased from Advanced Chem Tech.  Activation of amino acids was performed with 
HBTU (5 eq) and HOBt (5 eq) in the presence of DIPEA (5 eq) in DMF and NMP.  Peptide 
deprotection was carried out in 2% DBU and 2% piperidine in DMF for 2 cycles of 
approximately 15 min each.  Each coupling step was performed twice for approximately 30 
min.  All peptides were acetylated at the N-terminus with 5% acetic anhydride and 6% 2,6-
lutidine in DMF for 35 min.  Cleavage of the peptide from the resin was performed in 
95:2.5:2.5 TFA:TIPS:H2O for 3 h.  For peptides containing cysteine 94:2.5:2.5:1 TFA:EDT: 
H2O:TIPS was used.  TFA was evaporated and cleavage products were precipitated with cold 
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diethyl ether.  The peptide was extracted into water and lyophilized.  It was then purified by 
RP-HPLC using an Atlantis C-18 semi-preparative column and a gradient of 0 to 100% B 
over 45 min or 60 min, where solvent A was 95:5 water:acetonitrile with 0.1% TFA and 
solvent B was 95:5 acetonitrile: water with 0.1% TFA.  After purification, the peptide was 
lyophilized to a powder and identified with ESI-TOF mass spectroscopy. 
ii.  Cyclization of cysteine containing peptides 
 Peptides were cyclized by oxidizing the cysteine residues at the termini via stirring in 
a 10 mM phosphate buffer (pH 7.5) in 1% DMSO solution for 8 to 12 hours.  Cyclization of 
S123 required high dilution conditions to inhibit dimer formation.  The solution was then 
lyophilized to a powder and purified by RP-HPLC using the method described above. 
 iii.  DNA 
All DNA sequences were purchased from Integrated DNA Technologies with 
standard desalting.  Concentrations of the DNA strands were determined by UV-Vis using 
the extinction coefficient at 260 nm (ε260, 20 A = 243400 M
-1 
cm
-1
, ε260, 15 A = 183400 M
-1 
cm
-1
, 
ε260, 10 A = 147400 M
-1 
cm
-1
, ε260, 9 A = 111400 M
-1 
cm
-1
, ε260, 7 A = 87400 M
-1 
cm
-1
, ε260, 5 A = 
63400 M
-1 
cm
-1, ε260, ssDNA = 95500 M
-1 
cm
-1, ε260, csDNA = 112600 M
-1 
cm
-1
). 
iv.  Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) measurements were carried out at 25.0 °C with 
a VP-ITC MicroCal titration calorimeter.  All peptide and DNA samples were prepared in 
10mM sodium phosphate, 100mM NaCl, at pH 7.5.  The concentration of peptides was 40 
µM and ssDNA was 150 µM.  Concentrations of peptides were determined by UV-Vis after 
DTT and Gdn·HCl denaturation using the extinction coefficients for Trp and Tyr at 280 nm 
(ε280, Trp  = 5690 M
-1 
cm
-1
, ε280, Tyr  = 1170 M
-1 
cm
-1
).  The reference power was set to 10.  A 
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total of 25 injections of ssDNA into S123 were made: one 3 µL, ten 7 µL, ten 10 µL, and 
four 20 µL injections.  All data was processed on the Origin software and the plot was fit 
with the OneSites model.   
v.  Circular dichroism 
CD spectroscopy was performed on an Applied Photophysics Chirscan Plus using 
peptide concentrations between 40-60 μM in 10 mM sodium phosphate buffer, pH 7.5.  
Peptide concentrations were determined by UV-Vis using the extinction coefficients of Trp at 
280 nm (ε280, Trp = 5690 M
-1 
cm
-1
).  Spectra were collected from 260 to 185 nm at 0.5 nm 
intervals at 25 °C.   
vi.  NMR characterization 
 NMR samples were made to a concentration of at least 1mM in D2O buffered to pD 
7.0 (uncorrected) with 50 mM KPO4D2, 0.5mM DSS.  Samples were analyzed on a Varian 
Inova 600-MHz instrument.  One dimensional spectra were collected using 32K data points 
and between 8 and 36 scans using 1.5 s presaturation.  Two dimensional total correlation 
spectroscopy (TOCSY) and nuclear Overhauser spectroscopy (NOESY) were carried out 
using the pulse sequences from the Chempack software.  Scans in the TOCSY experiment 
were taken from 16 to 32 in the first dimension and from 64 to 128 in the second dimension.   
Scans in the NOESY experiments were taken from 32 to 64 in the first dimension and from 
128 to 512 in the second dimension with mixing times of 200-500 ms.  All spectra were 
analyzed using standard window functions (sinbell and Gaussian with shifting).  
Presaturation was used to suppress the water resonance.  Assignments were made by using 
standard methods as described by Wüthrich.
10
  All experiments were run at 298 K. 
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vii.  Determination of fraction folded 
To determine the unfolded chemical shifts, 6-mers were synthesized as unstructured controls 
and cyclic peptides for fully folded controls.  The chemical shifts for residues in the strand 
and one turn residue were obtained from each 6-mer peptide.  The chemical shifts of the fully 
folded state were obtained from disulfide cyclized peptides.  The overall fraction folded was 
determined using the extent of Hα glycine splitting observed in the glycines at the turns given 
in Equation 1: 
Fraction Folded   
         
         
               
where ΔδGly obs is the difference in the glycine Hα chemical shifts of the peptide of interest 
and ΔδGly 100 is the difference in the glycine Hα chemical shifts of the cyclic control peptide.   
 
 
Figure 2.6  Unambiguous NOEs (blue) for S123. 
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Figure 2.7  1H NMR spectrum for Strand 1: Ac-Cys-Arg-Trp-Val-Lys-Val-Asn-NH2 
 
 
Table 2.2  Hα chemical shift assignments (ppm) for Strand 1 
  Hα 
C 4.68 
R 4.26 
W 4.75 
V 4.13 
K 4.22 
V 4.02 
N 4.34 
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Figure 2.8  1H NMR spectrum for Strand 2: Ac-Gly-Cys-Trp-Ile-Lys-Lys-Cys-Asn-NH2 
 
 
Table 2.3  Hα chemical shift assignments (ppm) for Strand 2 
  Hα 
G 3.81 
C 4.70 
W 4.71 
I 4.01 
K 4.29 
K 4.19 
C 4.48 
N 4.41 
 
 
PPM 8.4 8.0 7.6 7.2 6.8 6.4 6.0 5.6 5.2 4.8 4.4 4.0 3.6 3.2 2.8 2.4 2.0 1.6 1.2 0.8 0.4 0.0 -0.4
p p
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Figure 2.9  1H NMR spectrum for Strand 3: Ac-Gly-Orn-Tyr-Trp-Leu-Lys-Cys-NH2 
 
 
Table 2.4  Hα chemical shift assignments (ppm) for Strand 3 
  Hα 
G 3.84 
O 4.14 
Y 4.60 
W 4.46 
L 4.31 
K 4.20 
C 4.44 
 
 
PPM 8.4 8.0 7.6 7.2 6.8 6.4 6.0 5.6 5.2 4.8 4.4 4.0 3.6 3.2 2.8 2.4 2.0 1.6 1.2 0.8 0.4 0.0 -0.4
p p
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Figure 2.10  1H NMR spectrum for S12C: Ac-Cys-Arg-Trp-Val-Lys-Val-Asn-Gly-Orn-Trp-
Ile-Lys-Lys-Cys-NH2 
 
 
Table 2.5  Proton chemical shift assignments (ppm) for S12C 
  α β γ δ ε 
C 5.08 3.45, 3.12 
R 4.72 1.96 1.74 3.09 
W 5.37 3.26, 3.02 
V 4.77 2.06 0.94 
K 4.07 1.26, 1.21 0.16, 0.23 0.59 2.58 
V 4.14 1.87 0.88 
N 4.36 3.08, 2.75 
G* 0.75 
O 4.71 1.87 1.59 3.24 
W 5.22 3.02, 2.36 
I 4.78 1.96 1.47, 1.25 0.94 (γ, CH3) 0.87 (δ, CH3) 
K 4.36 1.15, 1.05 0.18 0.42 2.30 
K 4.58 1.82 1.39, 1.32 1.63 2.92 
C 5.09 3.01       
* Glycine splitting value 
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Figure 2.11  1H NMR spectrum for S12: Ac-Arg-Trp-Val-Lys-Val-Asn-Gly-Orn-Trp-Ile-
Lys-Lys-NH2 
 
 
Table 2.6  Proton chemical shift assignments (ppm) for S12 
  α β γ δ ε 
R 4.36 1.83, 1.68 1.44 2.97 
W 5.31 3.35, 3.09 
V 4.77 2.11 0.98 
K 4.42 1.28, 1.13 0.01 0.52 2.39 
V 4.20 1.93 0.93 
N 4.43 3.13, 2.79 
G* 0.71 
O 4.74 1.98 1.81 3.12 
W 5.11 3.26, 3.13 
I 4.80 1.99 1.51, 1.27 0.99 (γ, CH3) 0.90 (δ, CH3) 
K 4.10 1.3 0.48, 0.36 0.64 2.63 
K 4.32 1.84 1.49 1.74 3.02 
* Glycine splitting value 
 
PPM 8.4 8.0 7.6 7.2 6.8 6.4 6.0 5.6 5.2 4.8 4.4 4.0 3.6 3.2 2.8 2.4 2.0 1.6 1.2 0.8 0.4 0.0 -0.4
p g
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Figure 2.12  1H NMR spectrum for S23C: Ac-Cys-Trp-Ile-Lys-Lys-Val-Asn-Gly-Orn-Tyr-
Trp-Leu-Lys-Cys-NH2 
 
 
Table 2.7  Proton chemical shift assignments (ppm) for S23C 
  α β γ δ ε 
C 5.04 3.09 
W 4.95 3.33 
I 4.31 2.19 0.99 (γ, CH3) 0.89 (δ, CH3) 
K 4.26 1.73 0.75, 0.50 0.97 
K 4.36 2.25 
V 4.57 2.27 0.94 
N 4.49 3.14, 2.86 
G* 0.67 
O 4.96 1.97 1.77, 1.60 2.86 
Y 4.82 2.88 
W 4.94 3.07 
L 4.46 2.27 0.97 
K 4.40 1.84 1.05, 0.96 1.64 3.04 
C 5.07 3.04       
* Glycine splitting value 
 
PPM 8.4 8.0 7.6 7.2 6.8 6.4 6.0 5.6 5.2 4.8 4.4 4.0 3.6 3.2 2.8 2.4 2.0 1.6 1.2 0.8 0.4 0.0 -0.4
p g
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Figure 2.13  1H NMR spectrum for S23: Ac-Orn-Trp-Ile-Lys-Lys-Val-Asn-Gly-Orn-Tyr-
Trp-Leu-Lys-Gln-NH2 
 
 
 
Table 2.8  Proton chemical shift assignments (ppm) for S23 
  α β γ δ ε 
O 4.23 1.59 1.45 2.88 
W 4.73 3.22 
I 4.11 1.73 1.34, 1.02 0.82 (γ, CH3) 0.79 (δ, CH3) 
K 4.12 1.71, 1.63 1.34 2.93 
K 4.18 1.61 2.91 
V 4.05 2.02 0.88 
N 4.66 2.84 
G* 0.12 
O 4.36 1.71, 1.56 1.32, 1.24 2.83 
Y 4.61 2.91 
W 4.65 3.18 
L 4.23 1.59 1.30 0.78 
K 4.20 1.73 1.3 2.90 
Q 4.26 2.08, 1.94 2.31     
* Glycine splitting value 
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Figure 2.14  1H NMR spectrum for S123: Ac-Cys-Arg-Trp-Val-Lys-Val-Asn-Gly-Cys-Trp-
Ile-Lys-Lys-Cys-Asn-Gly-Orn-Tyr-Trp-Leu-Lys-Cys-NH2 
 
 
Table 2.9  Proton chemical shift assignments (ppm) for S123 
  α β γ δ ε 
C 5.23 3.31, 3.07 
R 4.42 1.79 1.58 3.23 
W 5.57 3.16, 2.77 
V 4.58 2.06 1.05 
K 5.17 1.55 2.33 
V 4.18 1.96 0.91 
N 4.26 3.06, 2.81 
G* 0.68 
C 5.26 3.33, 3.01 
W 5.50 3.46, 2.92 
I 4.65 2.13 1.04  (CH3) 
K 5.25 1.32 0.54, 0.42 1.84 3.35 
K 4.62 2.11 1.58 1.84 3.23 
C 5.16 3.30, 3.00 
N 4.43 3.09, 2.80 
G* 0.61 
O 4.73 1.73 1.61 2.82 
Y 4.97 3.13, 2.86 
W 4.90 2.89, 2.70 
L 5.95 1.94 1.18 
K 4.53 1.87 1.58 1.74 3.22 
C 5.09 3.30, 3.06       
* Glycine splitting value 
PPM 9.0 8.0 7.0 6.0 5.0 4.0 3.0 2.0 1.0 0.0
p p p
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 CHAPTER III 
MUTANTS OF S123 TO UNDERSTAND NECESSARY MOTIFS  
FOR ssDNA RECOGNITION 
 
 
A.  Introduction 
 The marked increase in affinity for ssDNA by S123 led to the design of several 
mutants in order to investigate the origins of the nanomolar affinity.  Of particular interest 
were the use of Cys residues for disulfide cyclization and the contributions from Trp19.  It 
was proposed that the preorganization of hairpin 2 would impact the affinity for ssDNA more 
than the cyclization of hairpin 1 as it was determined that hairpin 1 is well-folded without 
modification (Chapter II).  It was previously shown that addition of a binding pocket to 
WKWK via formation of a dimer improved the affinity for ssDNA, as observed in the 
difference of the dissociation constants of WKWK and (WKWK)2, 40 µM
1
 and 3 µM.
2
  Thus 
we sought to understand if Trp19 in S123 played a role in providing an additional binding 
pocket.  These studies provide insight into the mode of binding of S123 to ssDNA. 
B.  Mutant designs 
To investigate the nanomolar affinity of S123 several mutants were designed to assess 
the importance of structural preorganization (Figure 3.1, Table 3.1).  The first peptide, 
Parent, contained no cysteines in order to evaluate how the addition of the third strand to 
WKWK affected folding and binding.  In this system, Cys1 was deleted to give Arg2 as the 
new N-terminal residue.  In addition, Cys9 was mutated to an Orn as it is favorable in the i+4 
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position of a type I’ turn.  Finally, Cys14 substituted with a Val as it is also favorable for the 
type I’ turn and Cys22 was mutated to a Gln, as Gln is the C-terminal residues in WKWK.   
S123C1 and S123C2 were constructed to probe which hairpin cyclization was crucial 
in S123 for recognition of ssDNA. In S123C1, Cys9 and Cys22 were mutated to Orn9 and 
Gln22 thereby removing the ability for cyclization of the second hairpin.  In S123C2, Cys1 
was removed and Cys14 was mutated to Val14 to inhibit cyclization of the first hairpin.  In 
S123-YKswitch, the position of Lys13 and Tyr18 were reversed from S123 to determine if a 
favorable cation-π-cation interaction between Arg2, Tyr13, and Lys18 would be promoted 
thereby increasing the β-sheet structure and the binding affinity for ssDNA.  It was 
hypothesized that Trp19 aided in the formation of a second binding pocket with Trp10.  Thus 
the peptide S123-W19L was synthesized in which Trp19 was mutated to a Leu which 
possesses a high β-sheet propensity, thereby not drastically altering the structure of the 
peptide.
2 
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oligo1 sequence: 5’- C C A T C G C T A C C - 3' 
 
Figure 3.1  Cartoon representation of mutants used of S123.  Changes from S123 to mutant 
are depicted in the corresponding color in the full structure.  In S123-YKswitch the Tyr and 
Lys that are switched are highlighted in green.  In S123-W19L, the Trp that is mutated to a 
Leu is highlighted in blue.  The single stranded sequence, oligo1, for binding experiments is 
also shown. 
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Table 3.1  Sequences of mutants of S123 
Peptide Sequence* 
Parent Ac-RWVKVNGOWIKKVNGOYWLKQ-NH2 
S123C1 Ac-CRWVKVNGOWIKKCNGOYWLKQ-NH2 
S123C2 Ac-RWVKVNGCWIKKVNGOYWLKC-NH2 
S123-W19L Ac-CRWVKVNGCWIKKCNGOYLLKC-NH2 
S123-YKswitch Ac-CRWVKVNGCWIKYCNGOKWLKC-NH2 
*Differences from S123 are in bold 
 
C.  Characterization of mutant peptide-ssDNA interactions 
 i.  Importance of β-hairpin cyclizations 
 Previous structural studies on the individual hairpins (Chapter II) of S123 determined 
that hairpin 2 (S23/S23C) was less structured than hairpin 1 (S12/S12C) even upon disulfide 
cyclization.  Based on these results the investigation of the contribution of cyclization at each 
hairpin in the full β-sheet peptide on both structure and function was performed by use of the 
Parent, S123C1, and S123C2 peptides.  The affinity for the mutant peptides for ssDNA was 
assessed by ITC, experimental details can be found in the experimental section (Table 3.2).  
The Parent peptide was found to bind ssDNA with a dissociation constant of 4.6 µM and a 
free energy of binding of -7.3 kcal/mol.  The binding stoichiometry was determined to be 1:2 
DNA to peptide by ITC.  This data is similar to what was observed for the (WKWK)2 peptide 
with the exception of the stoichiometry.
3
  The observed difference in stoichiometry can be 
thought to be attributed to the overall shape of the peptides, as the two binding pockets of 
Parent are placed across three strands while in (WKWK)2 there is one binding pocket in 
each β-hairpin, totaling 4 strands, thus allowing only one (WKWK)2 to occupy the ssDNA.  
The ability of Parent to recognize ssDNA with the same binding affinity as (WKWK)2 
confirmed that  incorporation of a binding pocket via a third strand was an effective method 
to enhance the recognition event.   
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These results show that the affinity of Parent is about 25-fold worse for ssDNA than 
S123 indicating that the disulfide bonds play an important role in the binding event.  S123C1 
was used to investigate the impact of cyclization of the first hairpin.  The dissociation 
constant for S123C1 bound to ssDNA was determined to be 5.5 µM and the free energy of 
binding was calculated to be -7.3 kcal/mol, which is the same as Parent.  These data suggest 
that the cyclization of hairpin 1 had minimal impact on the ability of the peptide to bind 
ssDNA, consistent with the hypothesis as hairpin 1 is already well-folded.  When hairpin 2 
was cyclized in peptide S123C2, it was found that nanomolar affinity was reinstated to give a 
Kd of 270 nM, however this is still higher than S123.  In these mutants, improvements in 
binding affinity were mirrored by favorable enthalpic terms.  The enthalpic contribution to 
free energy was determined to be -5.0 kcal/mol for S123C1 and -4.5 kcal/mol for Parent.  
This data further suggests that hairpin 1 cyclization does not impact affinity.  Cyclization of  
 
Table 3.2  Parameters characterizing the mutant interactions with oligo1* 
Peptide 
Kd, obs 
µM 
ΔH°obs 
kcal/mol 
ΔS°obs 
cal/mol·K 
ΔG°obs 
kcal/mol 
DNA: 
Peptide 
S123 0.17 (± 0.02) -17 (± 0.5) -24 (± 0.5) -9.3 (± 0.5) 1:3 
Parent 4.6 (± 1.0) -4.5 (± 0.5) 9.5 (± 0.5) -7.3 (± 0.5) 1:2 
S123C1 5.5 (± 1.0) -5.0 (± 0.5) 7.3 (± 0.5) -7.3 (± 0.5) 1:2 
S123C2 0.27 (± 0.02) -14 (± 0.5) -16 (± 0.5) -9.0 (± 0.5) 1:2 
*oligo1 sequence: 5’- C C A T C G C T A C C - 3', data presented are an average of 2 or 3 
trials. 
 
 
hairpin 2, S123C, led to a favorable decrease in enthalpy, -14 kcal/mol, which is similar to 
what was observed for the S123 interaction with oligo1, -17 kcal/mol.  Interestingly, both 
S123 and S123C2 binding to oligo1 led to unfavorable entropic contributions at -24 and -16 
cal/mol·K; while, Parent and S123C1 binding to oligo1 were entropically favorable with a 
ΔS°obs of 9.5 and 7.3 cal/mol·K.  This finding is counterintuitive, as it was expected that 
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preorganization of the system would lead to favorable entropic terms (further discussion in 
section D).  Regardless, the interaction of S123 and S123C2 with oligo1 displayed greater 
ΔG°obs, -9.3 and -9.0 kcal/mol, due to the marked decrease in ΔH°obs.  Further studies into 
this system are warranted to understand the unfavorable observed entropy of binding for 
S123 with oligo1. 
Structural studies of the mutants were conducted to further support the hypothesis that 
cyclization of the two strands was critical to binding.  The circular dichroism spectra of 
Parent displayed two minima at 210 nm and 195 nm indicating both β-sheet and random coil 
formation with the latter being dominant (Figure 3.2A).  Comparison of the CD data and the 
Hα chemical shifts (Figure 3.2B) revealed that the third strand is far less folded than strands 
1 and 2.  This result is consistent with the poor folding observed of the individual hairpin, 
S23onlyC (Chapter II).  Disulfide cyclization of the first hairpin, S123C1, also displayed a 
mixture of β-sheet and random coil structures; however, it is clear from the CD data that 
cyclization stabilized β-sheet formation as compared to Parent.  The chemical shifts of 
S123C1 support this hypothesis as evidenced by the greater downfield shifts in both the N- 
and C- termini residues as compared to Parent.  Interestingly, by circular dichroism, 
selective cyclization of the second hairpin does not appear to stabilize the global β-sheet 
structure as the CD data displayed minima at 195 nm and 212 nm in equal intensities.  
However, the lack of β-sheet enhancement reflected in the CD spectra could be due to 
different interactions between the aromatic residues in S123C2 versus the other peptides as is 
evidenced by the slight red shift in the observed β-sheet minimum at 212 nm and exciton 
coupling peak at 230 nm.   
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The chemical shifts of S123C2 suggest that cyclization of hairpin 2 does slightly 
enhance the folding of the entire β-sheet as the residues in strand 3 exhibited similar 
downfield shifting as in S123.  This effect comes at the expense of some of the residues in 
strands 2 and 3 that were shifted upfield compared to Parent.  Comparison of the fraction 
folded of each hairpin in the β-sheet provides a simplified picture of how cyclization impacts 
the structure (Table 3.3).  Hairpin 1 of Parent was found to be 92% folded, while hairpin 2 
was only 16% folded.  Cyclization of the first hairpin improved the folding of hairpin 1 with 
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Figure 3.2  (A) Circular dichroism spectra for S123 (red), Parent (brown), S123C1 (purple), 
and S123C2 (green) at 40-60 µM in 10 mM sodium phosphate buffer, pH 7.5 at 298K.  (B) 
Hα chemical shift differences for S123 (red), Parent (brown), S123C1 (purple), and S123C2 
(green) from random coil peptides.  Values calculated from data obtained at 293 K in 50 mM 
potassium phosphate-d2, pD 7.0 (uncorrected).  The Gly bars reflect the glycine splitting. 
 
 
Table 3.3  Fraction folded for β-sheet mutants 
 
Glycine Splitting* Fraction Folded 
Peptide Hairpin 1 Hairpin 2 Hairpin 1 Hairpin 2 
S123 0.68 0.61 0.91 0.91 
Parent 0.69 0.11 0.92 0.16 
S123C1 0.77 0.14 1.03 0.21 
S123C2 0.60 0.51 0.80 0.76 
* Obtained from spectra taken of at least 1 mM peptide in 50 mM KD2PO4, pH 7.0 
(uncorrected) at 298 K. 
 
 
minimal improvement in hairpin 2 folding (21%).  When only the second hairpin was 
cyclized, it was found that the folding of hairpin 2 dramatically improved to 76% at the 
expense of the folding of hairpin 1 (80%).  These structural studies support the hypothesis 
that the disulfide cyclizations imparted a well-folded β-sheet structure to the system which is 
necessary for nanomolar binding. 
ii.  Importance of Trp19 
 To verify that the Trp19 participates in the formation of a second binding pocket with 
Trp10, the mutant S123-W19L was characterized.  In order to accurately probe the 
contributions of Trp19 to binding of ssDNA, it was necessary to determine that the mutation 
of Trp19 to Leu did not impact β-structure.  The circular dichroism spectrum of S123-W19L 
exhibited a minimum at 210 nm consistent with the minimum observed for S123 (Figure 
3.4).  The difference in intensity can be attributed to loss of an aromatic residue that can 
participate in aromatic interactions which gives rise to the exciton coupling peak that can 
60 
 
influence the observed intensity of the β-sheet minimum.  The CD data is consistent with 
retention of β-sheet structure is retained with the Trp19Leu mutation. 
 
 
Figure 3.4  Circular dichroism spectra for S123 (red) and S123-W19L (grey) at 40-60 µM in 
10 mM sodium phosphate buffer, pH 7.5 at 298K. 
 
 
 The binding interaction between S123-W19L and ssDNA was characterized by ITC.  
The dissociation constant was determined to be 2.7 µM and the binding free energy was -7.5 
kcal/mol (Figure 3.5).  Interestingly, although S123-W19L is missing a potential aromatic 
binding pocket, the magnitude of interaction energy and affinity mirrors that of (WKWK)2 
binding to ssDNA with the exception of the binding stoichiometry.
3
  The binding 
stoichiometry for S123-W19L was found to be 1:3 DNA to peptide.  This suggests that 
additional contacts in the peptide stabilize the interaction with ssDNA.  As the stoichiometry 
of binding for S123-W19L and  
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Figure 3.5  Example of a binding isotherm obtained from ITC experiment with ssDNA (300 
µM) titrated in to S123-W19L (40 µM) at 298K in 10 mM sodium phosphate, 100 mM 
NaCl, pH 7.5.  The association constant was found to be 4.5 x 10
5
 M, enthalpy was -1.3 x 10
4
 
cal/mol, entropy was -16 cal/mol·K.  The ssDNA sequence is 5’-CCATCGCTACC-3’. 
 
S123 were identical, direct comparisons of the thermodynamic parameters could be made.   
As previously discussed in Chapter II, the stacking of adenine between the diagonal 
Trp resides of WKWK is worth -1.8 kcal/mol.
4
  This value is consistent with the 
experimentally observed difference between S123-W19L and S123 confirming that Trp19 is 
indeed participating in the recognition of ssDNA by providing an extra binding pocket with 
Trp10.   
 iii.  Importance of residue location 
 In S123-YKswitch, the position of Tyr18 and Lys13 were reversed to potentially aide 
in the formation of a stabilizing cation-π-cation interaction between residues 2, 13, and 18 
thus further enhancing binding affinity.  While the residues 13 and 18 are not on the binding 
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face, they can still be substituted as an indirect method to probe the importance of sequence 
on structure and on binding.  Interestingly, the disulfide cyclization of S123-YKswitch 
resulted in two distinct β-sheet peptides, a properly folded and “misfolded” β-sheet (Figure 
3.6).  The circular dichroism spectrum of S123-YKswitch-A displayed a minimum at 210 
nm consistent with similar β-sheet formation as with S123.  The Tyr-Lys switch could 
perturb the conformation of Trp19 as evidenced by the decrease in intensity of the exciton 
coupling peak and the minimum at 210 nm.  The CD spectrum of S123-YKswitch-B 
exhibited a shifted minimum at 205 nm and an increase in the intensity of the exciton 
coupling peak again indicating that the aromatic residues were not in the same conformation 
as in S123 (Figure 3.7).  As S123-YKswitch-B did not display a minimum at the same 
wavelength as S123, it was proposed that this peptide was “misfolded.”   
 
A B C 
   
Figure 3.6  Cartoon representation of hypothesized disulfide cyclizations of (A) the properly 
folded S123-YKswitch-A and (B) and (C) two possible configurations for a misfolded S123-
YKswitch-B. 
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Figure 3.7  Circular dichroism spectra for S123 (red), S123-YKswitch-A (blue) and S123-
YKswitch-B (yellow) at 40-60 µM in 10 mM sodium phosphate buffer, pH 7.5 at 298K. 
 
 
 Although the structures of the two separate S123-YKswitch peptides were not similar 
by CD, they exhibited very similar binding affinities and free energies.  The observed 
dissociation constant was found to be 6.9 and 6.7 µM for S123-YKswitch-A and S123-
YKswitch-B and the free energy was calculated to be -7.0 and -7.1 kcal/mol, respectively 
(Figure 3.8).  The greater than 40-fold difference in binding affinity as compared to S123 
provides evidence that the switch does not provide the desired stabilization and that sequence 
plays an important role in structure.  Additionally the binding stoichiometry was found to be 
1:2 DNA to peptide for both S123-YKswitch peptides.  This was surprising as S123-
YKswitch-A is structured in a similar manner to S123 and S123-W19L, which exhibited 1:3 
stoichiometry.  These data demonstrate that the simple switch of Tyr18 and Lys13 was not 
tolerated by the system and in fact dramatically decreased the binding affinity for ssDNA.  
Further NMR studies are required to elucidate the structure-function details. 
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A B 
  
Figure 3.8  Example of a binding isotherm obtained from ITC experiment with ssDNA (300 
µM) titrated in to (A) S123-YKswitch-A and (B) S123-YKswitch-B (40 µM) at 298K in 10 
mM sodium phosphate, 100 mM NaCl, pH 7.5.  For S123-YKswitch-A, the association 
constant was found to be 1.3 x 10
5
 M
-1
, enthalpy was -2.1 x 10
3
 cal/mol, entropy was 16 
cal/mol·K.  For S123-YKswitch-B, the association constant was found to be 1.4 x 10
5
 M
-1
, 
enthalpy was -3.4 x 10
4
 cal/mol, entropy was 12 cal/mol·K.  The ssDNA sequence, oligo1, is 
5’-CCATCGCTACC-3’. 
 
D.  Comparison of S123 to Mutants 
 Of the five mutants, S123 exhibited the tightest binding for oligo1 with a Kd
 
of 170 
nM.  Cyclization of only the first hairpin, S123C1, led to destabilization of the binding 
affinity, whereas cyclization of only the second hairpin, S123C2, exhibited similar 
nanomolar affinity as S123. These results suggest that preorganization of the second hairpin 
is more important in affinity for oligo1.  Substitution of Trp19 with a Leu led to a 10-fold 
decrease in affinity for oligo1.  And switching the positions of the Tyr18 with Lys13 led to a 
marked decrease in affinity for oligo1 regardless of the folding.  Of the thermodynamic 
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parameters, the observed enthalpy and overall observed free energy mirror the trends of the 
dissociation constant where a lower Kd yielded favorable enthalpic and free energy terms.  
However, the differences in the entropy and stoichiometry require more explanation (Table 
3.4). 
 The stoichiometry of peptide to oligo1 in all the mutants varied between 2:1 and 3:1, 
with only S123 and W19L exhibiting a 3:1 stoichiometry.  This could possibly be attributed 
to the amount of space that the peptides can occupy.   Both S123 and W19L are well folded, 
as demonstrated by the CD and NMR data shown previously, meaning the strands are more 
densely packed.  In the other mutants at least one strand is shown to be less folded allowing 
for the peptide to be more flexible to sample more conformations thus occupying more space 
and leading to a decrease in the ratio of peptide to DNA as compared with S123.  
 Perhaps the most interesting result from these data is the observed entropy of binding.  
Classically, preorganization is known to be favorable for binding by decreasing the entropic 
cost thus observing a favorable entropic term upon binding of a ligand.  However, in these 
results we observe the opposite trend; where in the case of the best peptide binders we 
observe a very unfavorable entropic term, ΔS°obs was -16 and -24 cal/mol·K for S123C1 and 
S123.  The mutants, Parent, S123C1/2 and YKswitch all displayed a favorably entropic 
term between 7-16 cal/ mol·K.  There are several possible reasons for this discrepancy, most 
likely a combination of factors contribute.  The entropy stemming from the system (peptide-
DNA) and the surroundings (buffer) must be considered.  When the peptide binds the single 
strand of DNA water molecules are released as part of the hydrophobic effect where two 
greasy surfaces contact each other, the Trp residues with the nucleobases.  This event would 
result in a favorable entropic term.  If the peptide is bound to at most two bases this leaves at 
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least five free bases, in the case of S123 where there is a 3:1 peptide to DNA ratio.  It is 
possible that the free bases could align on one side to free space for the peptides to bind.  
This could drive the formation of clathrate structures around the greasy patch of bases 
resulting in the observed unfavorable entropic term.  
 
Table 3.4  Parameters characterizing peptide interactions with oligo1* 
Peptide Kd obs, µM 
ΔH°obs, 
kcal/mol 
ΔS°obs, 
cal/mol·K 
ΔG°obs, 
kcal/mol 
Peptide: 
DNA 
Parent 4.6 (±0.1) -4.5 (±0.5) 9.5 (±0.5) -7.3 (±0.5) 2:1 
S123C1 5.5 (±0.1) -5.0 (±0.5) 7.3 (±0.5) -7.2 (±0.5) 2:1 
S123C2 0.27 (±0.02) -14 (±0.5) -16 (±0.5) -9.0 (±0.5) 2:1 
S123 0.17 (±0.02) -17 (±0.5) -24 (±0.5) -9.3 (±0.5) 3:1 
YKswitch 6.9/6.7 (±0.1) 
-2.3/-3.4 
(±0.5) 
16/12 (±0.5) 
-7.0/-7.1 
(±0.5) 
2:1 
W19L 2.7 (±0.1) -10 (±0.5) -10 (±0.5) -7.5(±0.5) 3:1 
*oligo1 sequence: 5’- C C A T C G C T A C C - 3', data presented are an average of 2 or 3 
trials. 
 
E.  Conclusions 
 The mutants Parent, S123C1, and S123C2 presented in this chapter were useful in 
determining that the structure of the β-sheet was crucial to achieve high affinity for ssDNA.  
Structural studies demonstrated that hairpin 1 was more well-folded than hairpin 2 in the 
three-stranded β-sheet; however, cyclization of both strands afforded two hairpins that were 
each 91% folded.  Additionally, it was found that preorganization of the system drove a 1:3 
DNA to peptide stoichiometry of binding.  S123-W19L demonstrated the importance of the 
additional binding pocket provided by Trp19, with a 15-fold increase in the dissociation 
constant from S123-W19L to S123.  It was also determined with S123-YKswitch peptides 
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that sequence was critical in proper folding and function of S123.  These systems provide 
insight into the features that can afford high affinity for protein-DNA interactions.   
E.  Experimental Section 
i.  Peptide synthesis and purification 
Peptides were synthesized by automated solid-phase peptide synthesis on a Thuramed 
Tetras peptide synthesizer using Fmoc-protected amino acids on CLEAR-amide resin 
purchased from Peptides International.  All natural Fmoc-[N]-protected amino acids were 
purchased from Advanced Chem Tech.  Activation of amino acids was performed with 
HBTU (5 eq) and HOBt (5 eq) in the presence of DIPEA (5 eq) in DMF and NMP.  Peptide 
deprotection was carried out in 2% DBU and 2% piperidine in DMF for 2 cycles of 
approximately 15 min each.  Each coupling step was performed twice for approximately 30 
min.  All peptides were acetylated at the N-terminus with 5% acetic anhydride and 6% 2,6-
lutidene in DMF for 35 min.  Cleavage of the peptide from the resin was performed in 
95:2.5:2.5 TFA:TIPS:H2O for 3 h.  For peptides containing cysteine 94:2.5:2.5:1 TFA:EDT: 
H2O:TIPS was used.  TFA was evaporated and cleavage products were precipitated with cold 
diethyl ether.  The peptide was extracted into water and lyophilized.  It was then purified by 
RP-HPLC using an Atlantis C-18 semi-preparative column and a gradient of 0 to 100% B 
over 45 min or 60 min, where solvent A was 95:5 water:acetonitrile with 0.1% TFA and 
solvent B was 95:5 acetonitrile: water with 0.1% TFA.  After purification, the peptide was 
lyophilized to a powder and identified with ESI-TOF mass spectroscopy. 
ii.  Cyclization of cysteine containing peptides 
 Peptides were cyclized by oxidizing the cysteine residues at the termini via stirring in 
a 10 mM phosphate buffer (pH 7.5) in 1% DMSO solution for 8 to 12 hours.  The solution 
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was then lyophilized to a powder and purified by RP-HPLC using the method described 
above. 
 iii.  DNA 
All DNA sequences were purchased from Integrated DNA Technologies with 
standard desalting.  Concentrations of the DNA strands were determined by UV-Vis using 
the extinction coefficient at 260 nm (ε260, ssDNA = 95500 M
-1 
cm
-1
). 
iv.  Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) measurements were carried out at 25.0 °C with 
a VP-ITC MicroCal titration calorimeter.  All peptide and DNA samples were prepared in 
10mM sodium phosphate, 100mM NaCl, at pH 7.5.  The concentration of peptides was made 
to 40 µM and ssDNA was made to be 300 µM or 150 µM.  Concentrations of peptides were 
determined by UV-Vis after DTT and Gdn·HCl denaturation using the extinction coefficient 
for Trp and Tyr at 280 nm (ε280, Trp  = 5690 M
-1 
cm
-1
, ε280, Tyr  = 1170 M
-1 
cm
-1
).  The reference 
power was set to 10.  A total of 26 injections of ssDNA into peptide were made: one 3 µL, 
ten 7 µL, ten 10 µL, four 20 µL, and one 30 µL injections.  All data was processed on Origin 
and the plot was fit with the OneSites model.   
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Figure 3.9  Example of a binding isotherm obtained from ITC experiment with ssDNA (300 
µM) titrated in to Parent (40 µM) at 298K in 10 mM sodium phosphate, 100 mM NaCl, pH 
7.5.  The association constant was found to be 2.5 x 10
5
 M, enthalpy was -4.4 x 10
4
 cal/mol, 
entropy was -10 cal/mol·K.  The ssDNA sequence is 5’-CCATCGCTACC-3’. 
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Figure 3.10  Example of a binding isotherm obtained from ITC experiment with ssDNA 
(300 µM) titrated in to S123C1 (40 µM) at 298K in 10 mM sodium phosphate, 100 mM 
NaCl, pH 7.5.  The association constant was found to be 1.7 x 10
5
 M, enthalpy was -4.9 x 10
3
 
cal/mol, entropy was 7 cal/mol·K.  The ssDNA sequence is 5’-CCATCGCTACC-3’. 
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Figure 3.11  Example of a binding isotherm obtained from ITC experiment with ssDNA 
(300 µM) titrated in to S123C2 (40 µM) at 298K in 10 mM sodium phosphate, 100 mM 
NaCl, pH 7.5.  The association constant was found to be 3.6 x 10
6
 M, enthalpy was -1.3 x 10
4
 
cal/mol, entropy was -15 cal/mol·K.  The ssDNA sequence is 5’-CCATCGCTACC-3’. 
 
v.  Circular dichroism 
CD spectroscopy was performed on an Applied Photophysics Chirscan Plus using 
peptide concentrations between 40-60 μM in 10 mM sodium phosphate buffer, pH 7.5.  
Peptide concentrations were determined by UV-Vis using the extinction coefficients of Trp at 
280 nm (ε280, Trp = 5690 M
-1 
cm
-1
).  Spectra were collected from 260 to 185 nm at 0.5 nm 
intervals at 25 °C.   
vi.  NMR characterization 
 NMR samples were made to a concentration of at least 1mM in D2O buffered to pD 
7.0 (uncorrected) with 50 mM KPO4D2, 0.5mM DSS.  Samples were analyzed on a Varian 
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Inova 600-MHz instrument.  One dimensional spectra were collected using 32K data points 
and between 8 and 36 scans using 1.5 s presaturation.  Two dimensional total correlation 
spectroscopy (TOCSY) and nuclear Overhauser spectroscopy (NOESY) were carried out 
using the pulse sequences from the Chempack software.  Scans in the TOCSY experiment 
were taken from 16 to 32 in the first dimension and from 64 to 128 in the second dimension.   
Scans in the NOESY experiments were taken from 32 to 64 in the first dimension and from 
128 to 512 in the second dimension with mixing times of 200-500 ms.  All spectra were 
analyzed using standard window functions (sinbell and Gaussian with shifting).  
Presaturation was used to suppress the water resonance.  Assignments were made by using 
standard methods as described by Wüthrich.
5
  All experiments were run at 298 K. 
 vii.  Determination of fraction folded 
To determine the unfolded chemical shifts, 6-mers were synthesized as unstructured controls 
and cyclic peptides for fully folded controls.  The chemical shifts for residues in the strand 
and one turn residue were obtained from each 6-mer peptide.  The chemical shifts of the fully 
folded state were obtained from disulfide cyclized peptides.  The overall fraction folded was 
determined using the extent of Hα glycine splitting observed in the glycines at the turns given 
in Equation 1: 
Fraction Folded   
         
         
               
where ΔδGly obs is the difference in the glycine Hα chemical shifts of the peptide of interest 
and ΔδGly 100 is the difference in the glycine Hα chemical shifts of the cyclic control peptide.   
 
73 
 
 
Figure 3.12  1H NMR spectrum for Parent: Ac-Arg-Trp-Val-Lys-Val-Asn-Gly-Orn-Trp-Ile-
Lys-Lys-Val-Asn-Gly-Orn-Tyr-Trp-Leu-Lys-Gln-NH2 
 
 
Table 3.4  Proton chemical shift assignments (ppm) for Parent 
  α β γ δ ε 
R 4.40 3.11 
W 5.05 3.14, 3.05 
V 4.68 2.03 0.91 
K 4.11 1.82 0.57, 0.42 1.15 
V 4.10 1.97 0.78 
N 4.36 3.03, 2.72 
G* 0.69 
O 4.66 1.89 1.71 3.02 
W 5.21 3.30, 3.02 
I 4.80 0.93 (CH3) 
K 4.35 1.16 -0.04 0.48 2.32 
K 4.40 1.67 1.51 1.67 3.11 
V 4.87 1.91 0.92 
N 4.56 2.88 
G* 0.11  
O 4.43 1.72 1.58 3.15 
Y 4.63 2.89, 2.75 
W 4.64 3.24, 3.13 
L 4.21 1.83 1.44 0.88 
K 4.17 0.49 0.76 
Q 4.27 2.10, 1.94 2.32     
*Glycine splitting value 
 
PPM 8.4 8.0 7.6 7.2 6.8 6.4 6.0 5.6 5.2 4.8 4.4 4.0 3.6 3.2 2.8 2.4 2.0 1.6 1.2 0.8 0.4 0.0 -0.4
p p p
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Figure 3.13  1H NMR spectrum for S123C1: Ac-Cys-Arg-Trp-Val-Lys-Val-Asn-Gly-Orn-
Trp-Ile-Lys-Lys-Cys-Asn-Gly-Orn-Tyr-Trp-Leu-Lys-Gln-NH2 
 
 
Table 3.5  Proton chemical shift assignments (ppm) for S123C1 
  α β γ δ ε 
C 5.17 2.88, 2.81 
R 4.67 1.80 1.65 3.10 
W 5.09 3.22, 3.08 
V 4.77 2.06 0.95 
K 4.08 1.17 0.22, 0.13 0.54 2.47 
V 4.13 1.85 0.86 
N 4.35 3.08, 2.73 
G* 0.77 
O 4.71 1.94 1.76 3.08 
W 5.30 3.25, 2.99 
I 4.81 1.94 1.49, 1.24 0.94 (γ, CH3) 0.81 (δ, CH3) 
K 4.36 1.14, 1.04 -0.14 0.43 2.28 
K 4.11 1.59 1.17 1.59 2.92 
C 5.23 2.91, 2.33 
N 4.61 3.20 
G* 0.14 
O 4.21 1.75 1.40 2.73 
Y 5.34 3.25, 3.01 
W 5.27 2.90 
L 4.30 1.51 1.38 0.86 
K 4.67 1.78 1.49 1.64 3.11 
Q 4.29 2.13, 1.96 2.34     
* Glycine splitting value 
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Figure 3.14  1H NMR spectrum for S123C2: Ac-Arg-Trp-Val-Lys-Val-Asn-Gly-Cys-Trp-
Ile-Lys-Lys-Val-Asn-Gly-Orn-Tyr-Trp-Leu-Lys-Cys-NH2 
 
 
Table 3.6  Proton chemical shift assignments (ppm) for S123C2 
  α β γ δ ε 
R 4.43 1.84 1.69 3.26 
W 5.39 2.62, 2.34 
V 4.59 2.28 1.08 
K 4.17 1.92 0.63 0.81 
V 4.06 
N 4.38 3.10, 2.78 
G* 0.60 
C 
W 5.39 2.61, 2.79 
I 4.74 
K 4.70 0.51, 0.39 0.70 
K 4.23 1.81 1.38 1.67 2.93 
V 4.74 2.28 1.08 
N 4.64 3.16, 2.78 
G* 0.51 
O 4.65 1.81 1.63 2.78 
Y 4.96 2.96, 2.84 
W 4.94 3.00 
L 5.31 1.86 1.05 
K 4.34 1.80 0.90 1.76 
C           
* Glycine splitting value 
 
 
PPM 8.4 8.0 7.6 7.2 6.8 6.4 6.0 5.6 5.2 4.8 4.4 4.0 3.6 3.2 2.8 2.4 2.0 1.6 1.2 0.8 0.4 0.0 -0.4
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CHAPTER IV 
DEVELOPMENT OF β-HAIRPIN PEPTIDE CYCLIZATION VIA  
THE CuAAC REACTION 
 
A.  Background and significance 
 i.  Disruption of protein-protein interactions 
 Protein-protein interactions (PPIs) are ubiquitous in biology, controlling a host of 
cellular processes including signal transduction, cell growth, translation, transcriptional 
activation, and DNA replication.
1
  Dysregulation of PPIs has been found to be a significant 
contributor in many disease states, such as in the p53-HDM2 interaction in cancer,
2
 sirtuin-
PGC1-α in diabetes,3 and CRP-PINK1 in atherosclerosis.4  A thorough understanding of how 
proteins interact will lead to efficacious drug design that can inhibit or stabilize the 
partnering of proteins thereby halting or slowing the progression of disease.   
Classically, proteins were thought to interact with each other through large, flat 
surfaces.  However, it has been shown that the interface of proteins contain “hot spots” 
consisting of a small subsets of amino acids (Figure 4.1A) where most of the PPI binding 
energy is localized estimated to be around ΔΔG ≥ 2 kcal/mol.5  Hot spots are typically found 
in structurally conserved motifs and are often part of small pockets, clefts or indentations in 
which another protein could complex.  Allosteric sites also regulate PPIs (Figure 4.1B), 
which involves binding of a molecule that influences distal folding of secondary structures 
thereby affecting the proteins ability to interact with other proteins.
1a
  Recent advances
6
 in 
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the identification of the hot spots and allosteric sites of proteins have made the design of 
molecules to interrupt these interactions possible.   
 
 
Figure 4.1  Targeting hotspots or allosteric sites.  Molecules can be designed to target (A) 
hotspots or (B) allosteric sites of proteins to regulate protein-protein interactions.    
 
 Typical approaches in the discovery of PPI inhibitors include high throughput 
screening (HTS) of synthetic chemical libraries and natural products, fragment screening, 
computational approaches based on x-ray crystallography and NMR structural data, and 
peptide and peptidomimetic approaches.
7, 1a
  The use of HTS of molecules made with 
diversity oriented synthesis (DOS) led to the discovery of Robotnikinin (Figure 4.2A), which 
inhibits the ShhN-Ptch1 protein interaction in the hedgehog signal transduction pathway 
thereby controlling the transcription of growth factors.
8
  In another example structure activity 
relationships were examined by NMR and used to find small molecules (Figure 4.2B) that 
could bind the Bcl-XL protein to inhibit its interaction with Bcl-2 which is involved in 
apoptosis.
9
  Bowman and Chmielewski utilized chemical modifications enhance the efficacy 
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of a known peptide (Figure 4.2C) that binds the HIV-1 protease dimer by mimicking the 
protein-protein interface.
10
  These examples demonstrate that undersatnding PPIs combined 
with modern techniques can lead to the successful discovery of modulators of PPIs. 
 
A 
 
 
 
B 
 
 
C 
 
 
 
Figure 4.2  Small molecules developed to target PPIs.  (A) Robotnikinin found to bind ShhN 
of the ShhN-Ptch1 interaction.  (B) ABT-263 designed to inhibit the Bcl-XL and Bcl-2 
interaction by binding Bcl-XL.  (C) Peptide mimic for disrupting the HIV-1 PR dimer 
protein.   
 
 Perhaps one of the most well studied PPIs is the p53-hDM2 interaction which is 
involved in apoptosis and cell cycle arrest.  It has been well documented that cancerous cells 
often over-express hDM2 which binds p53 thereby suppressing apoptosis and leading to 
tumor growth.
11
  Thus, this interaction has received much attention by several researchers to 
find viable methods of inhibiting hDM2 to promote apoptosis of tumor cells.  Verdine and 
co-workers utilized the peptide stapling strategy discussed in Chapter 1.C.i to stabilize the 
15-residue α-helix of p53 that inserts into a hydrophobic cleft on hDM2.12  This stapled helix 
maintained higher binding affinity than that of the native p53 and was able to restore p53 
activity in the presence of hDM2.  Robinson and coworkers employed a different peptide 
strategy involving the design of a cyclic β-hairpin peptide that mimicked the p53 α-helix.13  
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In this work, a range of cyclic β-hairpins were synthesized which contained residues 
determined to be essential for hDM2 binding in a similar spatial conformation as seen in p53.  
Successful hits were iteratively redesigned to afford a cyclic β-hairpin hDM2 inhibitor with 
nanomolar affinity (Figure 4.3) 
.  
A B 
  
Figure 4.3  (A) Cartoon representation of the p53-HDM2 complex showing the side chains 
of Phe19, Trp23, and Leu26 (blue) at the interface (PDB: 1YCR).  (B) β-hairpin mimic of the 
α-helix of hDM2 that binds p53 showing residues (blue) necessary for p53 recognition. 
 
   
All of the aforementioned examples led to successful inhibition of PPIs, but several of 
them utilized labor intensive methods, in particular that of Robinson’s β-hairpin systems.  
Cyclic peptides are a class of privileged structures in that they confer both preorganization 
and protease resistance.  However, they are notoriously difficult to synthesize and often are 
low yielding.  In the case of Robinson’s systems each, over 70 cyclic β-hairpins were 
synthesized and evaluated individually.  Herein, a simpler and higher yielding method of 
cyclization to stabilize and enhance the structure of β-hairpins was explored through 
incorporation of a 1,4-triazole linkage afforded by the CuAAC reaction.  Stabilized 
secondary structures could additionally be useful as tools to study cellular processes.  While 
the work presented here does not explicitly deal with disruption of PPIs, it demonstrates that 
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the CuAAC reaction can be used to stabilize β-hairpin peptides which have precedence for 
being suitable in the disruption of PPIs.   
 ii.  Previous studies of a well folded β-hairpin peptide, WKWK 
 Previously in our laboratory a very well-folded β-hairpin peptide was designed based 
off of Gellman’s peptide,14 which was designed to bind nucleotide bases, specifically ATP 
(Figure 4.4) with a Kd of 170 µM and ΔGbinding of -5.1 kcal/mol.
15
  This new peptide was 
named after its binding cleft, WKWK, and it utilizes two cross-strand Trp/Lys pairs for ATP 
recognition.  The two Trp in the binding pocket were intended to provide favorable stacking 
interactions with the nucleobase, while the flanking Lys residues provided favorable 
electrostatic interactions with the phosphates present in ATP (Figure 4.5).  Salt screen studies  
 
 
Figure 4.4  WKWK peptide structure designed for binding of nucleotides.  Sequence: Ac-
RWVKVNGOWIKQ-NH2.  Cross-strand Trp/Lys pairs (blue) play important roles in 
providing a binding cleft for nucleotides. 
 
 
demonstrated that these electrostatic interaction accounted for approximately -3 kcal/mol to 
the binding event between ATP and the WKWK receptor, which is consistent with the 
estimate of individual salt bridge contributions between phosphate and polyammonium 
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containing synthetic hosts in water.
16
  The intercalation of the adenine into the aromatic 
binding pocket of the peptide was estimated to contribute -1.8 kcal/mol to the recognition 
event.  These results were consistent with similar findings with aromatic stacking interactions 
between Tyr and adenine affording -2 kcal/mol.
17
  
The high β-hairpin population of WKWK was validated through alpha proton 
chemical shifts and 2-D NOESY NMR experiments.  NOEs between the Hα of cross-strand 
Trp/Lys residues confirmed that the peptide was in the proper registry for a type I’ turn.  
Additionally, it was observed that the Trp/Lys pairs in the hairpin alone form cation-π 
interactions further stabilizing the β-hairpin structure.  It was found that WKWK was 96% 
folded in reference to the fully folded disulfide cyclized peptide.   
 
 
Figure 4.5  Computational model based on the NMR structure of WKWK bound to ATP in 
water.
18 
  
 Since this peptide has been well characterized by our laboratory we sought to utilize 
WKWK to study how cyclization of β-hairpins via the CuAAC reaction would impact 
structure, function, and stability.  Different azide moieties and positions along the β-hairpin 
were assessed to provide a comprehensive method for synthesizing cyclic β-hairpins for a 
variety of purposes.  These differences will be discussed in detail in chapters 5 and 6. 
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B.  Development of CuAAC for cyclization of β-hairpins 
As one of the best click reactions, the copper(I) catalyzed azide-alkyne cycloaddition 
features an enormous rate acceleration of 10
7
 to 10
8
 over the uncatalyzed reaction.  
Understanding the mechanism of the CuAAC is crucial in developing the proper conditions 
for incorporation into β-hairpin systems.  The mechanism of the CuAAC has been proposed 
based on density functional theory (DFT) calculations (Figure 4.6).  The coordination of 
copper(I) to the alkyne has been shown to be slightly endothermic in acetonitrile but 
exothermic in water, which is consistent with an observed rate acceleration in water.  
However, initial coordination of Cu to the acetylene does not accelerate a 1,3-dipolar 
cycloaddition.  The coordination forms a π-complex and lowers the pKa of the alkyne C-H by  
 
 
Figure 4.6  CuAAC catalytic cycle. 
 
 
up to 9.8 units from ~25 which enables the formation of a copper acetylide.   The azide then 
displaces another ligand and binds to the copper.  This is then proposed to form an unusual 
six-membered Cu(III) metallacycle.  The barrier for this process has been calculated to be 
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considerably lower than the barrier for the uncatalyzed reaction.  The metallacycle 
subsequently undergoes a ring contraction to form the triazolyl-copper derivative followed 
by protonolysis delivering  the triazole product thus restores the Cu(I) catalyst into the 
catalytic cycle.
19
 
The cyclization of peptides required optimization of the CuAAC reaction conditions 
which utilized the peptide NHB-PheN3 (Figure 4.7A).  Several different conditions were 
screened based on literature precedence including both solid and solution phase methods.  
The various solid phase conditions that were tested to optimize the reaction are shown in 
Table 4.1.  Confirmation of reaction completion was verified by NMR (Figure 4.7B).  
Though nearly all the conditions tested afforded desired product there was some difficulty in 
isolating the product.  This is because the CuAAC was performed on crude peptide thus 
yielding several undesired cyclic byproducts.  As our focus is to develop a clean and quick 
method for CuAAC β-hairpin cyclization, on-bead conditions were abandoned.  However, it 
should be noted that these methods are viable in cases where peptide synthesis provides high 
crude yields of the desired peptide.   
 
Table 4.1  CuAAC conditions on NHB-PheN3 
 
Conditions on bead
**
 
NMR 
confirmation 
1
20 
CuI (0.4 mol%), DIPEA (0.75 mmol), THF at 40°C + 
2
21
 CuI (2 eq) and DIPEA (50 eq) + 
3
22
 20% DIPEA in DMF with 5mg/mL CuI + 
4
23
 
CuI (0.5eq), sodium L-ascorbate (1 eq), 2,6-lutidine (2 eq) in 
ACN: DMSO: H2O (8:2:1) 
- 
5
*24
 CuI (3 eq), DIPEA (45 eq),
 
sodium ascorbate (30 eq) in DMF + 
**
all reactions were run overnight under N2 
*
after overnight reaction, CuI (3 eq) + DIPEA (45 eq) was added to react 4-6 hours further. 
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A  
 
 
B 
 
Figure 4.7 (A) Structure of NHB-PheN3 peptide used to optimize CuAAC reaction 
conditions.  (B) Overlay of NMR spectra of non-cyclic NHB-PheN3 (blue) and CuAAC 
cyclized NHB-PheN3 (black).  Features used to track determine the success of the reaection 
includes disappearance of the alkyne proton (red), appearance of the triazole proton (green), 
shifts in the aromatic peaks from the PheN3, and the change in glycine splitting (yellow).   
 
  The focus then shifted to solution phase methods and was therefore critical to run the 
reaction in a solvent system that would ensure peptide solubility, e.g. water based systems.  
The CuAAC reaction can proceed under acidic or neutral conditions, however it has been 
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reported that the CuAAC is promoted by the addition of an exogenous base, or by the use of 
alkaline buffered media.
25
  It was found that reaction pH was critical in the development of 
the clicked cyclized peptide systems.  The CuAAC reaction proceeded much more rapidly 
when a basic (pH 8.5) sodium phosphate buffer was used compared to neutral (pH 7.0) 
buffered solutions.  As a result, basic buffer systems were employed in all further 
development. 
 A number of copper(I)-catalysts have been shown competent for the CuAAC 
reaction.
25c
  Perhaps the most widely used catalyst system is the in situ reduction of 
copper(II) sulfate to copper(I) using sodium ascorbate.  However for these systems, 
tetrakis(acetonitrile)copper(I) hexafluorophosphate was typically employed as the precatalyst 
in the synthesis of the cyclic peptides because it removed the need for any in situ reduction 
process.  In addition, this copper(I) catalyst was made for ease of setup as it has a larger 
molecular weight.  As a precautionary measure, sodium ascorbate was still incorporated into 
the reaction as it has been observed that the copper(I) species can oxidize over time.  It has 
commonly been observed that reaction mixtures containing a tris-(triazolylmethyl)amine 
ligand decreased reaction time and increased yields compared to reactions without the 
ligand.
y
  Comparable yields could be obtained in the absence of ligand only if excess 
copper(I) catalysts ( >10 eq.) was used, but byproducts of peptide oxidation were observed 
under these conditions.  Tetravalent ligands, such as the tris-(triazolylmethyl)amine, have 
been proposed to protect the copper(I) catalyst metal center from oxidation
y
 and thus 
maintaining higher concentrations of active catalyst during the course of the reaction.   
Cyclic voltammetry studies have shown that tris-(triazolyl)methyl amine ligands can increase 
the Cu(I)/Cu(II) redox couple by close to 0.3V.
26
  Researchers have also proposed the effect 
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of the ligands does not influence the copper oxidation state, but rather the copper aggregation 
state.
25c
  In the absence of accelerating ligands the reaction, under certain circumstances, 
demonstrates kinetics that are second order in Cu(I) and sometimes higher than first order in 
alkyne.
27
  Thus the tris-(triazolylmethyl)amine ligands were incorporated into the reaction. 
 Based on these studies it was determined that the optimal CuAAC conditions (Figure 
4.8) for hairpin cyclization were to use 2.7 equivalents of the tris-(triazolylmethyl)amine 
ligand with 1.8 equivalents of the copper (I) catalyst as well as two equivalents of sodium 
ascorbate.  Addition of the sodium ascorbate was necessary as it was frequently observed that 
the reaction mixture had a bluish hue before completion suggesting oxidation of the copper 
(I) catalyst as no measure to degas solvent was taken.  The cyclization reaction often went to 
completion within a few hours; however reaction times of 8-12 hours were typically 
employed.  After conjugation, reactions were diluted at least 10-fold with %A HPLC solvent 
(95:5:0.1 H2O:ACN:TFA), frozen and lyophilized.  The desired cyclic β-hairpins could be 
purified by RP-HPLC as described in the experimental section. 
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Figure 4.8  Synthesis of cyclic β-hairpin peptides using the CuAAC reaction.  (a) Standard 
Fmoc-SPPS with m, n, x, and y residues.  Coupling conditions: Fmoc-amino acid (4 eq), 
HBTU (4 eq), HOBt (4 eq), DIPEA (4 eq), DMF/NMP, 2 x 30 min; deprotection: 2% 
piperidine, 2% DBU, DMF, 2 x 15 min; Fmoc- azide containing amino acid or propargyl 
glycine(1.5-2 eq), HBTU (4 eq), HOBt (4 eq), DIPEA (4 eq).   (b) Cleavage from the SPPS 
support: TFA: TIPS: H2O (95:2.5:2.5), 3 hr; purification: RP-HPLC.  (c) CuAAC reaction: 
[Cu(CH3CN)4]PF6 (1.8 eq), tris-(triazolylmethyl)amine ligand (2.7 eq), sodium ascorbate (2 
eq), 10 mM phosphate buffer pH 8.5/acetonitrile (1:0.1, v:v), 12 hr; purification: RP-HPLC.  
(d) The tris-(triazolylmethyl)amine ligand is prepared from reaction of tripropargylamine 
with methyl azidoacetate (4 eq), DIPEA (3 eq), [Cu(CH3CN)4]PF6 (2 eq), 48 hr, 78%. 
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C.  Conclusions 
 All of the methods of CuAAC cyclization of β-hairpins outlined above were 
successful in cyclizing β-hairpin peptides.  However, the optimal conditions for this system 
were found to be those utilizing a tris-(triazolylmethyl)amine ligand to accelerate the 
reaction.  The conditions detailed in this chapter have been used in the synthesis of 
subsequent cyclic β-hairpins discussed in chapter V and VI where different azides and their 
positions were also assessed.  This method is advantageous in the preparation of cyclic β-
hairpin peptides that can be used for examination of protein-protein complexes and the study 
of cellular processes. 
D.  Experimental section 
 i.  Peptide synthesis and purification 
Peptides were synthesized by automated solid-phase peptide synthesis on a Thuramed 
Tetras peptide synthesizer using Fmoc-protected amino acids on CLEAR-amide resin 
purchased from Peptides International.  All natural Fmoc-[N]-protected amino acids were 
purchased from Advanced Chem Tech.  Fmoc-[N]-L-propargyl glycine and Fmoc-[N]-para-
azidophenylalanine were purchased from Anaspec.  Activation of amino acids was performed 
with HBTU (5 eq) and HOBt (5 eq) in the presence of DIPEA (5 eq) in DMF and NMP.  
Peptide deprotection was carried out in 2% DBU and 2% piperidine in DMF for 2 cycles of 
approximately 15 min each.  Each natural amino acid coupling step was performed twice for 
approximately 30 min.  Propargylglycine and azidophenylalanine (2 eq) were coupled once 
for 2 hr.  All peptides were acetylated at the N-terminus with 5% acetic anhydride and 6% 
2,6-lutidene in DMF for 35 min.  Cleavage of the peptide from the resin was performed in 
95:2.5:2.5 TFA:TIPS:H2O for 3 h.  TFA was evaporated and cleavage products were 
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precipitated with cold diethyl ether.  The peptide was extracted into water and lyophilized.  It 
was then purified by reverse-phase HPLC using an Atlantis C-18 semi-preparative column 
and a gradient of 0 to 100%B over 45 min or 60 min, where solvent A was 95:5 
water:acetonitrile with 0.1% TFA and solvent B was 95:5 acetonitrile: water with 0.1% TFA.  
After purification, the peptide was lyophilized to a powder and identified with ESI-TOF mass 
spectroscopy. 
 ii.  Synthesis of tris-(triazolylmethyl)amine ligand 
Methylbromoacetate (3.44 mmol, 1 eq) was dissolved in acetone (1.5 mL) and 
brought to 0° C.  Sodium azide (3.56 mmol, 1.03 eq) was dissolved in water (1.5 mL) and 
slowly added dropwise to the reaction mixture.  The mixture was then allowed to warm to 
room temperature and then heated to 65° C and stirred overnight.  Azidomethylacetate was 
extracted using CH2Cl2 (3 x 10 mL).  The organic layers were combined and dried over 
Na2SO4.  The organics were then rotary evaporated to give azidomethylacetate.  
Tripropargylamine (0.44 mmol, 1 eq) was dissolved in CH3CN (1 mL) and cooled to -5° C.  
To this was added azidomethylacetate (1.72 mmol, 3.9 eq) in CH3CN (1 mL) slowly over 5 
mins.  2,6-lutidine (0.44 mmol, 1 eq) and Cu(MeCN)4PF6 (0.0088 mmol, 2 mol %) was 
added.  The mixture was brought to room temperature then heated to 65°C and allowed to stir 
for 3 days under a N2 atmosphere.  The CH3CN was removed by rotary evaporation.  The 
product was purified by silica gel column chromatography (3 % MeOH in CH2Cl2) to give 
the desired product as an off white solid (82% yield).  
1
H NMR (400 MHz,CDCl3): δ 7.84 (s, 
1H), δ 5.18 (s, 2H), δ 3.79 (s, 2H), δ 3.78 (s, 3H).  High-resolution ESI-MS: m/z calculated 
for C18H24N10O6 (M + Cs+), 609.0935; observed 609.0920. 
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Figure 4.9  
1
H NMR of tris-(triazolylmethyl)amine ligand. 
 
iii.  Optimized reaction conditions for CuAAC 
To a solution of purified peptide (1 mM) in 10 mM phosphate, pH 8.5 buffer was 
added a premixed solution of the tris-(triazolylmethyl)amine ligand (2.7 eq) and 
[Cu(CH3CN)4][PF6] (1.8 eq) in acetonitrile.  Sodium ascorbate (2.1 eq) dissolved in minimal 
buffer was added to the reaction.  This solution was stirred overnight in the dark.  The 
reaction mixture was quenched with HPLC solvent (%A, 95:5:0.1 H2O:ACN:TFA) and 
lyophilized to a powder.  The reaction was further desalted followed by RP-HPLC 
purification with standard solvents where %A is 95:5:0.1 water: acetonitrile: TFA and %B is 
95:5:0.1 acetonitrile: water: TFA.  Yields were quantitative. 
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iv.  NMR characterization 
NMR samples were made to a concentration of at least 1mM in D2O buffered to pD 
7.0 (uncorrected) with 50 mM KPO4D2, 0.5mM DSS.  Samples were analyzed on a Varian 
Inova 600-MHz instrument.  One dimensional 
1
H spectra were collected using 32K data 
points and between 8 and 36 scans using 1.5 s presaturation.  
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 CHAPTER V 
INCLUSION OF AN AROMATIC AZIDE FOR CuAAC MEDIATED  
β-HAIRPIN CYCLIZATION 
 
 
A.  System design 
 The β-hairpins presented in this chapter are derived from the WKWK peptide 
previously investigated by our laboratory and discussed in Chapter IV.  The WKWK peptide 
was altered to stud the structural and functional impacts of the CuAAC mediated cyclization 
of β-hairpin peptides.  Initial studies utilized the type I’ turn sequence, VNGO, however 
concerns about the possible hydrolysis of the asparagine residue to aspartate
1
 under the basic 
reaction conditions led to substitution to the type II’ turn sequence, VpGO.  The azide and 
alkyne containing amino acids were placed along the peptide backbone at hydrogen bonded, 
non-hydrogen bonded, and terminal positions to determine the most effective position for 
CuAAC cyclization (Figure 5.1, Table 5.1).  For ease of peptide synthesis the commercially 
available aromatic azide, para-azido-L-phenylalanine (PheN3), was studied first.  In addition 
the inclusion of PheN3 could potentially create an aromatic pocket upon CuAAC cyclization 
with the corresponding propargylglycine.  This aromatic pocket can be useful in recognition 
of aromatic or positively charged molecules through aromatic packing or cation-π 
interactions.
2
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Figure 5.1  WKWK peptide with a type II’ turn (orange).  Azidophenylalanine (PheN3) and 
propargylglycine (Pra) were used as the alkyne and azide for the CuAAC reaction.  These 
residues were varied along the peptide backbone at either hydrogen bonded (blue), non-
hydrogen bonded (red), or terminal (green) positions. 
 
 
Table 5.1  Sequences of β-hairpin peptides using PheN3 and Pra 
Peptide* Sequence 
HB-aF Ac-RW(aF)KVpGOW(Pra)KQ-NH2 
NHB-aF Ac-R(aF)VKVpGOWI(Pra)Q-NH2 
Term-aF Ac-(Pra)RWVKVpGOWIKQ(aF)-NH2 
WKWKdP Ac-RWVKVpGOWIKQ-NH2 
aF RC Ac-R(aF)VKVp-NH2 
Pra RC Ac-GOWI(Pra)Q-NH2 
*Peptides were named after the position the azide and alkyne were placed.  Suffixes of U and 
C indicate non-cyclic and cyclic peptide. 
 
 
Aromatic cages are known motifs in proteins that bind aromatic moieties or cationic 
species.  Another avenue to stabilize β-hairpin structure and to create varied sizes of aromatic 
pockets using the same β-hairpin scaffold was explored by implementing a double click 
reaction (Figure 5.2A).  This was accomplished by incorporating a pair of cross-strand 
azidophenylalanines at the non-hydrogen bonded positions at residues 2 and 11.  A series of  
diyne compounds both commercially and synthetically available, were screened to determine 
if a larger pocket could be enforced without loss of structure.  The series included linear and 
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aromatic diynes as well as those capable of participating in hydrogen bonds to further add 
functionality for binding of guests (Figure 5.2B).  These systems provided information on the 
conformational and distance restraints for the double CuAAC cyclization of β-hairpins and 
illustrated the design principles that could be transferred to other systems.  These types of β-
hairpins could provide an avenue for several different applications, such as host-guest 
systems with biological molecules or as catalysts as exemplified in Miller’s work with stable 
β-turn catalysts.3 
 
 
 
Figure 5.2  (A) β-hairpin peptide, aFaF, structure utilized in double CuAAC cyclaztion 
where azidophenylalanines (blue) are cross-strand in a NHB site.  (B) Diynes screened in 
CuAAC reaction with aFaF. 
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B.  Structural insights of singly clicked β-hairpins using azidophenylalanine 
 The circular dichroism spectrum of HB-aF-U displayed a minimum at 215 nm 
indicative of global β-hairpin formation (Figure 5.3).  Upon completion of the click 
cyclization a minimum of 215 nm was no longer observed, consistent with the formation of a 
random secondary structure.  This finding suggested that cyclization of the HB-aF peptide 
did not result in a β-hairpin structure (Figure 5.3A).  It is important to note that aromatic 
residues can influence the CD spectrum such that different conformations from what is 
expected can be observed.  NMR analysis of non- HB-aF showed shifts consistent with the 
adoption of a β-hairpin conformation (Figure 5.3B).  However, the Hα chemical shifts of 
HB-aF-C displayed far less downfield shifting in comparison with HB-aF-U.  These data 
revealed that CuAAC cyclization did not enhance β-hairpin formation nor completely 
destabilize the structure when included at the hydrogen bonded position.  In WKWKdP it 
was previously observed that the Hα of either Lys residue can be shifted upfield due to ring 
current effects from cross-strand Trp residues.  This was also observed in the NMR of HB-
aF-C where both Lys residues were more upfielded shifted than HB-aF-U.  It is not 
unreasonable to propose that the cyclization reaction allowed each Trp and Lys to interact in 
the proper orientation for this phenomenon to be observed, as the site of the cyclization was 
between the two Trp/Lys pairs.  Overall, these data demonstrate that using PheN3 in the HB 
position perturbed the hairpin structure from the non-cyclic control and WKWKdP.   
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Figure 5.3  (A) Circular dichrosim spectra of HB-aF-U (dark blue) compared to HB-aF-C 
(light blue) at 298 K in 10mM sodium phosphate pH 7.0 buffer.  (B) Hα chemical shift 
differences for HB-aF-U (dark blue), HB-aF-C (light blue), and WKWKdP (black) from 
random coil peptides.  Values calculated from data obtained at 293 K in 50 mM potassium 
phosphate-d2, pD 7.0 (uncorrected).  *The Gly bars reflect the glycine splitting.   
 
 
 When the PheN3 and Pra were moved to non-hydrogen bonded position it was 
observed that there was no distinct change in the CD spectra.  Both NHB-aF-U and NHB-
aF-C display a minimum at 210 nm confirming their global β-hairpin structure (Figure 
5.4A).  Though their CD signals are nearly identical, NHB-aF-U and NHB-aF-C differ in 
their Hα shifts.  As stated in Chapter I, the chemical shift difference of the Hα’s in the HB 
sites are indicators of β-hairpin structure.  Interestingly, Val3Hα is shifted far upfield in 
NHB-aF-C compared to the non-cyclic peptide and WKWKdP (Figure 5.4B) suggesting 
loss in hydrogen bonding with Ile10 or another perturbation of the backbone caused by the 
CuAAC cyclization.  The residues in the other HB sites are also shifted upfield relative to the 
non-cyclic peptide.  Taken together these data show that the CuAAC cyclization in the NHB 
position using an PheN3 as the azide destabilizes the original β-hairpin structure seen in 
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WKWKdP perhaps by taking on a different twist and altering the backbone conformation.  
Further NMR studies are warranted to understand the structural aspects of this system. 
 
A 
  
B 
 
 
Figure 5.4  (A) Circular dichrosim spectra of NHB-aF-U (dark red) compared to NHB-aF-C 
(light red) at 298 K in 10mM sodium phosphate pH 7.0 buffer.  (B) Hα chemical shift 
differences for NHB-aF-U (dark red), NHB-aF-C (light red), and WKWKdP (black) from 
random coil peptides.  Values calculated from data obtained at 293 K in 50 mM potassium 
phosphate-d2, pD 7.0 (uncorrected).  The Gly bars reflect the glycine splitting.   
 
 
 The influence of the CuAAC reaction between terminal residues was subsequently 
investigated.  The CD spectra of Term-aF showed a loss in β-hairpin structure upon CuAAC 
cyclization (Figure 5.5).  The NMR of Term-aF-C was not obtained due to interest in 
another system covered in Chapter VI which showed promising results. Thus a proper 
comparison to the non-cyclic peptide was not carried out.  It therefore remains unknown how 
the hairpin structure was impacted when the CuAAC reaction was performed on the terminal 
positions using PheN3. 
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Figure 5.5  Circular dichrosim spectra of Term-aF-U (dark green) compared to Term-aF-C 
(light green) at 298 K in 10mM sodium phosphate pH 7.0 buffer.  
 
 
Collectively these studies demonstrated that the combination of PheN3 and Pra was 
not suitable for application in the CuAAC cyclization based β-hairpin stabilization.  It was 
found that in all positions the cyclic peptides were less folded β-hairpins than their non-cyclic 
counterparts; however, their structures were not completely disrupted.  The resultant short 
distances and rigidity of these systems appears to hinder proper β-hairpin formation thus a 
double CuAAC method was pursued such that more flexibility in the system is allowed 
(Figure 5.6).  Additionally the installation of a more flexible azide could also aide in proper 
β-hairpin folding by allowing the peptide to sample the proper conformation for the 
necessary non-covalent stabilizing interactions to form which will be covered in Chapter VI. 
 
A B 
 
 
  
Figure 5.6.  (A) Cartoon representation of a singly clicked β-hairpin peptide to provide 
structure stabilization.  (B) Cartoon representation of a doubly clicked β-hairpin peptide to 
introduce more conformational flexibility and a potential binding pocket. 
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C.  Preliminary work on double click reactions 
 A double click reaction was pursued on aFaF by incorporation of two PheN3 residues 
cross-strand in the NHB positions at 3 and 11 (Figure 5.2A).  Several diynes, both linear and 
aromatic, were screened to assess the effect of linker length and rigidity on hairpin structure 
(Figure 5.2B).  Table 5.2 outlines the results obtained from the double click reactions.   
 
Table 5.2  Results of aFaF double click reaction 
Diyne aFaF + diyne 
aFaF +  
2 diynes 
2 aFaF’s +  
2 diynes 
1 
 
+ - - 
2  + - - 
3 
 
+ - - 
4 
 
- + + 
5 
 
- + + 
6 
 
+ + - 
7 
 
- + + 
8 
 
- + - 
   + : presence of product, - : absence of product 
 
 
It was found that at concentrations of 0.8 to 1 mM aFaF in the CuAAC all the linear 
diynes, 1-3, had the propensity to form only the desired 1:1 aFaF to diyne conjugate.  
Macrocycle formation as opposed to a linear “open” species was confirmed by the presence 
of two distinct triazole protons in the NMR.  The aromatic diynes 4-8 were found to form a 
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variety of different conjugates ranging from 1:1, 1:2, and/or 2:2 peptide to diyne ratios.  Both 
the 1:1 and 2:2 peptide-diyne conjugates could be present as a linear “open” or cyclic 
“closed” species where as the 1:2 peptide-diyne conjugate would only be present as a linear 
species (Figure 5.7).  Reaction of aFaF with the two diethynylbenzene isomers, 4 and 5, and 
the isophthalic diyne 7, afforded a mixture of 1:2 and 2:2 peptide-diyne conjugates.  Reaction 
with 6 yielded a mixture of 1:1 and 1:2 peptide-diyne conjugates, with the latter being the 
major product.  Lastly, 8 was found to only yield a 1:2 conjugate.  These results demonstrate 
that flexibility in the diyne is required in order to promote the formation of a 1:1 peptide-
diyne macrocycle as evidenced by the results of the CuAAC of 1-3 with aFaF.   
 
 
Figure 5.7  Simplified cartoons of possible configurations for (A) 1:1, (B) 1:2, and (C) 2:2 
peptide-diyne conjugates. 
 
While it could be possible to bias these systems towards 1:1 peptide-diyne formation 
by lowering the concentrations of the alkyne and/or azide it has been shown that the CuAAC 
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does not proceed at azide concentrations lower than 1 mM and with ≤ 1 equivalent of alkyne.  
As these reactions were carried out under the conditions optimized for 1:1 peptide-diyne 
formation (aFaF: 0.8 to 1 mM, diyne: 1.2 eq) several conclusions about distance and 
rigidity/flexibility requirements for these doubly clicked systems can be made.  It was found 
that the distance between the alkyne moieties should be taken into account when 
incorporating aromatic groups as seen in 6 to 7, where loss of the extra conjugated aromatic 
system led to a loss in the formation of a 1:1 conjugate.  Additionally, it is clear that there is a 
need for flexibility in the diyne linker to promote 1:1 conjugate formation as demonstrated by 
the CuAAC reaction of the linear diynes 1-3, where the 1:1 peptide-diyne was the only 
product, and with diethynylbenzenes, 4 and 5, which did not form the 1:1 peptide-diyne.   
As the purpose of this project was to develop a monomeric cyclic β-hairpin, only the 
linear diynes, 1-3, were further characterized (Table 5.3).  An interesting trend was observed 
with the double CuAAC cyclization of aFaF with linear diynes.  The CD spectrum of the 
unmodified aFaF peptide displays slight β-hairpin structure with a broad minimum spanning 
from 200 nm to 220 nm (Figure 5.8A).  When cyclized with 1, to give aFaF-hex, the 
minimum at 205 nm becomes much sharper leading to a 2.5 fold decrease in the mean 
residue ellipticity, [θ].  However when 2 is incorporated, aFaF-hept adopts a different β-
hairpin conformation than aFaF-hex exhibiting two minima, at 215 nm and 200 nm.  The 
minimum at 215 nm is more characteristic of a typical β-hairpin where the minimum is 
typically between 210 nm and 215 nm.  However, the minimum of observed in a CD 
spectrum of a β-hairpin can shift due to exciton coupling from interactions between aromatic 
residues.  aFaF-oct was found to mirror aFaF-hex though the minimum was less intense and 
was comparable to the intensity of the minimum of the fully folded cyclic control peptide, 
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aFaF-Cys.
5
  Overall, the CD spectra indicate that aFaF-hex is the most folded as it 
possessed the greatest ellipticity.  It was observed that incorporation of a diyne with an even 
number of methylenes (1 and 3) afforded distinctly different conformations than the diyne 
with and odd number of methylenes (2).  Of the three cyclic peptides generated from the 
CuAAC reaction of 1-3 with aFaF, aFaF-hept most closely mimicked the unmodified 
peptide and this trend was substantiated by the NMR data.   
 
Table 5.3  Sequences of aFaF β-hairpin peptides 
Peptide Diyne Sequence 
aFaF -- Ac-R[aF]VKVpGOWIK[aF]Q-NH2 
aFaF-hex 1 Ac-R[aF(triazole-1)]VKVpGOWIK[aF(triazole-1)]Q-NH2 
aFaF-hept 2 Ac-R[aF(triazole-2)]VKVpGOWIK[aF(triazole-2)]Q-NH2 
aFaF-oct 3 Ac-R[aF(triazole-3)]VKVpGOWIK[aF(triazole-3)]Q-NH2 
aFaF-Cys -- Ac-CR[aF]VKVpGOWIK[aF]QC-NH2 
  
 
As discussed in Chapter I, downfield shifting of ≥ 0.1 ppm of the Hα protons along 
the peptide backbone relative to unfoled values indicates a β-sheet conformation.4  All of the 
aFaF peptides displayed β-hairpin character by NMR (Figure 5.8B).  The Hα chemical shift 
differences for the peptides at the HB residues followed the same trends observed in the 
corresponding CD spectra.  The Hα chemical shifts for the HB residues of aFaF-hex and 
aFaF-oct (Val3, Val5, Orn8, Ile10) were all shifted upfield, except for Orn8, relative to the 
same residues in aFaF and aFaF-hept.  This indicates that aFaF-hex and aFaF-oct adopt a 
distorted β-hairpin conformation relative to aFaF and aFaF-hept.  The upfield shifting of the 
HB residues suggested that there was less backbone hydrogen bonding in the aFaF-hex and 
aFaF-oct peptides which can be confirmed by further NMR studies.  
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Figure 5.8  (A) Circular dichrosim spectra of aFaF (blue), aFaF-hex (red), aFaF-hept 
(green), aFaF-oct (yellow), and aFaF-Cys (grey) at 25 °C in 10mM sodium phosphate pH 
7.0 buffer.  (B) Hα chemical shift differences for aFaF (blue), aFaF-hex (red), aFaF-hept 
(green), aFaF-oct (yellow), and aFaF-Cys (grey) from random coil peptides.  Values 
calculated from data obtained at 293 K in 50 mM potassium phosphate-d2, pD 7.0.  The Gly 
bars reflect the glycine splitting.   
 
 
The average of the Hα chemical shift differences of Val3, Val5, Orn8, and Ile10 have 
been shown to be the most accurate in determining fraction folded.
5
  Using these residues, 
aFaF-hept was found to have the most β-hairpin character with a fraction folded of 1.02 
followed by aFaF-oct at 0.71 and aFaF-hex at 0.69 (Table 5.4).  This data suggests that both 
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aFaF-hex and aFaF-oct are less folded than aFaF and are unfavorable for β-hairpin 
formation.  However, these values are derived from comparisons with aFaF-Cys which 
appears to form a hairpin with a different twist that is not accessible in aFaF-hex or aFaF-
oct.  It is also possible that the CuAAC cyclization disrupts the hydrogen bonding between 
Val3 and Ile10 and to a lesser extent between Val5 and Orn8 in aFaF-hex and aFaF-oct 
resulting in a decrease in the chemical shift differences.  This hypothesis can be confirmed by 
observing the amide proton shifts which would be shifted downfield if they were 
participating in hydrogen bonds.  Additionally, NMR studies to determine the deuterium-
hydrogen exchange rate of the amide protons would be useful as the protons involved in 
hydrogen bonding would exhibit slower exchange.  These results indicate that a direct 
comparison of the peptides via fraction folded by this method alone does not provide a clear 
understanding of structure formation.    
 
Table 5.4  Fraction folded for aFaF peptides reacted with 1-3
a 
Peptide Fraction Folded
b
 
aFaF 0.95 (± 0.01) 
aFaF-hex 0.69 (± 0.01) 
aFaF-hept 1.02 (± 0.01) 
aFaF-oct 0.71 (± 0.01) 
(a) Conditions: 20°C, 50 mM potassium phosphate-d2, pD 7.0 (uncorrected).  (b) Calculated 
using equation 1 
 
 
 Interactions between Lys4 and Trp9 were also characterized by NMR to determine 
how the CuAAC affected residues at the NHB face.  The chemical shift of the side chain 
protons are affected by the surrounding environment, in particular ring current effects from 
nearby aromatic systems.  The degree of upfield shifting of the lysine side-chain protons 
relative to the unfolded control is indicative of interactions between the lysine side-chain 
with the indole ring of the tryptophan.  In all of the peptides the Lys side chain protons 
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displayed extensive upfield shifting (Figure 5.9) signifying that Lys4 is in close proximity to 
the indole ring of Trp9.  Comparison of these data showed that Lys4 protons are shifted more 
upfield in aFaF-hex and aFaF-oct than the others suggesting a greater interaction between 
Lys4 and Trp9 in these two peptides.  This could contribute in the stabilization of the β-
hairpin structure near the turn residues, while the same interaction between Lys4 and Trp9 
could be less favored in aFaF-hept.  A comprehensive understanding of this system requires 
more NMR studies, mainly amide proton shifts and NOESY, to assess structural and 
conformational details of side-chain arrangements and interactions.  Again, a trend in the 
even versus odd number of methylene spacers in the diyne was observed.  Additionally, more 
linear diynes should be tested to determine if this trend holds true. 
 
 
 
Figure 5.9  Comparison of chemical shifts of Lys3 side chain protons for aFaF (blue), 
aFaF-hex (red), aFaF-hept (green), aFaF-oct (yellow), and aFaF-Cys (grey) relative to 
random coil values.  Conditions: 293 K in 50 mM potassium phosphate-d2, pD 7.0 
(uncorrected). 
 
 
D.  Conclusions 
 In this chapter the inclusion of an aromatic azide, PheN3, cross-strand from an alkyne, 
Pra, in a β-hairpin for the cyclization via the CuAAC reaction was investigated to determine 
the influence cyclization on β-hairpin formation.  It was found that inclusion of the CuAAC 
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functional amino acids at HB, NHB, and terminal positions was not efficacious for enhancing 
β-hairpin formation.  It was hypothesized that the use of a more flexible azide, would allow 
the system to adopt the proper β-hairpin conformation which will be presented in Chapter VI. 
 Initial results into a double click reaction in which longer linker lengths could be 
explored by reaction of two cross-strand PheN3’s with a series of diynes were also presented.  
It was shown that a number of different peptide-diyne conjugates could be formed via the 
CuAAC; however, only the linear diynes were further characterized as they exclusively 
formed a monomeric macrocycle.  From these studies it was found that an odd number of 
methylenes allowed the peptide to access the proper conformation, whereas an even number 
of methylenes resulted in a distorted structure that maximizes Trp-Lys interactions.  Perhaps 
the inherent twist of a β-hairpin was inhibited such that proper backbone hydrogen bonding 
could not occur.  If this hypothesis is indeed true, the data collectively suggests that the 
covalent modification of a double CuAAC cyclization is a suitable method of β-hairpin 
stabilization in cases where no stabilizing non-covalent interactions are present.  More work 
in this area is necessary to gain a full understanding of the structural impacts.  This system 
offers an avenue to sample several different peptide structures and side chain arrangements 
without affecting the sequence, which can be useful in host-guest systems.  Additionally the 
possibility of creating aromatic pockets for guest insertion should be explored. 
E.  Experimental section 
 i.  Peptide synthesis and purification 
Peptides used for the singly clicked hairpins were synthesized by automated solid-
phase peptide synthesis on a Thuramed Tetras peptide synthesizer using Fmoc-protected 
amino acids on CLEAR-amide resin purchased from Peptides International.  aFaF was 
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manually synthesized on CLEAR-amide resin.  All natural Fmoc-[N]-protected amino acids 
were purchased from Advanced Chem Tech.  Fmoc-[N]-L-propargyl glycine and Fmoc-[N]-
para-azidophenylalanine were purchased from Anaspec.  Activation of amino acids was 
performed with HBTU (5 eq) and HOBt (5 eq) in the presence of DIPEA (5 eq) in DMF and 
NMP.  Peptide deprotection was carried out in 2% DBU and 2% piperidine in DMF for 2 
cycles of approximately 15 min each.  Each coupling step was performed twice for 
approximately 30 min except for the Pra (2 eq) and PheN3 (2 eq) which were only coupled 
once for 2 hr.  All peptides were acetylated at the N-terminus with 5% acetic anhydride and 
6% 2,6-lutidene in DMF for 35 min.  Cleavage of the peptide from the resin was performed 
in 95:2.5:2.5 TFA:TIPS:H2O for 3 h.  For peptides containing cysteine 94:2.5:2.5:1 
TFA:EDT: H2O:TIPS was used.  TFA was evaporated and cleavage products were 
precipitated with cold diethyl ether.  The peptide was extracted into water and lyophilized.  It 
was then purified by RP-HPLC using an Atlantis C-18 semi-preparative column and a 
gradient of 0 to 100%B over 45 min or 60 min, where solvent A was 95:5 water:acetonitrile 
with 0.1% TFA and solvent B was 95:5 acetonitrile: water with 0.1% TFA.  After 
purification, the peptide was lyophilized to a powder and identified with ESI-TOF mass 
spectroscopy. 
 ii.  Cyclization of peptides using a disulfide bridge 
 The cyclic control peptide, aFaF-Cys, was cyclized by oxidizing the cysteine 
residues at the termini via stirring in a 10 mM phosphate buffer (pH 7.5) in 1% DMSO 
solution for 8 to 12 hours.  The solution was then lyophilized to a powder and purified by 
RP-HPLC using the method described above. 
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 iii.  Synthesis of diynes 
 Synthesis of N
2
,N
6
-di(prop-2-yn-1-yl)naphthalene-2,6-dicarboxamide (6) and N
1
,N
3
-
di(prop-2-yn-1-yl)isophthalamide (7).  The dicarboxylic acids, naphthalene-2,6-dicarboxylic 
acid and isophthalic acid, were activated with HBTU (3 eq) and HOBt (3 eq) in the presence 
of DIPEA (3 eq) in a 1:1 DCM:DMF mixture.  Propargylamine (2.4 eq) was then added and 
allowed to stir for 4 hours.  Solvent was removed in vacuo and product was recrystallized 
with ethanol.  Yields were between 60-80% for both 6 and 7.  
1
H NMR (400 MHz, DMSO-
d6) for 6: δ 9.14 (t, 2H), δ 8.51 (s, 2H), δ 8.10 (d, 2H), δ 7.98 (d, 2H), δ 4.12 (dd, 4H), δ 3.15 
(t, 2H).  
1
H NMR (400 MHz, DMSO-d6) for 7: δ 9.05 (t, 2H), δ 8.33 (s, 1H), δ 7.99 (d, 2H), 
δ 7.58 (t, 1H), δ 4.07 (m, 4H), δ 3.15 (m, 2H). 
 Synthesis of naphthalene diimide derived diyne (8).  To 1,4,5,8-
naphthalenetetracarboxylic acid was added propargylamine (2.4 eq) in isopropanol.  The 
reaction mixture was refluxed overnight and the volatiles were removed by rotary 
evaporation.  The crude mixture was dissolved in a 50:50 MeOH:CHCl3 solution and the 
product was filtered off to yield 41% 8.  
1
H NMR (400 MHz, DMSO-d6) for 8: δ 8.74 (s, 
4H), δ 4.82 (d, 4H), δ 3.20 (t, 2H). 
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Figure 5.10  
1
H NMR of 6. 
 
 
     
Figure 5.11  
1
H NMR of 7. 
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Figure 5.12  
1
H NMR of 8.  
 
 
iv.  General CuAAC reaction for peptide cyclization 
To a solution of purified peptide (1 mM) in 10 mM phosphate, pH 8.5 buffer was 
added a premixed solution of the tris-(triazolylmethyl)amine ligand (2.7 eq) and 
[Cu(CH3CN)4][PF6] (1.8 eq) in acetonitrile.  Sodium ascorbate (2.1 eq) dissolved in minimal 
buffer was added to the reaction.  This solution was stirred overnight in the dark.  The 
reaction mixture was quenched with %A HPLC solvent and lyophilized to a powder.  The 
reaction was further desalted followed by RP-HPLC purification with standard solvents 
where %A is 95:5:0.1 water: acetonitrile: TFA and %B is 95:5:0.1 acetonitrile: water: TFA.  
Yields were quantitative. 
 v.  General double CuAAC reaction for peptide cyclization 
Diynes 1-5 were purchased from Sigma-Aldrich chemicals.  To a solution of purified 
peptide (0.8 -1 mM) in 10 mM phosphate, pH 8.5 buffer was added diyne (1.2 eq) in DMF.  
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A premixed solution of the tris-(triazolylmethyl)amine ligand (2.7 eq) and 
[Cu(CH3CN)4][PF6] (1.8 eq) in acetonitrile was added to the reaction mixture.  Sodium 
ascorbate (2.1 eq) dissolved in minimal buffer was added to the reaction.  This solution was 
stirred overnight in the dark.  The reaction mixture was quenched with %A HPLC solvent 
and lyophilized to a powder.  The reaction was further desalted followed by RP-HPLC 
purification with standard solvents where %A is 95:5:0.1 water: acetonitrile: TFA and %B is 
95:5:0.1 acetonitrile: water: TFA.  Yields were quantitative. 
 vi.  Circular dichroism 
CD spectroscopy was performed on an Applied Photophysics Chirscan Plus using 
peptide concentrations between 40-60 μM in 10 mM sodium phosphate buffer, pH 7.5.  
Peptide concentrations were determined by UV-Vis using the extinction coefficients of Trp 
and PheN3 at 280 nm (ε280, Trp = 5690 M
-1 
cm
-1
 and ε280, PheN3 = 1280 M
-1 
cm
-1
).  Spectra were 
collected from 260 to 185 nm at 0.5 nm intervals at 25 °C.   
 vii.  NMR characterization 
 NMR samples were made to a concentration of at least 1 mM in D2O buffered to pD 
7.0 (uncorrected) with 50 mM KPO4D2, 0.5mM DSS.  Samples were analyzed on a Varian 
Inova 600-MHz instrument.  One dimensional spectra were collected using 32K data points 
and between 8 and 36 scans using 1.5 s presaturation.  Two dimensional total correlation 
spectroscopy (TOCSY) was carried out using the pulse sequences from the Chempack 
software.  Scans in the TOCSY experiment were taken from 16 to 32 in the first dimension 
and from 64 to 128 in the second dimension.  All spectra were analyzed using standard 
window functions (sinbell and Gaussian with shifting).  Presaturation was used to suppress 
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the water resonance.  Assignments were made by using standard methods as described by 
Wüthrich.
6
  All experiments were run at 298 K. 
 viii.  Determination of fraction folded 
 To determine the unfolded chemical shifts, 6-mers were synthesized as unstructured 
controls (aF RC and Pra RC) and a cyclic peptide for a fully folded control (aFaF-Cys).  
The chemical shifts for residues in the strand and one turn residue were obtained from each 
6-mer peptide.  The chemical shifts of the fully folded state were obtained from aFaF-Cys.  
The fraction folded on a per residue basis was determined from Equation 1: 
 raction  olded   
         
         
               
where δobs is the observed Hα chemical shift, δ0 is the Hα chemical shift of the unstructured 
6-mers, and δ100 is the Hα chemical shift of the cyclic control.  The overall fraction folded 
for the peptide was calculated by averaging the fraction folded of the residues Val3, Val5, 
Orn8, and Ile10.  These residues in the HB positions have been shown to be the most reliable 
in determining fraction folded.
5
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Figure 5.13  1H NMR spectrum for HB-aF-U: Ac-Arg-Trp-PheN3-Lys-Val-dPro-Gly-Orn-
Trp-Pra-Lys-Gln-NH2 
 
 
Table 5.5  Proton chemical shift assignments (ppm) for HB-aF-U 
  α β γ δ ε 
R 4.45 1.79 1.60 3.18 
W 4.95 3.24, 3.01 
aF 5.16 3.17, 3.07 
K 4.25 1.18, 1.10 0.46 0.66 2.59 
V 4.46 1.97 0.89 
dP 4.35 2.30 2.10, 1.96 3.83, 3.65 
G* 0.18 
O 4.68 1.95 1.80, 1.72 3.05 
W 5.32 3.29, 3.03 
Pra 4.39 2.64 
K 4.32 1.29 0.96, 0.79 0.31 2.35 
Q 4.89 2.13 2.38     
* Glycine splitting value 
 
PPM 8.4 8.0 7.6 7.2 6.8 6.4 6.0 5.6 5.2 4.8 4.4 4.0 3.6 3.2 2.8 2.4 2.0 1.6 1.2 0.8 0.4 0.0 -0.4
p p
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Figure 5.14  1H NMR spectrum for HB-aF-C: Ac-Arg-Trp-PheN3(triazole)-Lys-Val-dPro-
Gly-Orn-Trp-Pra(triazole)-Lys-Gln-NH2 
 
 
Table 5.6  Proton chemical shift assignments (ppm) for HB-aF-C 
  α β γ δ ε 
R 4.21 1.60 1.43 3.08 
W 4.92 2.13 
aF 4.77 3.19 
K 3.89 1.65 1.31 1.49 2.93, 2.79 
V 4.24 2.03 0.93 
dP 4.39 2.22 1.92 3.64, 3.41 
G* 0.20 
O 4.62 3.19, 3.02 
W 5.22 3.46, 2.14 
Pra 4.69 3.21 
K 4.12 0.74 0.87 
Q 4.48 2.88 3.21     
* Glycine splitting value 
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Figure 5.15  1H NMR spectrum for NHB-aF-U: Ac-Arg-PheN3-Val-Lys-Val-dPro-Gly-Orn-
Trp-Ile-Pra-Gln-NH2 
 
 
Table 5.7  Proton chemical shift assignments (ppm) for NHB-aF-U 
  α β γ δ ε 
R 4.37 1.92 1.60 2.32 
aF 4.94 3.02, 2.09 
V 4.74 1.90 0.88 
K 4.28 1.23, 1.03 0.15, 0.09 0.56 2.35 
V 4.59 2.00 0.89 
dP 4.34 2.30 2.07, 1.95 3.71, 3.81 
G* 0.17 
O 4.68 1.90 1.78, 1.69 3.30 
W 5.28 3.00, 2.83 
I 4.64 1.96 1.41, 1.22 093 (γ,CH3) 0.79 (δ,CH3) 
Pra 4.37 2.07 
Q 4.48 2.46 2.60     
* Glycine splitting value 
 
PPM 8.4 8.0 7.6 7.2 6.8 6.4 6.0 5.6 5.2 4.8 4.4 4.0 3.6 3.2 2.8 2.4 2.0 1.6 1.2 0.8 0.4 0.0 -0.4
p p p
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Figure 5.16  1H NMR spectrum for NHB-aF-C: Ac-Arg-PheN3(triazole)-Val-Lys-Val-dPro-
Gly-Orn-Trp-Ile-Pra(triazole)-Gln-NH2 
 
 
Table 5.8.  Proton chemical shift assignments (ppm) for NHB-aF-C 
  α β γ δ ε 
R 4.25 1.74 1.61 3.17 
aF 4.87 3.21, 3.10 
V 4.40 2.06 0.89 
K 4.20 1.88 0.90, 0.83 1.40, 1.16 
V 4.36 2.04 0.88 
dP 4.34 2.33 2.06, 1.94 3.81 
G* 0.27 
O 4.49 1.82 1.63 
W 5.00 3.34, 3.21 
I 4.41 1.88 093 (γ,CH3) 0.79 (δ,CH3) 
Pra 4.61 2.99, 2.84 
Q 4.39 2.18, 2.05 2.40     
* Glycine splitting value 
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Figure 5.17  1H NMR spectrum for Term-aF-U: Ac-Pra-Arg-Trp-Val-Lys-Val-dPro-Gly-
Orn-Trp-Ile-Lys-Gln-PheN3-NH2 
 
 
Table 5.9  Proton chemical shift assignments (ppm) for Term-aF-U 
  α β γ δ ε 
Pra 4.61 2.28 
R 4.43 1.98 1.78 2.18 
W 5.11 3.16, 3.04 
V 4.76 2.01 0.91 
K 3.95 1.30, 1.09 0.30 0.69 2.63 
V 4.51 2.01 0.91 
dP 4.35 2.33 2.10, 1.96 3.76 
G* 0.23 
O 4.75 1.95 1.75 3.09 
W 5.30 3.25, 2.94 
I 4.80 1.98 1.44, 1.24 0.95 (γ,CH3) 0.81 (δ,CH3) 
K 4.32 1.19, 1.00 -0.08 0.51 2.68 
Q 4.60 1.79. 1.56 3.17 
aF 4.56 3.13, 2.96       
* Glycine splitting value 
 
 
121 
 
 
Figure 5.18  1H NMR spectrum for aF RC: Ac-Arg-PheN3-Val-Lys-Val-dPro-NH2 
 
 
Table 5.10  Proton chemical shift assignments (ppm) for aF RC 
  α β γ δ ε 
R 4.17 1.62 1.42 3.11 
aF 4.66 3.12, 2.97 
V 4.43 2.06 0.97 
K 4.28 1.73 1.37 1.73 2.99 
V 4.01 1.95 0.88 
dP 4.41 2.29 2.02 3.88, 3.76   
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Figure 5.19  1H NMR spectrum for Pra RC: Ac-Gly-Orn-Trp-Ile-Pra-Gln-NH2 
 
 
Table 5.11  Proton chemical shift assignments (ppm) for Pra RC 
  α β γ δ ε 
G 3.84 
O 4.30* -- -- -- 
W 4.67 3.25 
I 4.08 1.72 1.37, 1.08 0.82 (γ,CH3) 0.67 (δ,CH3) 
pG 4.30* -- 
Q 4.30* -- --     
*Cannot distinguish side chain protons 
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Figure 5.20  1H NMR spectrum for aFaF: Ac-Arg-PheN3-Val-Lys-Val-dPro-Gly-Orn-Trp-
Ile-PheN3-Gln-NH2 
 
 
Table 5.12  Proton chemical shift assignments (ppm) for aFaF 
  α β γ δ ε 
R 4.46 1.77 1.56 3.18 
aF 5.24 2.99 2.84 
V 4.56 1.94 0.84 
K 4.20 1.19, 1.00 -0.04 0.52 2.41, 2.25 
V 4.46 1.89 0.87 
dP 4.32 2.31 2.07, 1.95 3.69, 3.80 
G* 0.18 
O 4.68 1.86 1.75 3.02 
W 4.92 3.00, 2.81 
I 4.71 1.98 1.39. 1.22 0.92 (γ,CH3) 0.78 (δ,CH3) 
aF 4.61 2.92, 2.72 
Q 4.35 1.98, 1.79 2.21     
* Glycine splitting value 
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Figure 5.21  1H NMR spectrum for aFaF-Cys: Ac-Cys-Arg-PheN3-Val-Lys-Val-dPro-Gly-
Orn-Trp-Ile-PheN3-Gln-Cys-NH2 
 
 
Table 5.13  Proton chemical shift assignments (ppm) for aFaF-Cys 
  α β γ δ ε 
C 5.10 3.02, 2.60 
R 4.38 1.93 2.05 2.34 
aF 5.38 3.06, 2.82 
V 4.59 1.94 0.86 
K 4.13 1.12, 0.98 -0.15 0.45 2.46, 2.25 
V 4.47 1.86 0.87 
dP 4.32 2.31 2.09, 1.91 3.87, 3.67 
G* 0.19 
O 4.70 1,89 1.73 3.02 
W 4.97 3.09, 2.92 
I 4.75 1.98 1.18 0.93 (γ,CH3) 
aF 4.68 3.22 
Q 4.61 2.05, 1.86 2.22 
C** 5.30 2.44       
* Glycine splitting value 
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Figure 5.22  1H NMR spectrum for aFaF-hex: Ac-Arg-PheN3(Hexadiyne-triazole)-Val-Lys-
Val-dPro-Gly-Orn-Trp-Ile-PheN3(Hexadiyne-triazole)-Gln-NH2 
 
 
Table 5.14  Proton chemical shift assignments (ppm) for aFaF-hex 
  α β γ δ ε 
R 4.32 1.82 1.68 3.20 
aF 5.33 3.23, 3.07 
V 4.45 1.98 0.85 
K 4.06 0.91, 0.81 -0.32 0.06 2.02 
V 4.43 1.85 0.87 
dP 4.30 2.31 2.05. 1.91 3.77 
G* 0.31 
O 4.68 1.89 1.72 3.06 
W 5.04 3.35, 3.00 
I 4.41 2.03 1.40, 1.33 0.92 (γ,CH3) 0.78 (δ,CH3) 
aF 4.57 2.76. 2.32 
Q 4.42 2.20, 2.08 2.43     
* Glycine splitting value 
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Figure 5.23  1H NMR spectrum for aFaF-hept: Ac-Arg-PheN3(Heptadiyne-triazole)-Val-
Lys-Val-dPro-Gly-Orn-Trp-Ile-PheN3(Heptadiyne-triazole)-Gln-NH2 
 
 
Table 5.15  Proton chemical shift assignments (ppm) for aFaF-hept 
  α β γ δ ε 
R 4.49 1.86 1.67 3.22 
aF 5.44 3.05, 2.78 
V 4.63 2.03 0.89 
K 4.25 1.15, 0.94 -0.12 0.47 2.34 
V 4.48 1.76 0.87 
dP 4.31 2.31 2.06, 1.92 3.78, 3.71 
G* 0.25 
O 4.64 1.85 1.68 3.00 
W 4.91 2.80, 2.58 
I 4.79 2.08 1.35 0.95 (γ,CH3) 0.82 (δ,CH3) 
aF 5.07 3.16, 2.99 
Q 4.34 2.12, 1.97 2.37     
* Glycine splitting value 
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Figure 5.24  1H NMR spectrum for aFaF-oct: Ac-Arg-PheN3(Octadiyne-triazole)-Val-Lys-
Val-dPro-Gly-Orn-Trp-Ile-PheN3(Octadiyne-triazole)-Gln-NH2 
 
 
Table 5.16  Proton chemical shift assignments (ppm) for aFaF-oct 
  α β γ δ ε 
R 4.39 1.83 1.68 3.19 
aF 5.46 3.15, 3.10 
V 4.46 4.46, 1.95 
K 4.07 0.95, 0.82 -0.35,-0.23 0.28 2.22 
V 4.43 1.95 0.83 
dP 4.29 2.27 2.04, 1.87 3.76, 3.65 
G* 0.23 
O 4.62 1.84 1.69 3.02 
W 4.57 2.63, 2.29 
I 4.52 2.02 1.40, 1.24 0.95 (γ,CH3) 0.81 (δ,CH3) 
aF 5.21 3.29, 3.10 
Q 4.46 2.18, 2.06 2.38     
* Glycine splitting value 
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 CHAPTER VI 
INCOPORATION OF FLEXIBLE AZIDES FOR CuAAC MEDIATED  
β-HAIRPIN CYCLIZATION 
 
 
A.  Introduction 
 It has previously been determined that the use of a rigid aromatic azide (Phe-N3) in 
the CuAAC mediated β-hairpin cyclization was not beneficial in stabilizing hairpin structure.  
Thus a flexible azide, azidolysine (LysN3, AzK), was incorporated into the WKWK peptide 
at various positions to allow the peptide to adopt a β-hairpin conformation.  Several different 
systems were designed, from well-folded systems to weakly folded systems, in order to 
assess the general applicability of the CuAAC mediated cyclization of β-hairpins and 
determine the best position and azide combination for enhancing β-hairpin structure. 
B.  System design 
 The β-hairpins designed for the CuAAC reaction presented in this chapter were also 
derived from WKWK.  Azidolysine and propargylglycine were varied along the peptide 
backbone at hydrogen bonded, non-hydrogen bonded, and terminal positions.  In addition, 
both a type II’, VpGO, and type I’, VNGO, turn sequence were assessed (Figure 6.1, Table 
6.1).  To further probe the structural impacts of CuAAC mediated cyclic β-hairpin formation 
the positions of the azide and alkyne were reversed.  The stability of the peptides derived 
from the type II’ turn sequences was determined by treatment with a protease, pronase E, to 
demonstrate that cyclization via the CuAAC reaction imparted protease resistance.  
Additionally, the thermal stability was determined by circular dichroism.  For the type I’ turn 
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peptides, the binding affinity for ATP was screened to determine if CuAAC cyclization 
influences function. 
 
 
Figure 6.1  Modifications of WKWK with either a Type I’ or Type II’ turn sequence 
(orange).  Azidolysine (AzK) and propargylglycine (Pra) were incorporated along the peptide 
backbone from a terminal (green), NHB (red), or HB (blue) position.  The impact of 
incorporating shorter azides (AzO, AzB, and AzP) was also assessed in the terminal position 
(R’) with a type II’ turn. 
 
 
Table 6.1  Sequences of WKWK modified peptides for CuAAC cyclization 
Peptide* Sequence** 
WKWK-pG Ac-RWVKVKpGOWIKQ-NH2 
WKWK-pG-Cys Ac-CRWVKVKpGOWIKQC-NH2 
HB-pG Ac-RW(AzK)KVpGOW(Pra)KQ-NH2 
NHB-pG Ac-R(AzK)VKVpGOWI(Pra)Q-NH2 
Term-pG Ac-(Pra)RWVKVpGOWIKQ(AzK)-NH2 
HB Ac-RW(AzK)KVNGOW(Pra)KQ-NH2 
NHB Ac-R(AzK)VKVNGOWI(Pra)Q-NH2 
Term Ac-(Pra)RWVKVNGOWIKQ(AzK)-NH2 
HB-rev Ac-RW(Pra)KVNGOW(AzK)KQ-NH2 
NHB-rev Ac-R(Pra)VKVNGOWI(AzK)Q-NH2 
Term-rev Ac-(AzK)RWVKVNGOWIKQ(Pra)-NH2 
*Peptides were named after the position the azide and alkyne were placed as well as the turn 
sequence.  Suffixes of U and C indicate non-cyclic and cyclic peptide. **Bold residues are 
able to participate in ATP recognition.  Underlined residues are involved in the turn 
sequence.  The lower case letter p represents the D-Proline residue. 
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The distance formed between the two strands upon CuAAC cyclization has 
previously been shown to impact structure when the azide and alkyne were placed in the non-
hydrogen bonded position of a TrpZip-derived β-hairpin peptide.1  Thus preliminary studies 
were conducted on the incorporation of varying lengths of the azide residue via removal of 
methylenes in azidolysine, at the terminal position of WKWK-pG with a type II’ turn.  In 
addition, a second class of β-hairpin peptides derived from WKFK and WKFK-pG was also 
investigated to assess the general imapact of CuAAC on folding (Table 6.2) using a less well-
folded hairpin.  In WKFK the inner Trp9 residue is mutated to a Phe thus removing a non-
covalent interaction thereby destabilizing the hairpin yielding a fraction folded of 67% as 
compared to 96% folded for WKWK.
2
  It was hypothesized that incorporation of a CuAAC 
covalent modification could restore structure in the absence of non-covalent interactions. 
 
Table 6.2  Sequence of WKFK modified peptides for CuAAC cyclization 
Peptide* Sequence 
WKFK-pG Ac-RWVKVpGOFIKQ-NH2 
WKFK-Cys Ac-CRWVKVpGOFIKQC-NH2 
TFK-AzK Ac-(Pra)RWVKVpGOFIKQ(AzK)-NH2 
TFK-AzO Ac-(Pra)RWVKVpGOFIKQ(AzO)-NH2 
TFK-AzB Ac-(Pra)RWVKVpGOFIKQ(AzB)-NH2 
TFK-AzP Ac-(Pra)RWVKVpGOFIKQ(AzP)-NH2 
HBFK-AzK Ac-RW(AzK)KVpGOF(Pra)KQ-NH2 
HBFK-AzO Ac-RW(AzO)KVpGOF(Pra)KQ-NH2 
HBFK-AzB Ac-RW(AzB)KVpGOF(Pra)KQ-NH2 
HBFK-AzP Ac-RW(AzP)KVpGOF(Pra)KQ-NH2 
WKFK
 Ac-RWVKVNGOFIKQ-NH2 
TFK-AzK-NG Ac-(Pra)RWVKVNGOFIKQ(AzK)-NH2 
HBFK-AzK-NG Ac-RW(AzK)KVNGOF(Pra)KQ-NH2 
*Peptides are named after the position the azide and alkyne are placed as well as the alkyne 
used and the turn type.  Suffixes of U and C denote non-cyclic and cyclic peptides. 
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C.  Positional impact on structure and stability of CuAAC in WKWK derived peptides 
with a type II’ turn 
i.  Influence on β-hairpin structure of the CuAAC mediated cyclization in the 
hydrogen bonded position at residues 3 and 10 
The circular dichroism spectrum of HB-pG-U displayed a minimum intensity at 212 
nm consistent with β-hairpin structure (Figure 6.2A).  A narrower CD signal at 215 nm was 
observed upon click cyclization, along with a corresponding increase in the signal at 190 nm 
indicative of β-hairpin formation.  In both non-cyclic and cyclic HB-pG there was no change 
in the exciton coupling peak at 230 nm which arises from interactions between aromatic 
residues.  These data suggest that click cyclization in the hydrogen bonded position maintains 
β-hairpin structure.   
 
A B 
  
 
Figure 6.2  (A) Circular dichrosim spectra of HB-pG-U (dark blue) compared to HB-pG-C 
(light blue) at 298 K in 10mM sodium phosphate pH 7.0 buffer.  (B) Hα chemical shift 
differences for HB-pG-U (dark blue), HB-pG-C (light blue), WKWK-pG (orange), and 
WKWK-pG-Cys (grey) from random coil peptides.  Values calculated from data obtained at 
293 K in 50 mM potassium phosphate-d2, pD 7.0 (uncorrected).  *Glycine shifts were 
unclear due to overlap with Hδ protons of the dPro residue in the NMR. 
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In addition to CD, the chemical shifts of the Hα protons were used to quantify hairpin 
folding.  The non-cyclic and cyclic HB-pG peptides displayed similar trends as the parent 
peptide, WKWK-pG, in their chemical shifts (Figure 6.2B).  In HB-pG-C, the hydrogen-
bonded residues (Azk3, V3, O8, Pra10) displayed greater downfield shifting than both HB-
pG-U and WKWK-pG, except for AzK3, which could be due to the formation of the 
triazole.  This suggests that cyclization results in a more folded hairpin.   
Interestingly the chemical shifts of the Lys residues of HB-pG-C varied from the 
other peptides where Lys4Hα was greatly shifted upfield and Lys11Hα was shifted far 
downfield.  While this differs from the cyclic control peptide, WKWK-pG-Cys, the upfield 
shifts of the Lys side-chain protons were still observed in HB-pG-C (Figure 6.3).  In 
WKWK, the side-chain protons of Lys cross-strand from Trp often exhibit upfield shifts due 
to ring current effects from the indole ring of Trp.  As the same trend was observed in HB-
pG-C it was hypothesized that the Trp-Lys interaction was not drastically altered.   
 
A B 
  
Figure 6.3  Chemical shift differences of lysine side chain protons for (A) Lys4 and (B) 
Lys11 in WKWK-pG (yellow), WKWK-pG-Cys (grey), and HB-pG-C (light blue) from 
random coil values. 
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Additional conformation of β-hairpin formation upon CuAAC cyclization was 
obtained from the 2-D NOESY NMR spectra.  The NOEs between cross-strand Hα protons 
confirmed the proper hairpin registry of HB-pG-U and HB-pG-C (Figure 6.4).  Comparison 
of the NOEs for non-cyclic and cyclic HB-pG peptides displayed more side-chain  side-
chain NOEs in the HB-pG-C peptide confirming that the CuAAC cyclization did result in a 
more folded β-hairpin.  Taken together, the CD and NMR data supports the conclusion that 
CuAAC mediated cyclization in the hydrogen bonded position enhances β-hairpin formation 
in peptides with a type II’ turn sequence. 
 
A B 
  
 
Figure 6.4  NO s observed between cross-strand Hα protons (blue), side-chain  side-chain 
(red), and the triazole proton (green) in (A) HB-pG-U and (B) HB-pG-C. 
 
  
ii.  Influence on β-hairpin structure of the CuAAC mediated cyclization in the 
non-hydrogen bonded position at residues 2 and 11 
The circular dichroism spectra of NHB-pG-U displayed two minima at 205 nm and 
215 nm (Figure 6.5A).  When cyclized to NHB-pG-C, the two minima were not as distinct 
and were half as intense as the non-cyclic peptide suggesting a lower degree of folding.  The 
Hα chemical shift differences of both non-cyclic and cyclic NHB-pG were indicative of 
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similar extents of β-hairpin formation (Figure 6.5B), as Hα chemical shifts of the HB 
residues did not differ significantly from NHB-pG-U to NHB-pG-C.  In both the non-cyclic 
and the cyclic NHB-pG, the Hα chemical shifts deviate measurably from WKWK-pG and 
from the cyclic control peptide.  It was hypothesized that the absence of the stabilizing Trp-
Lys pair resulted in a lower degree of hairpin formation.  The NOEs observed in the NHB-
pG peptides demonstrate that CuAAC cyclization in the NHB position serves only to bring 
the terminal ends in close proximity.  There were no new NOEs present between the side-
chains of NHB-pG-C compared to the NOEs present in NHB-pG-U indicating that the 
CuAAC cyclization did not enhance β-hairpin structure (Figure 6.6).  These findings are 
similar to what was observed by the D’Andrea group,1 and the data presented here 
demonstrates that the CuAAC in the NHB position did not enhance or destabilize β-hairpin 
structure.  
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Figure 6.5  (A) Circular dichrosim spectra of NHB-pG-U (dark red) compared to NHB-pG-
C (light red) at 298 K in 10mM sodium phosphate pH 7.0 buffer.  (B) Hα chemical shift 
differences for NHB-pG-U (dark red), NHB-pG-C (light red), WKWK-pG (orange), and 
WKWK-pG-Cys (grey) from random coil peptides.  Values calculated from data obtained at 
293 K in 50 mM potassium phosphate-d2, pD 7.0 (uncorrected).  *The Gly bars reflect the 
glycine splitting.   
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A B 
  
 
Figure 6.6  NO s observed between cross-strand Hα protons (blue), side-chain  side-chain 
(red), and the triazole proton (green) in (A) NHB-pG-U and (B) NHB-pG-C.   
 
iii.  Influence on β-hairpin structure of the CuAAC mediated cyclization in the 
terminal position at residues -1 and 13 
The circular dichroism spectra of the non-cyclic and cyclic Term-pG peptides 
displayed minima at 210 nm of equal intensity and a corresponding maximum at 190 nm 
(Figure 6.7A).  This is consistent with a high degree of folding in both peptides.  
Additionally, the Hα chemical shift differences of the non-cyclic and cyclic Term-pG did 
not differ from the cyclic control peptide, WKWK-pG-Cys (Figure 6.7B) again confirming 
β-hairpin structure.  Lys11Hα of Term-pG-C was the only residue that did not mirror the 
trend as the cyclic control.  However the side-chain protons still exhibited upfield shifting 
stemming from ring current effects of the cross-strand Trp2, suggesting that this Trp-Lys pair 
in the clicked peptide was still in close contact.  This was further supported by NOEs 
observed in Term-pG-C between an indole proton of the Trp2 sidechain and all of the 
sidechain protons of Lys11.  Additionally, there were significantly more NOEs between the 
internal Trp-Lys pair (Figure 6.8).  These data indicate that the CuAAC cyclization at the 
terminal position is an appropriate substitute for a disulfide bridge in the same position. The 
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CuAAC substitution could be particularly useful under reducing conditions in which solvent 
exposed disulfides would be reduced to the corresponding thiols.  
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Figure 6.7  (A) Circular dichrosim spectra of Term-pG-U (dark green) compared to Term -
pG-C (light green) at 298 K in 10mM sodium phosphate pH 7.0 buffer.  (B) Hα chemical 
shift differences for Term -pG-U (dark green), Term -pG-C (light green), WKWK-pG 
(orange), and WKWK-pG-Cys (grey) from random coil peptides.  Values calculated from 
data obtained at 293 K in 50 mM potassium phosphate-d2, pD 7.0 (uncorrected).  *The Gly 
bars reflect the glycine splitting.   
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Figure 6.8  NO s observed between cross-strand Hα protons (blue), side-chain  side-chain 
(red), and the triazole proton (green) in (A) Term-pG-U and (B) Term-pG-C.   
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 iv.  Thermal and proteolytic stability of type II’ turn CuAAC cyclized peptides 
 Having investigated the structural influence of the CuAAC cyclization of hairpin 
formation at different positions, the stability of these peptides was determined through 
thermal denaturation and enzymatic degradation.  All of the peptides were thermally 
denatured and monitored by circular dichroism to determine if click cyclization improved the 
thermal stability of β-hairpins.  A standard S-type melting curve was not observed over the 
temperature range assessed, thus only a qualitative assessment can be made for all clicked 
peptides.  Click cyclization of HB-pG resulted in an increase in thermal stability as there was 
a 20% difference in normalized ellipticity at 90 °C (Figure 6.9A).  In the non-hydrogen 
bonded position it was also observed that the CuAAC reaction afforded a more thermally 
stable peptide.  NHB-pG-U gradually unfolded with increasing temperature, while NHB-
pG-C exhibited only a 10% decrease in ellipticity over the temperature range (Figure 6.9B).  
Interestingly there did not appear to be any increase in thermal stability in the terminal 
position (Figure 6.9C).   
 
A B C 
   
 
Figure 6.9  Thermal stability assessed by circular dichroism of (A) HB-pG, (B) NHB-pG, 
and (C) Term-pG peptides from 20 °C to 90 °C in 10 mM phosphate buffer, pH 7.5.  
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Proteolytic stability of the non-cyclic and cyclic peptides was assessed by incubation 
with Pronase E, which is a mixture of non-specific endo- and exo- serine proteases.
3
  Table 
6.3 summarizes the half-life of each peptide under the conditions described in the 
experimental section.  The β-hairpin peptides were compared to a control unstructured 
peptide, Scrambled, which consisted of a random order of the residues in Term-pG.  The 
half-life of Scrambled was found to be 3 minutes, while the non-cyclic peptides HB-pG-U, 
NHB-pG-U, and Term-pG-U had half-lives of 15, 20, and 60 minutes.  The Term-pG-U 
was found to be the least susceptible to degradation compared to the other non-cyclic 
peptides, most likely due to being the most well-folded.
4
  The CuAAC cyclization improved 
resistance to proteolytic degradation on all accounts, where HB-pG-C had a half-life 18-fold  
 
Table 6.3  Half-lives of type II’ turn peptides treated with Pronase  * 
 t1/2 (min) 
Peptide U C 
Scrambled** 3 (± 5) -- 
HB-pG 15 (± 5) 280 (± 5) 
NHB-pG 20 (± 5) No observable degradation*** 
Term-pG 60 (± 5) > 300 
* Reactions carried out in 10 mM sodium phosphate, 140 mM NaCl, pH 7.6 at 37 °C. 
** Scrambled sequence: Ac-pQVIKRGOWW(Pra)(AzK)VK-NH2 
*** Over a 48 hour time period 
 
 
greater than HB-pG-U, NHB-pG-C showed no observable degradation, and Term-pG-C 
had a half-life at least 5-fold greater than Term-pG-U.  As the NHB-pG-C peptide did not 
degrade under the Pronase E conditions, its robustness was also tested using the protease, 
Trypsin which cleaves after basic amino acids, such as Arg and Lys.  Under trypsin 
degradation, NHB-pG-C had a half-life of 40 mins which was 4 times greater than the non-
cyclic peptide.  Additionally, the degradation products were analyzed by mass spectrometry 
which showed that only the termini were cleaved leaving an intact clicked cycle as the only 
140 
 
product.  Together these data demonstrated that click cyclization significantly increased 
protease resistance. 
D.  Positional impact on structure and stability of CuAAC in WKWK derived peptides 
with a type I’ turn 
i.  Influence on β-hairpin structure of the CuAAC mediated cyclization in the 
hydrogen bonded position 
Since the type I’ turn, Asn-Gly, is not as stabilizing as the type II’ turn, dPro-Gly, and 
also exhibits a different twist, the impact of the CuAAC on type I’ turn containing peptides 
was also investigated.  Additionally, the position of the azide and alkyne was investigated by 
reversing their location.  The circular dichroism spectra of HB-U and HB-rev-U displayed a 
broad minimum ranging from 200 nm to 215 nm suggestive of a mixture of structural 
conformations.  The CuAAC reaction on these two peptides led to a distinct structural change 
as reflected in the CD spectra, which showed a sharper and more intense minimum at 212 nm 
indicative of increased hairpin character in HB-C and HB-rev-C (Figure 6.10A).  Exciton 
coupling at 225 nm from the diagonal Trp2 and Trp9 interactions also confirmed the 
formation of a β-hairpin.  The chemical shift differences correlated with the trend seen in the 
circular dichroism spectra as nearly all the Hα’s in the cyclic peptides exhibited more 
downfield shifting than the non-cyclic peptides (Figure 6.10B).    Additionally, the fraction 
folded as determined by glycine splitting indicated that CuAAC cyclization in the hydrogen 
bonded position stabilized β-hairpin formation (Table 6.4). These data are consistent with the 
previously observed results from the type II’ turn containing peptides. 
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Figure 6.10  (A) Circular dichrosim spectra of HB-U (red), HB-C (blue), HB-rev-U (black), 
and HB-rev-C (green) at 298 K in 10mM sodium phosphate pH 7.0 buffer.  (B) Hα chemical 
shift differences for HB-U (red), HB-C (blue), HB-rev-U (black), HB-rev-C (green), and 
WKWK (yellow) from random coil peptides.  Values calculated from data obtained at 293 K 
in 50 mM potassium phosphate-d2, pD 7.0 (uncorrected).  *The Gly bars reflect the glycine 
splitting.   
 
 
Table 6.4  Fraction folded of HB peptides 
 
Fraction Folded 
Peptide Gly Splitting
a Hα shifta 
WKWK 0.96 0.92 
HB-U 0.64 0.57 
HB-C 0.88 0.95 
HB-rev-U 0.79 0.69 
HB-rev-C 0.92 0.92 
a 
Calculated using equation 2.  
b
 Calculated using equation 1. 
 
Further examination of the chemical shift differences showed that the interactions 
between the Trp-Lys pairs were reversed in the HB-rev peptides from the WKWK peptide.  
In the WKWK peptide Lys4Hα was shifted downfield and Lys11Hα was shifted upfield 
whereas in the HB-rev peptides the opposite was seen.  This indicated that position of the 
azide and alkyne can impact the structure, which was also confirmed by the observed NOEs.  
The HB-rev peptides exhibited far more NOEs than the corresponding HB peptides (Figure 
6.11).  There were far more contacts between the Trp-Lys pairs in the HB-rev peptides 
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suggesting that placing the alkyne in the first strand was more favorable for hairpin 
formation.  This difference could be attributed to the inherent twist of hairpins and the 
packing of hydrophobic residues in the HB face.
6
  Altogether these data demonstrate that 
click cyclization in the HB position stabilized β-hairpin structure relaive to the parent 
peptide. 
 
A B 
  
C D 
 
 
Figure 6.11  NO s observed between cross-strand Hα protons (blue), side-chain  side-chain 
(red), and the triazole proton (green) in (A) HB-U, (B) HB-C, (C) HB-rev-U, and (D) HB-
rev-C. 
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ii.  Influence on β-hairpin structure of the CuAAC mediated cyclization in the 
non-hydrogen bonded position 
Replacement of the structurally stabilizing Trp2 and Lys11 cross-strand pair with 
AzK and Pra deterred β-hairpin folding as observed in the circular dichroism spectra of 
NHB-U, which displayed two minima at 205 nm and 215 nm.  NHB-rev-U was not fully 
soluble and formed a gel-like substance under the CD conditions (10 mM sodium phosphate, 
pH 7.5) and required much lower pH to attain solubility; thus, a CD spectrum was not 
acquired.  This supported the fact that position of the CuAAC functional groups is important 
as was observed with the hydrogen bonded position.  NHB-C and NHB-rev-C showed 
evidence of hairpin formation by the sharp decrease in ellipticity at 215 nm (Figure 6.12A).   
 
A B 
  
Figure 6.12  (A) Circular dichrosim spectra of NHB-U (red), NHB-C (blue), NHB-rev-U 
(black), and NHB-rev-C (green) at 298 K in 10mM sodium phosphate pH 7.0 buffer.  (B) Hα 
chemical shift differences for of NHB-U (red), NHB-C (blue), NHB-rev-U (black), NHB-
rev-C (green), and WKWK (yellow) from random coil peptides.  Values calculated from 
data obtained at 293 K in 50 mM potassium phosphate-d2, pD 7.0 (uncorrected).  Data for 
NHB-rev-U was acquired at 293 K in 50 mM acetate, pD 4.0 (uncorrected). *The Gly bars 
reflect the glycine splitting.   
 
 
The slight shoulder at 205 nm suggested that some population of an unknown structure also 
seen in NHB-U existed in the CuAAC cyclized peptides.  However, the β-hairpin structure is 
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dominant, supported by the maximum at 195 nm.  The Hα chemical shift differences agreed 
with the CD data with most of the residues in the cyclic peptides exhibiting greater downfield 
shifting than those of the non-cyclic peptides and more closely matching the shifts observed 
in WKWK (Figure 6.12B).  The fraction folded calculated from the glycine splitting 
increased significantly from 88% and 73% to 96% and 95% upon CuAAC cyclization for 
NHB and NHB-rev, respectively (Table 6.5).  These data demonstrate that covalent linkage 
at the non-hydrogen bonded site restores the stability previously obtained via noncovalent 
interaction in WKWK. 
 
Table 6.5  Fraction folded of NHB and NHB-rev peptides 
 
Fraction Folded 
Peptide Gly Splitting Hα shift 
WKWK 0.96 0.92 
NHB-U 0.88 0.94 
NHB-C 0.96 0.80 
NHB-rev-U 0.73 0.63 
NHB-rev-C 0.95 0.81 
 
 
In NHB-U, a strong NO  was observed between Lys4Hα abd Trp9Hα confirming the 
expected strand registry (Figure 6.13A).  However, no NO s were seen between AzK2Hα 
and Pra11Hα indicative of fraying of the strands.  This is not surprising, given that the 
stabilizing Trp-Lys cross-strand pair in the parent sequence was removed.  There were 
additional contacts between the side chains of Lys4 and Trp9 as well as an NOE between 
Trp9Hα and Val3Hα, suggesting that Trp9 is sandwiched between AzK2 and Lys4.  It was 
observed that NHB-C was also in the correct strand registry, thus confirming that click 
cyclization in the non-hydrogen bonded position did not alter the type of hairpin formed 
(Figure 6.13B).  Interestingly, NHB-rev-U did not display any cross-strand Hα NO s 
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suggesting a lack of defined β-hairpin structure.  Instead NOEs were observed between the 
indole ring of Trp9 with Val3Hα and Lys4Hα.  Additionally the NO  between Trp9Hα and  
 
A B 
  
C D 
  
Figure 6.13  NO s observed between cross-strand Hα protons (blue), side-chain  side-chain 
(red), and the triazole proton (green) in (A) NHB-U, (B) NHB-C, (C) NHB-rev-U, and (D) 
NHB-rev-C.  The NMR spectra for NHB-rev-U was acquired at 50 mM acetate buffer, pD 
4.0 (uncorrected). 
 
 
AzK11Hα suggested that strand 2 folded back on itself (Figure 6.13C).  Upon click 
cyclization no cross-strand NOEs were observed to confirm correct strand registry.  The 
strong NOEs present between Pra2Hα/Lys4Hα and Trp9Hα/AzK11 implicated cradling of 
the hairpin where the terminal ends were sandwiched on top of the residues near the turn 
(Figure 6.13D).  NOEs between Trp9 and Lys4 as well as the triazole proton validate this 
proposed structure.  While it does not appear that CuAAC cyclization of NHB-rev aided in 
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the formation of the expected β-hairpin it did restore solubility and stabilization of a new 
structure. 
iii.  Influence on β-hairpin structure of the CuAAC mediated cyclization in the 
terminal position 
The circular dichroism spectra of Term-U and Term-rev-U displayed minima at 212 
nm with corresponding maxima at 195 nm indicating global β-hairpin conformation.  The 
cyclic counterparts Term-C and Term-rev-C exhibited more intense minima at the same 
wavelength suggesting of an increase in hairpin structure (Figure 6.14A).  Additional 
confirmation of proper structure was evidenced by the exciton coupling peak at 225 nm 
stemming from the diagonal Trp interactions.  The Hα chemical shift differences of all the 
terminal position peptides did not differ drastically from WKWK.  This was reflected in the  
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Figure 6.14  (A) Circular dichrosim spectra of Term-U (red), Term-C (blue), Term-rev-U 
(black), and Term-rev-C (green) at 298 K in 10mM sodium phosphate pH 7.0 buffer.  (B) 
Hα chemical shift differences for Term-U (red), Term-C (blue), Term-rev-U (black), 
Term-rev-C (green), and WKWK (yellow) from random coil peptides.  Values calculated 
from data obtained at 293 K in 50 mM potassium phosphate-d2, pD 7.0 (uncorrected).  *The 
Gly bars reflect the glycine splitting.   
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fraction folded (Table 6.6) which showed all peptides to be greater than 90% folded.  The 
few aspects to consider when comparing the Hα shifts include the residues Lys11, AzK, and 
Pra.  Lys11Hα was shifted upfield in Term-U and Term-rev-C as was observed in WKWK 
which provided evidence that position of the AzK and Pra impacted structure.  In both Term 
and Term-rev CuAAC cyclization afforded AzK to be shifted far upfield and Pra to be 
shifted downfield from the non-cyclic peptides.  These data suggested that the terminal ends 
were pulled closer together as was also evidenced by the downfield shifting of Arg1Hα.  
Regardless, there was no difference in the NOESY spectra between the non-cyclic and cyclic 
terminal position peptides (Figure 6.15).  These results demonstrate that the terminal position 
for the CuAAC cyclization did not dramatically enhance nor inhibit β-hairpin formation. 
 
Table 6.6  Fraction folded of Term and Term-rev peptides 
 
Fraction Folded 
Peptide Gly Splitting Hα shift 
WKWK 0.96 0.92 
Term-U 0.99 0.98 
Term-C 0.99 0.95 
Term-rev-U 0.96 0.93 
Term-rev-C 0.99 0.93 
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Figure 6.15  NO s observed between cross-strand Hα protons (blue), side-chain  side-chain 
(red), and the triazole proton (green) in (A) Term-U, (B) Term-C, (C) Term-rev-U, and (D) 
Term-rev-C. 
 
iv.  Thermal stability of type I’ turn CuAAC cyclized peptides 
The thermal stability of the type I’ turn peptides was assessed in the same way as the 
type II’ turn peptides by thermal denaturation monitored by circular dichroism.  No direct 
measurement of melting temperature could be made as no standard S-curve was observed.  In 
all positions the cyclic peptide exhibited increased thermal stability compared to the non-
cyclic peptides (Figure 6.16) as expected from cyclic structures.  From this it can be 
confirmed that CuAAC cyclization of peptides affords stability to β-hairpins regardless of the 
position of the reaction.        
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Figure 6.16  Thermal stability assessed by circular dichroism of (A) HB, (B) NHB, and (C) 
Term peptides from 5 °C to 95 °C in 10 mM phosphate buffer, pH 7.5.  
 
 
v.  Recognition of ATP by CuAAC cyclized peptides 
As discussed earlier in Chapter IV, WKWK has been shown to bind ATP with a 
dissociation constant of 170 µM.
5
  To determine if the CuAAC cyclization alters the function 
of the β-hairpin peptide, the efficacy of the cyclic Term and HB peptides to bind ATP were 
assessed by fluorescence quenching, as reported previously.
5
  Term-C and Term-rev-C 
were determined to having a binding constant to ATP of 110 µM and 140 µM (Table 6.7).  
HB-C and HB-rev-C also recognized ATP with comparable affinity with binding constants 
of 150 µM and 270 µM.  These results show that the CuAAC cyclization in the terminal and 
hydrogen bonded positions do not significantly alter the function of the peptides, supporting 
that the overall β-hairpin structure was maintained and that the CuAAC reaction is a suitable 
method for β-hairpin cyclization. 
 
Table 6.7  Binding Constants of Term and HB peptides for ATP 
Peptide Kd, µM (error) 
WKWK 170 
Term-C 110 (30) 
Term-rev-C 140 (20) 
HB-C 150 (20) 
HB-rev-C 270 (20) 
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E.  Preliminary results of varying the chain length of azidolysine 
 Preliminary experiments were carried out to determine if varying the distance 
between the two strands would improve β-hairpin structure.  To start, the terminal position 
was assessed of the WKWK-pG peptide.  Different lengths of the azide were incorporated, 
from 1-4 methylene spacers: azidoalanine (AzP), azidohomoalanine (AzB), azidoornithine 
(AzO), and azidolysine (AzK).  The circular dichroism of the CuAAC cyclized peptides 
using the four different azides displayed very similar spectra with minima at 208 nm (Figure 
6.17A).  One notable difference between the peptides was the gradual decrease in the exciton 
coupling peak with decrease in the number of methylene spacers which could be attributed to  
 
A B 
  
 
Figure 6.17  (A) Circular dichrosim spectra of Term-pG-AzK-U (red), Term-pG-AzK-C 
(blue), Term-pG-AzO-C (green), Term-pG-AzB-C (orange), and Term-pG-AzP-C 
(purple) at 298 K in 10mM sodium phosphate pH 7.0 buffer.  (B) Hα chemical shift 
differences for Term-pG-AzK-U (red), Term-pG-AzK-C (blue), Term-pG-AzO-C (green), 
Term-pG-AzB-C (orange), and Term-pG-AzP-C (purple) from random coil peptides.  
Values calculated from data obtained at 293 K in 50 mM potassium phosphate-d2, pD 7.0 
(uncorrected).  Glycine shifts were unclear due to overlap with the Hδ protons of dPro.  The 
residue N3 represents the azide that was incorporated. 
 
 
slight nuances in the spatial arrangement of the Trp residues, which was also exemplified in 
the Hα shifts of the Trp2.  The Hα chemical shift differences of the cyclic peptides did not 
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differ from each other from residues 3-10.  However, an overall trend was observed at the 
terminal residues, where the Hα protons were less downfield shifted with decreasing 
methylenes in the azide (Figure 6.17B).  It was determined that there was no marked change 
in structure with differing lengths of the azide used in this system. 
As there did not appear to be a distinct impact on structure upon decreasing the length 
of the azide in the terminal position, a new model peptide, WKFK, was utilized.  This 
system was investigated because it was found to be less folded than the WKWK peptide.  
WKFK with a type II’ turn sequence was previously found to be only 86% folded as 
compared to WKWK at 96% folded.
2
  It was hypothesized that the CuAAC reaction could 
be useful in stabilizing weakly folded systems.    
The circular dichroism spectra of the CuAAC cyclic peptides in the terminal position 
all displayed a β-hairpin structure with minima from 205 nm to 210 nm (Figure 6.18A).  
With an increase in the chain length of the azide the peptide took on a different conformation 
as exhibited by the blue shift of the minimum of the CD spectra.  However, when AzK was 
incorporated the minimum was restored, suggesting that TFK-AzK-C (terminal positions 
substitutaions of WKFK) formed a similar structure as WKFK.  In all cases, the peptides 
were not more well-folded than the parent or the fully cyclized control as supported by the 
Hα chemical shift differences (Figure 6.18B).    
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Figure 6.18  (A) Circular dichrosim spectra of WKFK (red), TFK-AzK-C (blue), TFK-
AzO-C (green), TFK-AzB-C (orange), TFK-AzP-C (purple), and WKFK-Cys (grey) at 298 
K in 10mM sodium phosphate pH 7.0 buffer.  (B) Hα chemical shift differences for WKFK 
(red), TFK-AzK-C (blue), TFK-AzO-C (green), TFK-AzB-C (orange), TFK-AzP-C 
(purple), and WKFK-Cys (grey) from random coil peptides.  Values calculated from data 
obtained at 293 K in 50 mM potassium phosphate-d2, pD 7.0 (uncorrected).  Glycine shifts 
were unclear due to overlap with the Hδ protons of dPro.  The residue N3 represents the 
azide that was incorporated. 
 
 
 The hydrogen bonded position of WKFK was also assessed to determine if this 
position would yield a more well-folded peptide with different azide residues as no desired 
result was achieved by incorporation of the CuAAC residues at the terminal positions.  There 
was no trend observed amongst the HBFK cyclic peptides.  By circular dichroism none of 
the CuAAC cyclized peptides afforded a similar structure to that of WKFK (Figure 6.19A).  
The CD of the cyclic peptide with AzK displayed two minima at 215 nm and 190 nm 
indicating two different populations which were also present in HBFK-AzO-C in different 
ratios.  HBFK-AzB-C had only one minimum at 195 nm suggestive of random coil 
formation.  CuAAC reaction with AzP led to a peptide with no observable structure by CD.  
These data confirm that indeed substitutions to the HB face are less tolerated.
e
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shift differences reflected the observed global conformations by CD where the cyclic 
peptides were not comparable in Hα shifts to either WKFK or WKFK-Cys (Figure 6.19B). 
Though all the cyclic peptides displayed similar trends in Hα shifts, the extent of downfield 
shifting was significantly less than WKFK confirming that the hydrogen bonded position 
was not ideal for the CuAAC reaction in WKFK. 
 
A B 
  
 
Figure 6.19  (A) Circular dichrosim spectra of WKFK (red), HBFK-AzK-C (blue), HBFK-
AzO-C (green), HBFK-AzB-C (orange), HBFK-AzP-C (purple), and WKFK-Cys (grey) at 
298 K in 10mM sodium phosphate pH 7.0 buffer.  (B) Hα chemical shift differences for 
WKFK (red), HBFK-AzK-C (blue), HBFK-AzO-C (green), HBFK-AzB-C (orange), 
HBFK-AzP-C (purple), and WKFK-Cys (grey) from random coil peptides.  Values 
calculated from data obtained at 293 K in 50 mM potassium phosphate-d2, pD 7.0 
(uncorrected).  Glycine shifts were unclear due to overlap with the Hδ protons of dPro.  The 
residue N3 represents the azide that was incorporated. 
 
 
 These results indicated that utilization of the CuAAC reaction at the terminal and 
hydrogen bonded positions in the cyclization of the WKFK peptide was not fruitful for β-
hairpin stabilization.  However, the work presented in Chapter VI.B demonstrated that the 
use of the CuAAC was beneficial in a similar system, WKWK-pG, which is more well-
folded than WKFK.  There are two major factors that should be considered when comparing 
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these systems: the stabilizing side chain interactions and the turn sequence.  Both of the 
peptides utilized the type II’ turn sequence, VpGO, which is a very strong turn promoter.  In 
WKFK the internal stabilizing Trp-Lys pair was mutated to a Phe-Lys resulting in a 
destabilization of the folded state.  It can be concluded that for the CuAAC cyclization to 
structurally enhance or maintain β-hairpins with a VpGO turn the unmodified peptide should 
already be well-folded via stabilizing side chain interactions. 
F.  Preliminary results of the CuAAC cyclization with WKFK-NG 
 As the incorporation of azide residues into the WKFK peptide with a rigid type II’ 
turn did not yield structurally stable cyclic peptides, the incorporation of the less rigid type I’ 
turn, VNGO, in WKFK was pursued.  Preliminary results were obtained for peptides 
containing AzK at the terminal and hydrogen bonded positions of WKFK-NG.  The circular 
dichroism spectrum for TKFK-AzK-NG-U displayed two minima at 205 nm and 195 nm 
(Figure 6.20A).  Upon CuAAC cyclization the ellipticity at these two minima was more 
intense; however, the shoulder at 195 nm was less pronounced signifying enhancement of the 
β-hairpin population at 205 nm.  The CD spectrum for HBFK-AzK-NG-U displayed a 
minimum around 195 nm indicative of random coil formation.  The cyclization afforded a 
peptide with a broad minimum spanning from 200 nm to 215 nm with a corresponding 
maximum at 190 nm.  Though the magnitude of the ellipiticty of HBFK-AzK-NG-C was 
less than the non-cyclic peptide, the shift in the minimum signified that CuAAC cyclization 
in the HB position stabilized β-hairpin formation.   
 The chemical shift differences of the TFK-AzK-NG peptides correlated with the CD 
data to show that nearly all of the residues were shifted more downfield than either the 
unmodified peptide or the non-cyclic peptide (Figure 6.20B).  This was also reflected in the 
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fraction folded (Table 6.8).  The unmodified WKFK-NG was 67% folded
b
 while TFK-AzK-
NG-U was 79% folded.  This was not surprising, as TFK-AzK-NG-U had two extra residues 
at the termini thus providing further stabilization of the hairpin.  CuAAC cyclization 
provided a peptide that was 89% folded.  The NMR data also implied that CuAAC 
cyclization at the terminal positions greatly stabilized β-hairpin formation though not as well 
as the fully folded control with a disulfide linkage as in WKFK-NG-Cys.  These results 
showed promise in stabilizing β-hairpins with a flexible turn sequence.  Incorporation of 
shorter azides in these peptide systems should be further pursued to examine if a β-hairpin 
that equals the folding of the disulfide linked peptide can be accomplished. 
 
A B 
  
Figure 6.20  (A) Circular dichroism spectra for HBFK-AzK-NG (dashed lines) and TFK-
AzK-NG peptides (bold lines) at 298 K in 10mM sodium phosphate pH 7.0 buffer.  (B) Hα 
chemical shift differences for WKFK-NG
2
 (black), TFK-AzK-NG-U (dark gren), TFK-
AzK-NG-C (light green), and WKFK-NG-Cys
2
 (dark grey) from random coil peptides.  
Values calculated from data obtained at 293 K in 50 mM potassium phosphate-d2, pD 7.0 
(uncorrected).  Glycine shifts were unclear due to overlap with the Hδ protons of dPro.  The 
residue N3 represents the azide that was incorporated. 
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Table 6.8  Fraction folded of TFK-AzK-NG peptides by glycine splitting 
Peptide Fraction Folded 
WKFK-NG* 0.67 (±0.01) 
TFK-AzK-NG-U 0.79 (±0.01) 
TFK-AzK-NG-C 0.89 (±0.01) 
* From reference 2 
 
G.  Conclusions 
 In this chapter several different systems were probed to determine the optimal 
position, turn type, and spacing for the CuAAC cyclization of β-hairpin peptides.  It was 
found that peptides containing the type II’ turn sequence, VpGO, were not ideal for the 
CuAAC mediated cyclization due to the rigidity of the turn.  This method provided moderate 
enhancement of β-hairpin structure in peptide systems displaying high folding prior to 
modification.  In cases where the peptides did not possess non-covalent stabilizing 
interactions, the CuAAC cyclization was found to disrupt folding.  The CuAAC did provide 
some structural stabilization in the type II’ turn containing peptides and was useful in 
providing both thermal and proteolytic stability. 
 The CuAAC cyclization of peptides containing the type I’ turn sequence, VNGO, 
yielded structurally more stable β-hairpins in all positions relative to the type II’ turn 
peptides.  The result was expected since the VNGO turn sequence is more flexible and 
tolerant to change relative to the VpGO turn.  The cyclization did not perturb the function of 
the hairpin as was assessed by the ability of the cyclic peptides to recognize ATP.  
Additionally, the cyclization imparted an increased thermal stability to these systems relative 
to the non-cyclic peptides.  Initial results with the modified WKFK peptides with the type I’ 
turn demonstrated that the CuAAC cyclization enhanced β-hairpin structure to poorly folded 
systems.  However, modifications of WKFK with the strong turn promoting sequence, 
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VpGO, was not suitable for CuAAC cyclization in the HB positions.  Further work should be 
pursued on other poorly folded β-hairpin systems to define a generally applicable method for 
all positions.  In general, the use of the CuAAC reaction afforded an approach to synthesize 
cyclic β-hairpins in a robust, quick, and high yielding manner, which can further be used to 
produce cyclic β-hairpin peptides for inhibition of protein-protein interactions. 
H.  Experimental section 
i.  Peptide synthesis and purification 
Peptides were synthesized by automated solid-phase peptide synthesis on a Thuramed 
Tetras peptide synthesizer using Fmoc-protected amino acids on CLEAR-amide resin 
purchased from Peptides International.  All natural Fmoc-[N]-protected amino acids were 
purchased from Advanced Chem Tech.  Fmoc-[N]-L-propargyl glycine was purchased from 
Anaspec and Fmoc-[N]-L-Lysine was purchased from Novabiochem.  All azides were 
synthesized as described below.  Activation of amino acids was performed with HBTU and 
HOBt in the presence of DIPEA in DMF and NMP.  Peptide deprotection was carried out in 
2% DBU and 2% piperidine in DMF for 2 cycles of approximately 15 min each.  Each 
coupling step was performed twice for approximately 30 min except for the Pra (2 eq) and 
AzX (2 eq) which were only coupled once for 2 hr.  All peptides were acetylated at the N-
terminus with 5% acetic anhydride and 6% 2,6-lutidene in DMF for 35 min.  Cleavage of the 
peptide from the resin was performed in 95:2.5:2.5 TFA:TIPS:H2O for 3 h.  For peptides 
containing cysteine 94:2.5:2.5:1 TFA:EDT: H2O:TIPS was used.  TFA was evaporated and 
cleavage products were precipitated with cold diethyl ether.  The peptide was extracted into 
water and lyophilized.  It was then purified by RP-HPLC using an Atlantis C-18 semi-
preparative column and a gradient of 0 to 100%B over 45 min or 60 min, where solvent A 
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was 95:5 water:acetonitrile with 0.1% TFA and solvent B was 95:5 acetonitrile: water with 
0.1% TFA.  After purification, the peptide was lyophilized to a powder and identified with 
ESI-TOF mass spectroscopy. 
 ii.  Cyclization of peptides using a disulfide bridge 
 The cyclic control peptides were cyclized by oxidizing the cysteine residues at the 
termini via stirring in a 10 mM phosphate buffer (pH 7.5) in 1% DMSO solution for 8 to 12 
hours.  The solution was then lyophilized to a powder and purified by RP-HPLC using the 
method described above. 
iii. Synthesis of α-N-Fmoc-ε-azido-L-Lysine and AzO, AzB, and AzP.  Fmoc-
Lysine-OH was purchased from Novabiochem, Fmoc-Ornithine-OH, Fmoc-Diaminobutyric 
acid, Fmoc-diaminopropionic acid were purchased from Anaspec.  Fmoc-Lysine-OH, or 
other Fmoc-amine-OH, (2.7 mmol, 1 eq), potassium carbonate (5.5 mmol, 2 eq), and copper 
(II) sulfate pentahydrate (0.028 mmol, 1 mol %) were stirred in MeOH (15 mL) for 10 mins.  
Imidazole-1-sulfonyl azide·HCl (3.3 mmol, 1.2 eq) was then added.  (Precautionary 
measures should be taken when handling imidazole-1-sulfonyl azide·HCl as it can be a 
source of ignition.  It should only be stored in small quanitities, <1 g, and be kept under inert 
conditions.)   This was allowed to react overnight.  The reaction mixture was diluted with 
water (2.5 mL) and the MeOH was removed via rotary evaporation.  The reaction was diluted 
with more water (30 mL) and acidified with HCl (ca. 1 mL).  Crude product was extracted 
into ethyl acetate (3 x 25 mL).  The organic layers were combined and dried over MgSO4.  
Fmoc-Azidolysine-OH was purified by silica gel column chromatography (3-10% MeOH in 
CH2Cl2) to give the desired product as a white solid (80% yield).  
1
H NMR (400 MHz, 
CD3OD): δ 7.69 (d, J = 7.6, 2H), δ 7.60 (t, J = 8.0, 2H), δ7.31 (t, J = 7.2, 2H), δ 7.24 (t, J = 
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7.2, 2H), δ 4.30 (d, J = 6.8, 2H), δ 4.19 (m, 1H), δ 4.13 (t,J = 6.8, 1H), δ 3.17 (m, 2H), δ 
1.90-1.35 (m, 6H) 
 iv.  General CuAAC reaction for peptide cyclization 
To a solution of purified peptide (1 mM) in 10 mM phosphate, pH 8.5 buffer was 
added a premixed solution of the tris-(triazolylmethyl)amine ligand (2.7 eq) and 
[Cu(CH3CN)4][PF6] (1.8 eq) in acetonitrile.  Sodium ascorbate (2.1 eq) dissolved in minimal 
buffer was added to the reaction.  This solution was stirred overnight in the dark.  The 
reaction mixture was quenched with %A HPLC solvent and lyophilized to a powder.  The 
reaction was further desalted followed by RP-HPLC purification with standard solvents 
where %A is 95:5:0.1 water: acetonitrile: TFA and %B is 95:5:0.1 acetonitrile: water: TFA.  
Yields were quantitative. 
 v.  Circular dichroism 
CD spectroscopy was performed on an Applied Photophysics Chirscan Plus using 
peptide concentrations between 40-60 μM in 10 mM sodium phosphate buffer, pH 7.5.  
Peptide concentrations were determined by UV-Vis using the extinction coefficients of Trp 
and PheN3 at 280 nm (ε280, Trp = 5690 M
-1 
cm
-1
 and ε280, PheN3 = 1280 M
-1 
cm
-1
).  Spectra were 
collected from 260 to 185 nm at 0.5 nm intervals at 25 °C.  For thermal denaturation, spectra 
were collected between 5 °C and 95 °C at 5 °C intervals. 
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Figure 6.21  Thermal denaturation by circular dichroism of WKWK-pG modified peptides: 
(A) HB-pG-U, (B) HB-pG-C, (C) NHB-pG-U, (D) NHB-pG-C, (E) Term-pG-U, and (F) 
Term-pG-C from 25 °C to 90 °C in 5 °C increments.   
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Figure 6.22  Thermal denaturation by circular dichroism of WKWK modified peptides: (A) 
HB-U, (B) HB-C, (C) NHB-U, (D) NHB-C, (E) Term-U, and (F) Term-C from 5 °C to 90 
°C in 5 °C increments.   
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 vi.  NMR characterization 
 NMR samples were made at a concentration of at least 1mM in D2O buffered to pD 
7.0 (uncorrected) with 50 mM KPO4D2, 0.5mM DSS.  Samples were analyzed on a Varian 
Inova 600-MHz instrument.  One dimensional spectra were collected using 32K data points 
and between 8 and 36 scans using 1.5 s presaturation.  Two dimensional total correlation 
spectroscopy (TOCSY) and nuclear Overhauser spectroscopy (NOESY) were carried out 
using the pulse sequences from the Chempack software.  Scans in the TOCSY experiment 
were taken from 16 to 32 in the first dimension and from 64 to 128 in the second dimension.   
Scans in the NOESY experiments were taken from 32 to 64 in the first dimension and from 
128 to 512 in the second dimension with mixing times of 200-500 ms.  All spectra were 
analyzed using standard window functions (sinbell and Gaussian with shifting).  
Presaturation was used to suppress the water resonance.  Assignments were made by using 
standard methods as described by Wüthrich.
7
  All experiments were run at 298 K. 
 vii.  Determination of fraction folded 
 To determine the chemical shifts in the unfolded state, 6-mers were synthesized as 
unstructured controls and cyclic peptides for fully folded controls.  The chemical shifts for 
residues in the strand and one turn residue were obtained from each 6-mer peptide.  The 
chemical shifts of the fully folded state were obtained from disulfide cyclized peptides.  The 
fraction folded on a per residue basis was determined from Equation 1: 
Fraction Folded   
         
         
               
where δobs is the observed Hα chemical shift, δ0 is the Hα chemical shift of the unstructured 
6-mers, and δ100 is the Hα chemical shift of the cyclic control.  The overall fraction folded 
for the peptide was calculated by averaging the fraction folded of the residues Val3, Val5, 
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Orn8, and Ile10.  These residues in the HB positions have been shown to be the most reliable 
in determining fraction folded. 
 The overall fraction folded was also determined using the extent of Hα glycine 
splitting observed in the turn residue of Gly7 given in Equation 2: 
 raction  olded   
         
         
               
where ΔδGly obs is the difference in the glycine Hα chemical shifts of the peptide of interest 
and ΔδGly 100 is the difference in the glycine Hα chemical shifts of the cyclic control peptide.
8
   
 
 
Figure 6.23  
1
H NMR spectrum for AzK RC (RC: random coil): Ac-Arg-AzK-Val-Lys-Val-
dPro-NH2 
 
 
Table 6.9  Hα proton chemical shifts for AzK RC 
  Hα (ppm) 
R 4.25 
AzK 4.36 
V 4.00 
K  4.29 
V 4.08 
dP 4.42 
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Figure 6.24  1H NMR spectrum for WKWK-pG: Ac-Arg-Trp-Val-Lys-Val-dPro-Gly-Orn-
Trp-Ile-Lys-Gln-NH2 
 
 
Table 6.10  Proton chemical shift assignments (ppm) for WKWK-pG 
  α β γ δ ε 
R 4.48 1.77 1.60 3.20 
W 5.23 3.26, 3.05 
V 4.67 2.01 0.91 
K  4.29 0.98, 1.28 -0.06 0.50 2.39 
V 4.49 1.91 0.89 
dP 4.33 2.32 2.09, 1.94 3.82, 3.74 
G* 0.20 
O 4.72 1.92 1.76 3.05 
W 5.23 3.26, 3.05 
I 4.73 1.91 1.45, 1.22 0.91 (γ,CH3) 0.81 (δ,CH3) 
K 3.97 1.22 0.26 0.57 2.55 
Q 4.32 2.03, 1.90 2.27     
*Glycine splitting value 
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Figure 6.25  1H NMR spectrum for WKWK-pG-Cys: Ac-Cys-Arg-Trp-Val-Lys-Val-dPro-
Gly-Orn-Trp-Ile-Lys-Gln-Cys-NH2 
 
 
Table 6.11  Proton chemical shift assignments (ppm) for WKWK-pG-Cys 
  α β γ δ ε 
C 5.07 3.11, 2.98 
R 4.70 1.87 1.72, 1.54 3.2 
W 5.32 3.22, 3.02 4.68 1.99 0.89 
V 4.68 1.99 0.89 
K  4.27 1.19, 0.97 -0.08 0.51 2.39 
V 4.49 1.91 0.88 
dP 4.33 2.31 2.08, 1.92 3.75 
G* 0.21 
O 4.73 1.92 1.76 3.05 
W 5.10 3.19, 3.06 
I 4.74 1.92 1.45, 1.22 0.91 (γ,CH3) 0.78 (δ,CH3) 
K 4.03 1.23 0.18 0.60 2.57 
Q 4.57 2.04, 1.85 2.23 
C 5.20 3.00, 2.85       
*Glycine splitting value 
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Figure 6.26  1H NMR spectrum for HB-pG-U: Ac-Arg-Trp-AzK-Lys-Val-dPro-Gly-Orn-
Trp-Pra-Lys-Gln-NH2 
 
Table 6.12  Proton chemical shift assignments (ppm) for HB-pG-U 
  α β γ δ ε 
R 4.43 1.71 1.62 3.19 
W 5.12 3.28, 3.08 
AzK 4.83 1.55 1.33 1.77 
K  4.27 1.32 0.30, 0.57 1.04 2.40 
V 4.48 2.04 0.90 
dP 4.36 2.31 2.07, 1.94 3.72 
G* -- 
O 4.71 1.91 1.77 3.07 
W 5.09 3.27, 3.07 
Pra 4.99 2.73, 2.66 
K 3.96 1.30 0.46, 0.58 0.76 2.67 
Q 4.29 2.06, 1.91 2.31     
*Glycine shifts were not clear from NMR 
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Figure 6.27  1H NMR spectrum for HB-pG-C: Ac-Arg-Trp-AzK-Lys-Val-dPro-Gly-Orn-
Trp-Pra-Lys-Gln-NH2 
 
 
Table 6.13  Proton chemical shift assignments (ppm) for HB-pG-C 
  α β γ δ ε 
R 4.47 1.77 1.59, 1.69 3.19 
W 5.35 3.28, 3.06 
AzK 4.29 1.70 0.92 1.15 
K  3.88 1.18 0.32 0.53 2.64 
V 4.53 2.01 0.92 
dP 4.37 2.32 2.07, 1.94 3.75, 3.67 
G* -- 
O 4.80 1.93, 1.84 1.67 3.07 
W 5.06 3.27, 3.01 
Pra 5.14 3.32 
K 4.53 0.05, 0.42 1.02 2.50 
Q 4.30 2.05, 1.89 2.31     
*Glycine shifts were not clear from NMR 
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Figure 6.28  1H NMR spectrum for NHB-pG-U: Ac-Arg-AzK-Val-Lys-Val-dPro-Gly-Orn-
Trp-Ile-Pra-Gln-NH2 
 
 
Table 6.14  Proton chemical shift assignments (ppm) for NHB-pG-U 
  α β γ δ ε 
R 4.36 1.75 1.61 3.19 
AzK 5.03 1.36 1.80, 1.71 3.03 
V 4.58 1.97 0.85 
K  4.22 1.16, 0.95 0.01 0.49 2.30 
V 4.46 1.94 0.87 
dP 4.31 2.29 1.90, 2.04 3.76, 3.69 
G* 0.20 
O 4.66 1.85 1.70 2.99 
W 4.94 3.07, 2.96 
I 4.62 1.94 1.38, 1.17 0.89 (γ,CH3) 0.78 (δ,CH3) 
Pra 4.80 2.70 
Q 4.37 2.09, 1.94 2.30     
*Glycine splitting value 
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Figure 6.29  1H NMR spectrum for NHB-pG-C: Ac-Arg-AzK-Val-Lys-Val-dPro-Gly-Orn-
Trp-Ile-Pra-Gln-NH2 
 
 
Table 6.15  Proton chemical shift assignments (ppm) for NHB-pG-C 
  α β γ δ ε 
R 4.30 1.80 1.59 3.22 
AzK 4.30 1.66, 1.54 0.70 1.05 4.55, 4.54 
V 4.58 1.96 0.88 
K  4.30 1.21, 0.88 -0.06 0.28, 0.46 
V 4.46 1.86 0.86 
dP 4.30 2.3 2.07, 1.90 3.80, 3.69 
G* 0.20 
O 4.63 1.86 1.71 3.01 
W 4.91 3.06, 2.85 
I 4.58 1.96 1.27 0.88 (γ,CH3) 0.80 (δ,CH3) 
Pra 4.92 3.23 
Q 4.41 2.14,2.01 2.34     
*Glycine splitting value 
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Figure 6.30  1H NMR spectrum for Term-pG-U: Ac-Pra-Arg-Trp-Val-Lys-Val-dPro-Gly-
Orn-Trp-Ile-Lys-Gln-AzK-NH2 
 
 
Table 6.16  Proton chemical shift assignments (ppm) for Term-pG-U 
  α β γ δ ε 
Pra 4.68 2.48 
R 4.62 1.78 1.57 3.18 
W 5.31 3.24, 3.01 
V 4.68 1.99 0.89 
K  4.30 1.19, 0.97 -0.07 0.5 
V 4.50 1.90 0.88 
dP 4.33 2.32 2.08, 1.93 3.80, 3.73 
G* 0.20 
O 4.72 1.90 1.75 3.04 
W 5.09 3.17, 3.04 
I 4.76 1.95 1.42, 1.22 0.92 (γ,CH3) 0.80 (δ,CH3) 
K 3.99 1.24 0.46. 0.31 0.60 2.61 
Q 4.46 2.02, 1.85 2.23 
AzK 4.30 2.75 1.41 1.58 3.29 
*Glycine splitting value 
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Figure 6.31  1H NMR spectrum for Term-pG-C: Ac-Pra-Arg-Trp-Val-Lys-Val-dPro-Gly-
Orn-Trp-Ile-Lys-Gln-AzK-NH2 
 
 
Table 6.17  Proton chemical shift assignments (ppm) for Term-pG-U 
  α β γ δ ε 
Pra 4.82 2.94, 2.77 
R 4.69 1.82 1.62 3.20 
W 5.27 3.29, 3.07 
V 4.67 2.02 0.92 
K  4.31 1.20, 0.99 0.04 0.51 2.38 
V 4.50 1.92 0.88 
dP 4.34 2.33 1.95, 2.11 3.81, 3.74 
G* 0.21 
O 4.74 1.93 1.77 3.07 
W 5.10 3.18, 3.03 
I 4.76 1.97 1.45, 1.24 0.95 (γ,CH3) 0.84 (δ,CH3) 
K 4.15 1.17 0.45, 0.23 0.65 2.47 
Q 4.47 2.02, 1.84 2.24 
AzK 4.06 1.89 1.12 1.58, 1.47 4.38, 4.36 
*Glycine splitting value 
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Figure 6.32  1H NMR spectrum for HB-U: Ac-Arg-Trp-AzK-Lys-Val-Asn-Gly-Orn-Trp-
Pra-Lys-Gln-NH2 
 
 
Table 6.18  Proton chemical shift assignments (ppm) for HB-U 
  α β γ δ ε 
R 4.32 1.69 1.54 3.14 
W 4.99 3.27, 3.10 
AzK 4.63 1.74, 1.67 1.26 1.52 3.25 
K  4.00 1.39 0.68 0.86 2.73 
V 4.11 2.01 0.89 
N 4.45 2.98, 2.73 
G* 0.48 
O 4.58 1.88 1.70 3.03 
W 4.90 3.27, 3.12 
Pra 4.78 2.67, 2.41 
K 4.31 1.35, 1.19 0.48 0.79, 0.64 2.43 
Q 4.27 2.06, 1.92 2.30     
*Glycine splitting value 
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Figure 6.33  1H NMR spectrum for HB-C: Ac-Arg-Trp-AzK-Lys-Val-Asn-Gly-Orn-Trp-
Pra-Lys-Gln-NH2 
 
 
Table 6.19  Proton chemical shift assignments (ppm) for HB-C 
  α β γ δ ε 
R 4.49 1.75 1.63 3.22 
W 5.30 3.32, 3.13 
AzK 4.82 1.93, 1.67 0.86 1.16 4.30, 4.26 
K  3.90 1.28 0.33, 0.57 1.17 2.68 
V 4.21 1.97 0.92 
N 4.41 3.05, 2.80 
G* 0.66 
O 4.80 1.75 1.63 3.12 
W 5.07 3.31, 3.02 
Pra 5.13 3.35 
K 4.54 0.44 1.06, 0.93 
Q 4.32 2.08, 1.94 2.33     
*Glycine splitting value 
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Figure 6.34  1H NMR spectrum for HB-rev-U: Ac-Arg-Trp-Pra-Lys-Val-Asn-Gly-Orn-Trp-
AzK-Lys-Gln-NH2 
 
 
Table 6.20  Proton chemical shift assignments (ppm) for HB-rev-U 
  α β γ δ ε 
R 4.41 1.68 1.58 3.17 
W 5.17 3.29, 3.06 
Pra 4.87 2.67 
K  4.34 1.28 0.53 1.15 2.39 
V 4.11 1.90 0.90 
N 4.41 3.02, 2.76 
G* 0.59 
O 4.64 1.91 1.75 3.06 
W 4.92 3.25, 3.12 
AzK 4.71 1.82, 1.75 1.40 1.59 3.32 
K 3.92 1.37 0.63 0.82 2.72 
Q 4.28 2.04, 1.91 2.29     
*Glycine splitting value 
 
175 
 
 
Figure 6.35  1H NMR spectrum for HB-rev-C: Ac-Arg-Trp-Pra-Lys-Val-Asn-Gly-Orn-Trp-
AzK-Lys-Gln-NH2 
 
 
Table 6.21  Proton chemical shift assignments (ppm) for HB-rev-C 
  α β γ δ ε 
R 4.48 1.77 1.61 3.18 
W 5.32 3.35, 3.07 
Pra 5.20 3.35 
K  4.34 1.00 0.03, 0.18 0.27 2.30 
V 4.15 1.88 0.82 
N 4.39 3.03, 2.77 
G* 0.69 
O 4.71 1.93 1.75 3.08 
W 4.92 3.26, 3.07 
AzK 4.79 1.96 1.26 1.75 4.32 
K 4.05 1.32, 1.20 0.43 0.7 2.71 
Q 4.27 2.01, 1.86 2.20     
*Glycine splitting value 
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Figure 6.36  1H NMR spectrum for NHB-U: Ac-Arg-AzK-Val-Lys-Val-Asn-Gly-Orn-Trp-
Ile-Pra-Gln-NH2 
 
 
Table 6.22  Proton chemical shift assignments (ppm) for NHB-U 
  α β γ δ ε 
R 4.61 1.85 1.69 3.01 
AzK 4.37 1.78 1.63 1.94 
V 4.57 1.99 0.88 
K  4.30 1.08, 1.18 0.09, 0.14 0.52 2.32 
V 4.10 1.83 0.85 
N 4.38 3.00, 2.72 
G* 0.63 
O 4.99 1.70, 1.81 1.39 3.05 
W 4.87 3.10 
I 4.58 1.94 1.39, 1.18 0.89 (γ,CH3) 0.82 (δ,CH3) 
Pra 4.76 2.71 
Q 4.38 2.11, 1.94 2.31     
*Glycine splitting value 
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Figure 6.37  1H NMR spectrum for NHB-C: Ac-Arg-AzK-Val-Lys-Val-Asn-Gly-Orn-Trp-
Ile-Pra-Gln-NH2 
 
 
Table 6.23  Proton chemical shift assignments (ppm) for NHB-C 
  α β γ δ ε 
R 4.30 1.78 1.51 3.21 
AzK 4.29 1.64 0.71 1.06 4.56 
V 4.65 1.97 0.85 
K  4.37 1.12 -0.11, 0.16 0.40, 0.91 2.04 
V 4.09 1.79 0.84 
N 4.33 3.04, 2.71 
G* 0.72 
O 4.62 1.86 1.69 3.00 
W 4.84 3.12 
I 4.59 1.98 1.35, 1.28 0.89 (γ,CH3) 0.78 (δ,CH3) 
Pra 4.09 2.42, 2.31 
Q 4.41 2.11, 2.01 2.33     
*Glycine splitting value 
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Figure 6.38  1H NMR spectrum for NHB-rev-U: Ac-Arg-Pra-Val-Lys-Val-Asn-Gly-Orn-
Trp-Ile-Lys-AzK-Gln-NH2 
 
 
Table 6.24  Proton chemical shift assignments (ppm) for NHB-rev-U 
  α β γ δ ε 
R 4.40 1.84, 1.79 1.65 3.20 
Pra 4.80 3.11 
V 4.49 2 0.87 
K  4.31 0.63 1.27, 1.17 2.42 
V 4.10 1.87 0.85 
N 4.42 3.00, 2.73 
G* 0.55 
O 4.57 1.83 1.69 3.01 
W 5.08 2.73, 2.67 
I 4.45 1.91 1.40, 1.19 0.88 (γ,CH3) 0.77 (δ,CH3) 
AzK 4.54 1.77 1.43 1.60 
Q 4.37 2.10, 1.97 2.33     
*Glycine splitting value 
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Figure 6.39  1H NMR spectrum for NHB-rev-C: Ac-Arg-Pra-Val-Lys-Val-Asn-Gly-Orn-
Trp-Ile-Lys-AzK-Gln-NH2 
 
 
Table 6.25  Proton chemical shift assignments (ppm) for NHB-rev-C 
  α β γ δ ε 
R 4.32 1.80 1.63 3.21 
Pra 4.87 3.14 
V 4.65 1.98 0.86 
K  4.29 1.07, 1.16 0.00 0.44 2.29 
V 4.10 1.81 0.84 
N 4.36 3.04, 2.71 
G* 0.71 
O 4.65 1.87 1.71 3.03 
W 5.34 3.17, 3.06 
I 4.57 1.92 1.36, 1.21 0.88 (γ,CH3) 0.81 (δ,CH3) 
AzK 4.21 1.78, 1.98 0.94, 1.13 1.56 4.43, 4.37 
Q 4.31 2.05, 1.96 2.29     
*Glycine splitting value 
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Figure 6.40  1H NMR spectrum for Term-U: Ac-Pra-Arg-Trp-Val-Lys-Val-Asn-Gly-Orn-
Trp-Ile-Lys-Gln-AzK-NH2 
 
 
Table 6.26  Proton chemical shift assignments (ppm) for Term-U 
α β γ δ ε 
Pra 4.70 2.51 
R 4.64 1.79 1.58 3.19 
W 5.35 3.28, 3.00 
V 4.73 2.00 0.91 
K  4.36 1.06, 1.16 -0.11 0.46 2.31 
V 4.14 1.85 0.87 
N 4.37 3.08, 2.75 
G* 0.74 
O 4.70 1.93 1.76 3.07 
W 5.05 3.20, 3.08 
I 4.79 1.98 1.25,1.46 0.96 (γ,CH3) 0.83 (δ,CH3) 
K 4.03 1.26 0.39, 0.47 0.67 2.65 
Q 4.49 2.06, 1.87 2.25 
AzK 4.32 1.78 1.43 1.60 3.30 
*Glycine splitting value 
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Figure 6.41  1H NMR spectrum for Term-C: Ac-Pra-Arg-Trp-Val-Lys-Val-Asn-Gly-Orn-
Trp-Ile-Lys-Gln-AzK-NH2 
 
 
Table 6.27  Proton chemical shift assignments (ppm) for Term-C 
α β γ δ ε 
Pra 4.80 2.92, 2.76 
R 4.67 1.79 1.60 3.19 
W 5.30 3.29, 3.04 
V 4.69 2.00 0.90 
K  4.35 1.13, 1.06 -0.10 0.43 2.29 
V 4.13 1.84 0.86 
N 4.36 3.08, 2.75 
G* 0.74 
O 4.70 1.92 1.75 3.06 
W 5.04 3.18, 3.07 
I 4.76 1.96 1.44, 1.24 0.93 (γ,CH3) 0.84 (δ,CH3) 
K 4.18 1.18 0.41 0.70 2.47 
Q 4.46 2.00, 1.84 2.23 
AzK 4.07 1.87 1.11 1.47, 1.57 4.36 
*Glycine splitting value 
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Figure 6.42  1H NMR spectrum for Term-rev-U: Ac-AzK-Arg-Trp-Val-Lys-Val-Asn-Gly-
Orn-Trp-Ile-Lys-Gln-Pra-NH2 
 
 
Table 6.28  Proton chemical shift assignments (ppm) for Term-rev-U 
  α β γ δ ε 
AzK 4.38 1.62 1.34 1.47 3.24 
R 4.58 1.85, 1.77 1.58 3.19 
W 5.28 3.29, 3.00 
V 4.67 2.00 0.89 
K  4.32 1.06, 1.16 -0.10 0.46 2.32 
V 4.12 1.84 0.86 
N 4.36 3.06, 2.73 
G* 0.72 
O 4.67 1.91 1.74 3.06 
W 5.01 3.18, 3.05 
I 4.78 1.97 1.44, 1.23 0.95 (γ,CH3) 0.82 (δ,CH3) 
K 4.21 1.22 0.46 0.86 2.56 
Q 4.50 2.05, 1.87 2.26 
Pra 4.46 2.71, 2.45       
*Glycine splitting value 
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Figure 6.43  1H NMR spectrum for Term-rev-C: Ac-AzK-Arg-Trp-Val-Lys-Val-Asn-Gly-
Orn-Trp-Ile-Lys-Gln-Pra-NH2 
 
 
Table 6.29  Proton chemical shift assignments (ppm) for Term-rev-C 
  α β γ δ ε 
AzK 4.09 1.65 0.43 1.42 4.35 
R 4.64 1.72 1.56 3.16 
W 5.27 3.19,2.95 
V 4.67 1.94 0.83 
K  4.31 1.00, 1.10 -0.19 0.41 2.24 
V 4.09 1.79 0.83 
N 4.32 3.04, 2.71 
G* 0.74 
O 4.66 1.94 1.74 3.03 
W 4.98 3.14, 3.03 
I 4.78 1.97 1.41, 1.24 0.91 (γ,CH3) 0.82 (δ,CH3) 
K 4.07 1.39 0.60 0.99 2.71 
Q 4.46 1.89, 1.72 2.14 
Pra 4.70 3.28, 2.93       
*Glycine splitting value 
PPM 8.4 8.0 7.6 7.2 6.8 6.4 6.0 5.6 5.2 4.8 4.4 4.0 3.6 3.2 2.8 2.4 2.0 1.6 1.2 0.8 0.4 0.0 -0.4
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Figure 6.44  1H NMR spectrum for Term-pG-AzO-C: Ac-Pra-Arg-Trp-Val-Lys-Val-dPro-
Gly-Orn-Trp-Ile-Lys-Gln-AzO-NH2 
 
 
Table 6.30  Proton chemical shift assignments (ppm) for Term-pG-AzO-C 
  α β γ δ ε 
Pra 4.70 3.01, 2.81 
R 4.60 1.77 1.62 3.20 
W 5.19 3.29, 3.06 
V 4.67 2.03 0.92 
K 4.33 1.20, 0.99 -0.04 0.51 2.34 
V 4.49 1.91 0.88 
dP 4.33 2.31 2.10, 1.89 3.76 
G* 0.21 
O 4.72 1.90 1.75 3.05 
W 5.09 3.18, 3.02 
I 4.75 1.96 1.45, 1.23 0.91 (γ,CH3) 0.80 (δ,CH3) 
K 4.11 1.19 0.44, 0.32 0.65 2.44 
Q 4.36 1.98, 1.83 2.22 
AzO 4.42 1.95 1.,76, 1.63 3.54   
*Glycine splitting 
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Figure 6.45  1H NMR spectrum for Term-pG-AzB-C: Ac-Pra-Arg-Trp-Val-Lys-Val-dPro-
Gly-Orn-Trp-Ile-Lys-Gln-AzB-NH2 
 
 
Table 6.31  Proton chemical shift assignments (ppm) for Term-pG-AzB-C 
  α β γ δ ε 
Pra 4.50 2.99, 2.84 
R 4.56 1.77 1.58 3.19 
W 5.12 3.30, 3.06 
V 4.66 2.04 0.93 
K 4.32 1.21, 0.97 0.00 0.51 
V 4.49 1.91 0.87 
dP 4.33 2.32 2.07, 1.94 3.76 
G* 0.21 
O 4.71 1.90 1.76 3.05 
W 5.10 3.16, 2.99 
I 4.75 1.93 1.46, 1.23 0.92 (γ,CH3) 0.84 (δ,CH3) 
K 4.17 1.08, 1.20 0.40 0.59 2.35 
Q 4.39 2.02, 1.85 2.21 
AzB 4.58 2.37, 2.21 3.81     
*Glycine splitting 
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Figure 6.46  1H NMR spectrum for Term-pG-AzP-C: Ac-Pra-Arg-Trp-Val-Lys-Val-dPro-
Gly-Orn-Trp-Ile-Lys-Gln-AzP-NH2 
 
 
Table 6.32  Proton chemical shift assignments (ppm) for Term-pG-AzP-C 
  α β γ δ ε 
Pra 4.55 3.02, 2.84 
R 4.42 1.80 1.66 3.23 
W 5.06 3.11, 3.00 
V 4.66 2.03 0.93 
K 4.33 1.20, 0.98 0.01 0.53 
V 4.49 1.89 0.89 
dP 4.33 2.32 2.07, 1.95 3.75 
G* 0.21 
O 4.68 1.83 1.75 3.03 
W 5.02 3.30, 3.05 
I 4.76 1.95 1.41, 1.21 0.94 (γ,CH3) 0.82 (δ,CH3) 
K 4.10 1.12 0.50 0.85 2.33 
Q 4.35 1.98, 1.78 2.18 
AzP 4.54 4.37       
*Glycine splitting 
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Figure 6.47  1H NMR spectrum for FK RC: Ac- Gly-Orn-Phe-Ile-Lys-Gln-NH2 
 
 
Table 6.33  Proton chemical shift assignments (ppm) for FK RC 
  α β γ δ ε 
G 3.83 
O 4.19 1.76 1.41 3.00 
F 4.65 3.07 
I 4.07 1.74 1.43, 1.12 0.84 (γ,CH3) 0.69 (δ,CH3) 
K 4.25 1.79 1.45 1.61 3.32 
Q 4.32 2.12, 1.98 2.35     
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Figure 6.48  1H NMR spectrum for WKFK: Ac-Arg-Trp-Val-Lys-Val-dPro-Gly-Orn-Phe-
Ile-Lys-Gln-NH2 
 
 
Table 6.34  Proton chemical shift assignments (ppm) for WKFK 
  α β γ δ ε 
R 4.32 1.70 1.57 3.11 
W 5.14 2.88 2.76 
V 4.57 2.05 0.92 
K 4.44 1.61 0.86, 0.51 1.33, 1.17 2.60 
V 4.52 1.94 0.91 
dP 4.37 2.33 2.11, 1.96 3.84, 3.72 
G -- 
O 4.67 1.91 1.73 3.05 
F 5.12 3.06 
I 4.65 1.88 1.41, 1.19 0.92 (γ,CH3) 0.82 (δ,CH3) 
K 4.31 1.60 0.86, 0.58 1.3 2.59 
Q 4.26 1.46 1.76     
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Figure 6.49  1H NMR spectrum for WKFK-Cys: Ac-Cys-Arg-Trp-Val-Lys-Val-dPro-Gly-
Orn-Phe-Ile-Lys-Gln-Cys-NH2 
 
 
Table 6.35  Proton chemical shift assignments (ppm) for WKFK-Cys 
  α β γ δ ε 
C 5.22 2.89, 2.79 
R 4.74 1.92 1.75 3.09 
W 5.26 3.10, 2.96 
V 4.63 1.88 0.94 
K 4.40 1.66, 1.35 0.49 0.92, 1.16 2.67 
V 4.55 1.95 0.92 
dP 4.4 2.35 2.16, 2.00 3.88, 3.74 
G -- 
O 4.73 1.91 1.57 3.23 
F 5.11 3.13, 3.04 
I 4.74 1.84 1.46, 1.24 0.96 (γ,CH3) 0.86(δ,CH3) 
K 4.04 1.31 0.45/0.23 0.71 2.61 
Q 4.63 2.07 2.26 
C 5.24 2.38       
 
PPM 9.0 8.0 7.0 6.0 5.0 4.0 3.0 2.0 1.0 0.0
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Figure 6.50  1H NMR spectrum for TKFK-AzK-U: Ac-Pra-Arg-Trp-Val-Lys-Val-dPro-
Gly-Orn-Phe-Ile-Lys-Gln-AzK-NH2 
 
 
Table 6.36  Proton chemical shift assignments (ppm) for TFK-AzK-U 
  α β γ δ ε 
Pra 4.62 2.48, 2.30 
R 4.57 1.75 1.53 3.17 
W 5.18 3.02 
V 4.54 2.02 0.90 
K 3.98 1.33 0.64, 0.50 0.83 2.67 
V 4.52 1.94 0.92 
dP 4.37 2.34 2.10, 1.96 3.84, 3.74 
G -- 
O 4.68 1.90 1.73 3.04 
F 5.14 2.92, 2.82 
I 4.67 1.92 1.43, 1.22 0.91 (γ,CH3) 0.81 (δ,CH3) 
K 4.45 1.61 0.87, 0.58 1.36, 1.27 2.62 
Q 4.44 2.04, 1.84 2.23 
AzK 4.29 1.77 1.42 1.6 3.29 
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Figure 6.51  1H NMR spectrum for TKFK-AzK-C: Ac-Pra-Arg-Trp-Val-Lys-Val-dPro-
Gly-Orn-Phe-Ile-Lys-Gln-AzK-NH2 
 
 
Table 6.37  Proton chemical shift assignments (ppm) for TFK-AzK-C 
  α β γ δ ε 
Pra 4.62 2.91, 2.76 
R 4.54 1.72 1.56 3.16 
W 5.07 3.13, 3.03 
V 4.51 1.91 0.89 
K 4.50 1.92 0.65 1.58, 1.30 2.56 
V 4.45 0.90 
dP 4.36 2.33 2.09, 1.95 3.82, 3.74 
G -- 
O 4.67 1.82 1.71 3.02 
F 5.11 2.93, 2.82 
I 4.60 1.91 1.40, 1.20 0.93 (γ,CH3) 0.80 (δ,CH3) 
K 4.11 1.76 0.63 1.27, 0.98 2.52 
Q 4.44 2.01, 1.81 2.23 
AzK 4.23 1,77 1.14 1.57   
 
 
PPM 8.4 8.0 7.6 7.2 6.8 6.4 6.0 5.6 5.2 4.8 4.4 4.0 3.6 3.2 2.8 2.4 2.0 1.6 1.2 0.8 0.4 0.0 -0.4
192 
 
 
Figure 6.52  1H NMR spectrum for TKFK-AzO-U: Ac-Pra-Arg-Trp-Val-Lys-Val-dPro-
Gly-Orn-Phe-Ile-Lys-Gln-AzO-NH2 
 
 
Table 6.38  Proton chemical shift assignments (ppm) for TFK-AzO-U 
  α β γ δ ε 
Pra 4.62 2.50, 2.30 
R 4.56 1.8 1.71 3.16 
W 5.2 3.03 
V 4.56 2.04 0.92 
K 4.45 1.62 0.85, 0.56 1.36, 1.24 2.57 
V 4.52 1.94 0.92 
dP 4.37 2.34 2.16, 1.96 3.86, 3.73 
G -- 
O 4.68 1.93 1.80 3.02 
F 5.14 2.91, 2.78 
I 4.68 1.79 1.45, 1.23 0.94 (γ,CH3) 0.83 (δ,CH3) 
K 3.98 1.36 0.66, 0.51 0.84 
Q 4.44 2.05, 1.83 2.22 
AzO 4.33 1.89 1.76 3.33   
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Figure 6.53  1H NMR spectrum for TKFK-AzO-C: Ac-Pra-Arg-Trp-Val-Lys-Val-dPro-
Gly-Orn-Phe-Ile-Lys-Gln-AzO-NH2 
 
 
Table 6.39  Proton chemical shift assignments (ppm) for TFK-AzO-C 
  α β γ δ ε 
Pra 4.52 2.98, 2.83 
R 4.49 1.69 1.55 3.16 
W 4.99 3.17, 3.03 
V 4.52 1.93 0.90 
K 4.56 1.56 0.83, 0.67 1.32 2.55 
V 4.42 0.92 
dP 4.36 2.33 2.10, 2.94 3.83, 3.74 
G -- 
O 4.65 1.87 1.73 3.03 
F 5.09 2.96, 2.81 
I 4.61 1.94 1.42, 1.20 0.93 (γ,CH3) 0.80 (δ,CH3) 
K 4.16 1.45, 1.28 0.76 1.09 2.58 
Q 4.41 1.99, 1.84 2.26 
AzO 4.18 1.71 1.52 3.88   
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Figure 6.54  1H NMR spectrum for TKFK-AzB-U: Ac-Pra-Arg-Trp-Val-Lys-Val-dPro-Gly-
Orn-Phe-Ile-Lys-Gln-AzB-NH2 
 
 
Table 6.40  Proton chemical shift assignments (ppm) for TKFK-AzB-U 
  α β γ δ ε 
Pra 4.62 2.50, 2.29 
R 4.58 1.78 1.71 3.16 
W 5.19 3.03, 2.85 
V 4.55 2.95 0.92 
K 4.44 1.64 0.55 1.33 
V 4.51 1.94 0.95 
dP 4.37 2.31 2.10, 1.95 3.84, 3.72 
G -- 
O 4.67 1.90 1.76 3.04 
F 5.15 2.92, 2.79 
I 4.68 1.78 1.42, 1.21 0.94 (γ,CH3) 0.88 (δ,CH3) 
K 3.95 1.34 0.49 0.80, 0.68 
Q 4.32 2.09, 1.94 2.37 
AzB 4.46 1.94 3.43     
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Figure 6.55  1H NMR spectrum for TKFK-AzB-C: Ac-Pra-Arg-Trp-Val-Lys-Val-dPro-Gly-
Orn-Phe-Ile-Lys-Gln-AzB-NH2 
 
 
Table 6.41 Proton chemical shift assignments (ppm) for TKFK-AzB-C 
  α β γ δ ε 
Pra 4.41 3.00, 2.85 
R 4.43 1.66 1.51 3.14 
W 4.99 3.20, 3.10 
V 4.52 1.92 0.93 
K 4.53 1.56 0.80, 0.67 1.31 2.54 
V 4.44 2.06 0.94 
dP 4.37 2.32 2.10, 1.94 3.83, 3.75 
G -- 
O 4.65 1.90 1.78, 1.69 3.02 
F 5.10 2.97, 2.82 
I 4.59 1.93 1.43, 1.23 0.96 (γ,CH3) 0.83 (δ,CH3) 
K 4.15 1.43 0.72 1.23, 1.03 2.49 
Q 4.41 2.02, 1.88 2.26 
AzB 4.26 2.31, 2.22 4.00     
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Figure 6.56  1H NMR spectrum for TKFK-AzP-U: Ac-Pra-Arg-Trp-Val-Lys-Val-dPro-Gly-
Orn-Phe-Ile-Lys-Gln-AzP-NH2 
 
 
Table 6.42  Proton chemical shift assignments (ppm) for TKFK-AzP-U 
  α β γ δ ε 
Pra 4.58 2.47, 2.28 
R 4.56 1.83 1.72 3.14 
W 5.19 3.02 
V 4.55 2.02 0.96 
K 4.45 1.33 0.59 0.96 
V 4.52 1.94 0.97 
dP 4.37 3.71, 2.32 2.12, 1.91 3.83, 3.71 
G -- 
O 4.67 1.88 1.72 3.00 
F 5.14 2.89, 2.80 
I 4.66 1.94 1.43, 1.20 0.99 (γ,CH3) 
K 3.94 1.32 0.64, 0.55 0.81 2.92 
Q 4.46 2.03, 1.82 2.25 
AzP 4.25         
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Figure 6.57  1H NMR spectrum for TKFK-AzP-C: Ac-Pra-Arg-Trp-Val-Lys-Val-dPro-Gly-
Orn-Phe-Ile-Lys-Gln-AzP-NH2 
 
 
Table 6.43  Proton chemical shift assignments (ppm) for TKFK-AzP-C 
  α β γ δ ε 
Pra 4.54 3.14, 3.04 
R 4.38 1.70 1.60 3.18 
W 4.93 3.12, 3.06 
V 4.52 1.93 0.92 
K 4.56 1.62 0.90, 0.73 1.37 2.62 
V 4.47 2.05 0.94 
dP 4.37 2.32 2.07, 1.94 3.72, 3.82 
G -- 
O 4.59 1.86 1.70 3.01 
F 4.99 2.93, 2.79 
I 4.59 1.94 1.40, 1.22 0.93 (γ,CH3) 0.81 (δ,CH3) 
K 4.20 1.42 0.88, 0.75 1.27 2.50 
Q 4.38 2.15 
AzP 4.48 2.49       
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Figure 6.58  1H NMR spectrum for HBFK-AzK-U: Ac-Arg-Trp-AzK-Lys-Val-dPro-Gly-
Orn-Phe-Pra-Lys-Gln-NH2 
 
 
Table 6.44  Proton chemical shift assignments (ppm) for HBFK-AzK-U 
  α β γ δ ε 
R 4.31 1.7 1.48 3.13 
W 4.92 3.19, 3.11 
AzK 4.59 1.73 1.28 1.56 3.28 
K 4.42 1.65 0.95 1.43 2.70 
V 4.49 2.03 0.95 
dP 4.40 2.30 2.08, 1.98 3.80, 3.72 
G -- 
O 4.57 1.90 1.72 3.01 
F 5.04 3.00, 2.83 
Pra 4.81 2.65 
K 4.05 1.48 0.87 1.11/1.01 2.77 
Q 4.29 2.08, 1.90 2.30     
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Figure 6.59  1H NMR spectrum for HBFK-AzK-C: Ac-Arg-Trp-AzK-Lys-Val-dPro-Gly-
Orn-Phe-Pra-Lys-Gln-NH2 
 
 
Table 6.45  Proton chemical shift assignments (ppm) for HBFK-AzK-C 
  α β γ δ ε 
R 4.43 1.73 1.56 3.18 
W 4.94 3.13, 3.04 
AzK 4.62 1.64 1.02, 0.78 1.42 2.74 
K 4.36 1.85 1.08 1.66 
V 4.42 0.95 
dP 4.41 2.29 2.00 3.71, 3.60 
G -- 
O 4.59 1.90 1.79 3.08 
F 5.05 3.24 
Pra 4.60 1.65 
K 3.94 1.43 0.88, 0.77 1.03 2.76 
Q 4.31 2.04, 1.90 2.32     
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Figure 6.60  1H NMR spectrum for HBFK-AzO-U: Ac-Arg-Trp-AzO-Lys-Val-dPro-Gly-
Orn-Phe-Pra-Lys-Gln-NH2 
 
 
Table 6.46  Proton chemical shift assignments (ppm) for HBFK-AzO-U 
  α β γ δ ε 
R 4.30 1.66 1.51 3.13 
W 4.89 3.16 
AzO 4.58 1.71 1.52 3.29 
K 4.40 1.65 1.01 1.46 2.71 
V 4.48 2.02 0.93 
dP 4.40 2.31 2.05, 1.95 3.81, 3.72 
G -- 
O 4.57 1,84 1.72 3.01 
F 5.03 3.01, 2.85 
Pra 4.78 2.67 
K 4.06 1.46 0.88 1.06 2.77 
Q 4.28 2.06, 1.92 2.32     
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Figure 6.61  1H NMR spectrum for HBFK-AzO-C: Ac-Arg-Trp-AzO-Lys-Val-dPro-Gly-
Orn-Phe-Pra-Lys-Gln-NH2 
 
 
Table 6.47  Proton chemical shift assignments (ppm) for HBFK-AzO-C 
  α β γ δ ε 
R 4.16 1.57 1.40 3.05 
W 4.68 3.27, 3.18 
AzO 4.33 1.81 1.66, 1.45 
K 4.44 1.72 1.19 1.59 
V 4.33 2.04 0.94 
dP 4.42 2.28 2.00 3.72 
G -- 
O 4.43 2.28 1.98 2.81 
F 4.87 3.06, 2.83 
Pra 4.80 3.24 
K 4.22 1.79 1.34 1.64 2.91 
Q 4.30 2.11, 1.98 2.35     
 
 
202 
 
 
Figure 6.62  1H NMR spectrum for HBFK-AzB-U: Ac-Arg-Trp-AzB-Lys-Val-dPro-Gly-
Orn-Phe-Pra-Lys-Gln-NH2 
 
 
Table 6.48  Proton chemical shift assignments (ppm) for HBFK-AzB-U 
  α β γ δ ε 
R 4.27 1.65 1.48 3.11 
W 4.83 3.14 
AzB 4.66 2.01, 1.99 3.31 
K 4.38 1.66 1.04 1.49 2.76 
V 4.48 2.02 0.91 
dP 4.41 2.31 2.06, 1.96 3.81, 3.73 
G -- 
O 4.66 2.01 1.89 3.32 
F 5.01 3.02, 2.87 
Pra 4.34 2.68 
K 4.10 1.54, 1.45 1.01, 0.90 1.18 2.76 
Q 4.29 2.05, 1.92 2.30     
 
PPM 8.4 8.0 7.6 7.2 6.8 6.4 6.0 5.6 5.2 4.8 4.4 4.0 3.6 3.2 2.8 2.4 2.0 1.6 1.2 0.8 0.4 0.0 -0.4
203 
 
 
Figure 6.63  1H NMR spectrum for HBFK-AzB-C: Ac-Arg-Trp-AzB-Lys-Val-dPro-Gly-
Orn-Phe-Pra-Lys-Gln-NH2 
 
 
Table 6.49  Proton chemical shift assignments (ppm) for HBFK-AzB-C 
  α β γ δ ε 
R 4.29 1.65 1.45 3.09 
W 4.86 3.10 
AzB 4.56 2.42 4.41 
K 4.18 1.80 1.43 1.70 2.99 
V 4.35 2.85 1.3 
dP 4.42 2.15 1.96, 1.77 3.44 
G -- 
O 4.32 3.02 
F 4.30 2.91, 2.61 
Pra 4.67 3.10 
K 4.02 1.98 0.86 1.01 3.68 
Q 4.29 2.09, 1.97 2.34     
 
PPM 8.4 8.0 7.6 7.2 6.8 6.4 6.0 5.6 5.2 4.8 4.4 4.0 3.6 3.2 2.8 2.4 2.0 1.6 1.2 0.8 0.4 0.0 -0.4
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Figure 6.64  1H NMR spectrum for HBFK-AzP-U: Ac-Arg-Trp-AzP-Lys-Val-dPro-Gly-
Orn-Phe-Pra-Lys-Gln-NH2 
 
 
Table 6.50  Proton chemical shift assignments (ppm) for HBFK-AzP-U 
  α β γ δ ε 
R 4.30 1.44 1.49 3.10 
W 4.97 3.22, 3.13 
AzP 4.80 3.63 
K 4.46 1.65 1.00 1.44 2.68 
V 4.49 2.02 0.81 
dP 4.40 2.31 2.04, 1.97 3.77 
G -- 
O 4.54 1.86 1.72 3.01 
F 4.98 3.02, 2.88 
Pra 4,75 2.66 
K 4.08 1.48 1.03, 0.94 1.16 2.78 
Q 4.27 2.06, 1.92 2.30     
 
PPM 8.4 8.0 7.6 7.2 6.8 6.4 6.0 5.6 5.2 4.8 4.4 4.0 3.6 3.2 2.8 2.4 2.0 1.6 1.2 0.8 0.4 0.0 -0.4
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Figure 6.65  1H NMR spectrum for HBFK-AzP-C: Ac-Arg-Trp-AzP-Lys-Val-dPro-Gly-
Orn-Phe-Pra-Lys-Gln-NH2 
 
 
Table 6.51  Proton chemical shift assignments (ppm) for HBFK-AzP-C 
  α β γ δ ε 
R 4.32 1.80 1.63 2.98 
W 4.76 3.28, 3.16 
AzP 4.55 3.16 
K 4.27 1.71 1.27 1.61 2.84 
V 4.32 1.71 1.43 
dP 4.47 2.15 2.05, 1.91 3.75, 3.66 
G -- 
O 4.32 
F 4.65 2.99, 2.81 
Pra 4.55 
K 4.23 1.6 1.01, 0.92 1.36 3.06 
Q 4.32 2.11, 2.02 2.36     
PPM 8.4 8.0 7.6 7.2 6.8 6.4 6.0 5.6 5.2 4.8 4.4 4.0 3.6 3.2 2.8 2.4 2.0 1.6 1.2 0.8 0.4 0.0 -0.4
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Figure 6.66  1H NMR spectrum for TFK-AzK-NG-U: Ac-Pra-Arg-Trp-Val-Lys-Val-Asn-
Gly-Orn-Phe-AzK-Lys-Gln-NH2 
 
 
Table 6.52  Proton chemical shift assignments (ppm) for TFK-AzK-NG-U 
  α β γ δ ε 
Pra 4.56 2.5 
R 4.50 1.74 1.53 3.14 
W 5.12 3.06 
V 4.48 2.01 0.89 
K 4.41 2.04, 1.83 1.35, 1.19 1.55 2.56 
V 4.13 1.91 0.91 
N 4.47 3.03, 2.74 
G* 0.57 
O 4.61 1.88 1.74 3.04 
F 4.97 2.89 
I 4.59 1.92 1.44, 1.22 0.93 (γ,CH3) 0.81 (δ,CH3) 
K 4.02 1.40 0.74 1.02 2.73 
Q 4.42 2.03, 1.83 2.24 
AzK 4.28 1.75 1.42 1.58 3.29 
*Glycine splitting 
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Figure 6.67  1H NMR spectrum for TFK-AzK-NG-C: Ac-Pra-Arg-Trp-Val-Lys-Val-Asn-
Gly-Orn-Phe-AzK-Lys-Gln-NH2 
 
 
Table 6.53  Proton chemical shift assignments (ppm) for TFK-AzK-NG-C 
  α β γ δ ε 
Pra 4.57 2.91, 2.77 
R 4.50 1.71 1.52 3.18 
W 5.06 3.20, 3.06 
V 4.44 0.90 
K 4.48 1.49 0.78, 0.60 1.28 2.48 
V 4.14 1.87 0.84 
N 4.4 3.05, 2.76 
G* 0.64 
O 4.63 1.86 1.7 3.03 
F 4.99 2.98, 2.84 
I 4.56 1.93 1.42, 1.23 0.94 (γ,CH3) 0.81 (δ,CH3) 
K 4.15 1.67 0.89, 0.75 1.35, 1.13 2.59 
Q 4.45 2.00, 1.86 2.26 
AzK 4.33 1.75   1.59 2.36 
*Glycine splitting 
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viii.  Peptidase concentration 
Enzymes were purchased from Sigma-Aldrich, pronase E from Streptomyces griseus 
(EC 3.4.24.31) as a solid and trypsin from bovine pancrease as a lyophilized powder 
containing lactose.  Pronase E and trypsin were brought up in 10 mM sodium phosphate, 140 
mM NaCl buffer, pH 7.6 to 0.3 mg/mL.   
ix.  Peptide degradation reactions 
The procedure for peptidase studies was adapted from Seebach et al.
9
  For each 
reaction, 0.25 mM peptide in the phosphate buffer (140 mM Na
+
/K
+
Cl
-
 buffer pH 7.6) was 
reacted with the appropriate concentration of enzyme at 37°C.  A 75 μL aliquot was removed 
after 0, 5, 10, 15, 30, 45, 60, 90, 120, 190, 270, 360, 480, 600, 720, 840, 1100, 1260, 1440, 
1680 min time points, quenched with 10 μL glacial acetic acid and 15 μL of buffer, bringing 
the final volume to 100 μL.  A 10 μL aliquot was injected on a Waters Alliance 2695 with an 
Atlantis C-18 column using a 0-40%B in 45 mins gradient.  The acetic acid peak was used as 
an internal control to account for differences in the injection volumes by the autosampler.  
The parent peak and the acetic acid peak were integrated using the accompanying software.  
To determine the fraction of full-length peptides remaining at each of the time points, the 
peak area for the full-length peptides was divided by the peak are at the zero time point.   
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Figure 6.68  Overlay of HPLC traces monitoring Pronase E degradation of Scramble at 280 
nm over 24 hours. 
 
 
 
Figure 6.69  Overlay of HPLC traces monitoring Pronase E degradation of HB-pG-U at 280 
nm over 24 hours. 
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Figure 6.70  Overlay of HPLC traces monitoring Pronase E degradation of HB-pG-C at 280 
nm over 24 hours. 
 
 
  
Figure 6.71  Overlay of HPLC traces monitoring Pronase E degradation of NHB-pG-U at 
280 nm over 24 hours. 
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Figure 6.72 Overlay of HPLC traces monitoring Pronase E degradation of NHB-pG-C at 
280 nm over 24 hours. 
 
 
 
Figure 6.73  Overlay of HPLC traces monitoring Pronase E degradation of Term-pG-U at 
280 nm over 24 hours. 
 
 
A
U
0.000
0.005
0.010
0.015
0.020
0.025
Minutes
10.00 20.00 30.00 40.00
A
U
0.000
0.010
0.020
0.030
0.040
0.050
0.060
0.070
0.080
Minutes
10.00 20.00 30.00 40.00
212 
 
 
Figure 6.74  Overlay of HPLC traces monitoring Pronase E degradation of Term-pG-C at 
280 nm over 24 hours. 
 
 
 
Figure 6.75  Overlay of HPLC traces monitoring Trypsin degradation of  NHB-pG-U at 280 
nm over 24 hours. 
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Figure 6.76  Overlay of HPLC traces monitoring Trypsin degradation of  NHB-pG-C at 280 
nm over 24 hours. 
 
x.  Fluorescence quenching experiments with ATP.  
Peptide samples were prepared by dissolving purified peptide in 10 mM acetate 
buffer, pH 5.0.  The concentrations of the peptide was determined in 5M guanidine 
hydrochloride using the absorbance of the Trp residues at 280 nm (ε = 5690 M-1 cm-1).  An 
ATP stock solution was prepared by dissolving in 10 mM acetate buffer, pH 5.0,  and the 
concentration was determined using the absorbance at 260 nm (ε = 15400 M-1 cm-1).  ATP 
concentrations were prepared via serial dilutions.  Samples were prepared where the peptide 
host concentrations were held constant with increasing concentrations of guest.  Fluorescence 
scans were obtained at 25°C using an excitation wavelength of 297 nm for Trp.  Emission 
was monitored between at 348 nm.  The emission intensities of Trp at 348 nm as a function 
of nucleotide concentration were fit to this binding equation: 
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in Kaleidagraph, where I is the observed fluorescence intensity, I0 is the initial intensity, I8 is 
the fluorescence intensity at binding saturation, [L] is the concentration of ATP added, and 
Kd is the dissociation constant. 
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Figure 6.77  Fluorescence quenching titrations of (A) Term-C (red) and Term-rev-C (blue) 
and (B) HB-C (blue) and HB-rev-C (red) with ATP at 5 µM peptide in 10 mM acetate 
buffer, pH 5.0 at 25 °C 
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